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Inflammatory bowel diseases represent a group of chronic conditions characterized by 
relapsing inflammation within the gastrointestinal tract. Crohn's disease and Ulcerative 
colitis are the 2 major forms of idiopathic inflammatory bowel disease. 
 
IBD is an extremely heterogeneous disease in what regards disease presentation, course and 
prognosis. The coexistence of other diseases may influence IBD´s clinical course. For 
example, patients with concomitant IBD and primary sclerosing cholangitis (PSC) have a 
distinctive phenotype, with milder colonic disease activity, more right-sided inflammation, 
more extensive disease and higher incidence of colorectal neoplasia. Furthermore, the co-
existence of IBD bears a poor prognosis in PSC, increasing the risk of hepatobiliary 
malignancy, need for liver transplant or death. The reason for this distinctive phenotype is 
unknown, but a deeper understanding of the mechanisms underlying it could provide further 
insights into disease pathogenesis.  
 
PSC is an obstructive cholestatic disease associated with changes in the bile acid pool. 
Therefore, bile acids (BA) and BA receptors could play a hypothetical role. BA homeostasis 
is tightly regulated by the activation of BA receptors expressed in the intestine. The 
interaction between BA and their intestinal receptors has been shown to play a key role not 
only in enterohepatic circulation, but also in the regulation of inflammatory liver and 
intestinal responses, intestinal barrier function and antibacterial defense. Furthermore, the 
reciprocal interaction between BA and gut flora in the intestine may be of relevance in the 
context of IBD, where an imbalance between the protective and harmful bacteria (dysbiosis) 
has been demonstrated. Altogether, these data suggest that in PSC-IBD patients, the gut-
liver axis could be involved and contribute to disease phenotype. The goal of this project is 
to provide new insights into this special phenotype, focusing on the interactions between 
BA, BA receptors, and microbiome, and studying specific aspects of the natural history of 
patients with PSC-IBD.  
 
We started by studying the expression of the main bile acid receptor (FXR) in PSC-IBD 
versus IBD alone, and its relationship with inflammation, dysplasia and location in the colon.  





severity of inflammation in UC. Furthermore, patients with PSC-UC had diminished FXR 
expression in the proximal colon compared to UC patients. This finding could contribute to 
the higher risk of proximal neoplasia in PSC patients.  
Recognizing the involvement of FXR in the control of inflammation and bacterial responses 
in the gut, and the important role of the gut microbiome in the pathogenesis of IBD, we next 
explored the differences in the mucosa-associated and stool-associated microbiota in PSC-
IBD versus IBD alone. Our first work in this area compared the mucosa-associated 
microbiome between PSC-IBD and IBD alone patients, in different locations in the colon. 
Biopsies taken during surveillance colonoscopy from the terminal ileum, right and left colon 
from patients with PSC-IBD, IBD alone and healthy volunteers were collected and 
sequenced using 16s rRNA for the study of the microbiome. We observed that the overall 
microbiome profile was similar across multiple locations in the gut from the same individual 
regardless of disease status, and therefore the phenotypic differences observed between PSC-
IBD and IBD alone in the right versus the left colon are not explained by variations in the 
gut microbiome alone. We also showed that the mucosa associated-microbiome of PSC 
patients was characterized by an enrichment of bacteria known to be involved in bile acid 
handling, and gut homeostasis, therefore suggesting indeed a role of gut flora in PSC-IBD’s 
special phenotype.  
Motivated by these findings we then sought to explore the correlations between stool 
microbiome and bile acid profile. For this study, we recruited Portuguese patients with PSC-
IBD and IBD alone patients. All patients had extensive colitis. From each patient 
demographic and clinical information as well as disease clinical and endoscopic activity 
scores were recorded. Each patient conducted a food-frequency questionnaire and nutritional 
analysis as well. In this study patients collected a paired fasting stool and serum sample for 
bile acid analysis. The stool sample was also studied and analyzed with 16S sequencing for 
the characterization of the gut microbiota. In this study, we observed that patients with PSC-
IBD had distinct microbiota and microbiota-stool BA correlations as compared to IBD alone. 
Interestingly, one of the taxa enriched in PSC-IBD in this study was the Fusobacterium 
genus, a taxon known to be involved in colorectal cancer.  
Finally, we wanted to study two very clinical and important questions in the management of 
patients with PSC-IBD: the rates of colorectal neoplasia in PSC-IBD in the current ear of 
improved endoscopic surveillance, and the fate of low-grade dysplasia. These are very 





manage low-grade dysplasia in IBD in a conservative way with increased surveillance, since 
the progression to high-grade dysplasia and colorectal cancer seems to be infrequent. 
However, whether this premise was true for PSC-IBD as well remained to be defined. 
Therefore, we conducted a multicentre study on almost 300 patients with PSC-IBD and 1600 
patients with IBD alone and considered their longitudinal endoscopic and pathological data. 
We confirmed that PSC remains a strong independent risk factor for aCRN in IBD. 
Furthermore, we observed that there is a faster progression to advanced colorectal neoplasia, 
highlight the peculiarities of PSC-IBD´s special phenotype.  Therefore, our findings add 
further credence to current recommendations for careful annual colonoscopic surveillance 
in this high-risk population and consideration of colectomy once LGD is detected. 
It is evident that the cross talk between the liver and the colon in PSC-IBD patients, is worth 
exploring as it can provide important pieces of information that could lead to the 
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As doenças inflamatórias intestinais (DII) representam um grupo de doenças crónicas 
caracterizadas por inflamação recidivante do trato gastro-intestinal. A doença de Crohn e a 
Colite Ulcerosa são as duas principais formas de doença inflamatória intestinal idiopática. 
 
A DII é uma doença extremamente heterogénea em termos de apresentação da doença, curso 
e prognóstico. Além disso, é uma doença multissistémica, podendo fazer-se acompanhar de 
várias manifestações extra-intestinais (MEI). A coexistência de algumas destas outras 
doenças pode influenciar o curso clínico da DII. Por exemplo, doentes com DII e colangite 
esclerosante primária (CEP-DII) concomitante, têm um fenótipo e um comportamento 
clínico distintos. Estes doentes apresentam frequentemente doença cólica mais extensa 
(pancolites), contudo com atividade endoscópica e histológica mais ligeira e daí com curso 
clínico da sua doença inflamatória mais favorável. Curiosamente, e ao contrário do que se 
verifica na colite ulcerosa, em que a atividade inflamatória é mais marcada no cólon 
esquerdo, vários estudos demonstraram que na CEP-DII a atividade inflamatória é mais 
marcada no cólon direito. Além disso, estes doentes apresentam um risco de neoplasia 
coloretal significativamente aumentado, que por motivos não conhecidos, e também em 
contraste com a colite ulcerosa (onde a neoplasia coloretal é mais frequente no cólon 
esquerdo), é mais frequente no cólon direito. A razão para este fenótipo distinto permanece 
desconhecida, mas uma compreensão mais profunda dos mecanismos subjacentes poderia 
fornecer mais informações sobre a patogénese da doença. 
 
A CEP é uma doença colestática obstrutiva, associada com alterações no pool de sais bilares. 
Assim, os ácidos biliares (AB) e os recetores dos AB podem ter um papel hipotético. A 
homeostasia dos AB é fortemente regulada pela ativação de recetores expressos no intestino. 
A interação entre AB e os seus recetores intestinais mostrou desempenhar um papel 
fundamental não apenas na circulação entero-hepática, mas também na regulação das 
respostas inflamatórias no fígado e intestino, função de barreira intestinal e defesa 
antibacteriana. Além disso, a interação recíproca entre os AB e a flora intestinal podem ser 
particularmente relevante no contexto da DII, onde um desequilíbrio entre bactérias 
protetoras e prejudiciais (disbiose) foi demonstrado. Globalmente, estes dados sugerem que 





fenótipo da doença. O objetivo deste projeto é fornecer novos conhecimentos sobre este 
fenótipo especial, com um foco nas interações entre AB, recetores dos AB e microbioma, 
assim como estudar aspetos específicos da história natural da CEP-DII. 
 
Começámos por estudar a expressão do recetor principal dos ácidos biliares, o recetor 
Farnesóide X, em doentes com CEP-DII e DII, em relação com o grau de inflamação no 
cólon, a localização no cólon e os vários graus de displasia e cancro colorectal. Para o efeito 
recuperámos amostras em parafina armazenadas no Hospital Mount Sinai em Nova Iorque 
e realizámos imuno-histoquímica para este recetor. Verificámos que existe um gradiente 
proximal-distal da expressão do recetor ao longo do cólon, uma vez que significativamente 
mais amostras do cólon direito apresentavam marcação forte em relação com amostras do 
cólon esquerdo. Além disso, verificámos que quer em doentes com DII e doentes com CEP-
DII havia uma correlação negativa da expressão do recetor com a gravidade da atividade 
inflamatória no colon. De forma interessante, verificámos que em doentes com CEP-DII, o 
recetor se encontrava globalmente diminuído no cólon direito, mesmo na ausência de 
inflamação ativa. Finalmente, em amostras com displasia observámos uma marcação 
diminuída do recetor inversamente proporcional ao grau da lesão. Tendo em conta o papel 
do FXR na carcinogénese coloretal, os nossos dados sugerem que a sub-expressão deste 
marcador poderia estar envolvida no processo de carcinogénese acelerada na CEP-DII. Além 
disso, reconhecendo o envolvimento do FXR no controle da inflamação e regulação das 
respostas bacterianas no intestino, assim como o papel importante do microbioma intestinal 
na etiopatogenia da DII, decidimos explorar as diferenças do microbioma entre doentes com 
CEP-DII e DII. O primeiro trabalho realizado nesta área foi realizado em doentes que se 
apresentavam para realização de colonoscopia de vigilância (CEP-DII e DII) e voluntários 
saudáveis. Atendendo às várias diferenças entre cólon direito e cólon esquerdo em doentes 
com CEP-DII e DII, estávamos também interessados em explorar se diferenças na 
composição do microbioma associado à mucosa poderiam estar envolvidos neste aspeto do 
fenótipo. Assim, foram colhidas biopsias adicionais para isolamento de DNA bacteriano e 
sequenciação do gene 16rRNA. Observámos que não havia diferenças significativas entre a 
composição microbiana entre os diferentes locais do cólon, pelo que as diferenças 
fenotípicas observadas entre CEP-DII e a DII entre o cólon direito e esquerdo não são 
explicadas pelas variações do microbioma intestinal. Contudo verificámos que o 





grupos bacterianos que se sabe estarem envolvidos no metabolismo dos sais biliares, 
sugerindo, portanto, um eventual papel da flora intestinal, no fenótipo especial da CEP-DII. 
Motivado por esses achados, procurámos explorar as correlações entre o microbioma fecal 
e o perfil de AB fecais. Para esse efeito recrutámos doentes portugueses com CEP-DII e DII 
apenas. Todos os pacientes tinham colite extensa. Recolhemos informações demográficas, 
clínicas, assim como os scores de atividade clínica e endoscópica de todos os doentes. Além 
disso, cada doente realizou também um questionário de frequência alimentar e análise 
nutricional. Todos os doentes colheram uma amostra de soro e fezes para análise de ácidos 
biliares. A amostra de fezes também foi estudada e analisada com o recurso a sequenciação 
16S para a caracterização do microbioma intestinal. Neste estudo, verificámos que embora 
não existissem diferenças estaticamente significativas na proporção de AB fecais 
individuais, o pool de AB era globalmente distinto entre a CEP-DII e a DII. Além disso, 
comprovámos que os doentes com CEP-DII apresentavam interações distintas entre o 
microbioma e os sais biliares fecais em comparação com os doentes com DII apenas. 
Curiosamente, um dos grupos taxonómicos enriquecidos na CEP-DII neste estudo foi o 
género Fusobacterium, previamente descrito como estando envolvido no cancro coloretal.   
Finalmente, pretendemos estudar duas questões clínicas de especial relevância no manejo de 
pacientes com CEP-DII: as taxas de neoplasia coloretal numa era de melhor vigilância 
endoscópica e o grau de progressão da displasia coloretal de baixo grau. Estas são questões 
muito importantes do ponto de vista clínico, uma vez que na DII há uma tendência crescente 
para o manejo de displasia de baixo grau de forma conservadora, uma vez que a progressão 
para displasia de alto grau e cancro coloretal parece ser pouco frequente. No entanto, 
permanece por esclarecer se esta premissa também se pode aplicar em doentes com CEP-
DII, que têm um risco basal muito elevado. Assim, realizámos um estudo multicêntrico com 
quase 300 doentes com CEP-DII e 1600 doentes com DII, e estudámos os seus dados 
endoscópicos e histopatológicos longitudinais. Confirmámos que, apesar de todos os 
avanços no tratamento da DII e nas técnicas de vigilância endoscópica, a CEP continua a ser 
um fator de risco independente para o desenvolvimento de displasia de alto grau e cancro 
coloretal. Além disso, observámos que, quando existe o diagnóstico displasia de baixo grau, 
existe uma rápida progressão para a neoplasia coloretal avançada, destacando mais uma vez 
as peculiaridades do fenótipo especial da CEP-DII. Assim, os nossos achados reforçam as 
recomendações atuais de vigilância endoscópica anual cuidadosa nesta população de alto 





Deste conjunto de estudos é pois evidente que o cross-talk entre o fígado e o cólon em 
doentes com CEP-DII, pode fornecer informações importantes que poderiam levar ao 
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INFLAMMATORY BOWEL DISEASE ASSOCIATED WITH PRIMARY 












INFLAMMATORY BOWEL DISEASE  
 
Inflammatory bowel disease (IBD) represents a group of chronic conditions characterized 
by relapsing-remitting inflammation within the gastrointestinal tract. There are two major 
types of IBD: Crohn´s disease and Ulcerative colitis. All ages can be affected, but IBD 
typically affect young patients. Being a chronic disease with a young age of onset, IBD has 
a major impact on the personal and professional life of patients. It can lead to progressive 
bowel damage and disability, with a significant number of patients needing surgery over 
time1, 2. Besides the intestinal manifestations, other organs and several types of extra-
intestinal manifestations can also affect patients and have an impact in quality of life and 
prognosis. 
 
Clinical symptoms and diagnosis 
Clinical presentation varies depending on the segment affected and type of involvement. In 
Crohn’s disease, any segment of the GI tract, from the mouth to the anus, can be affected 
but most frequently disease is located in the terminal ileum and proximal colon. The 
inflammation in CD is typically asymmetric, segmental and transmural1. Three patterns of 
involvement can be seen: inflammatory, stricturing and fistulizing. The typical symptoms in 
CD are abdominal pain, chronic diarrhea and other features suggestive of IBD (eye, skin, 
joints complaints, perianal manifestations and family history of IBD). Weight loss, anorexia, 
fatigue and low-grade fever are frequently present, independent of disease location. In some 
patients, subclinical inflammation over the years, results in fibrotic strictures, and 
postprandial abdominal pain, distension and vomiting may be the presenting complaints. 
Due to the transmural nature of inflammation patients can present with abscesses, 
inflammatory masses, or fistulae to adjacent organs or skin (Figure 1). Perianal disease 






Figure 1 – Crohn´s disease classification based on disease behaviour. The figure depicts the three 
types of behaviour of Crohn´s disease as per the Montreal classification represented in magnetic 
resonance enterography (MRE) and illustrated, with typical symptoms. Upper left MRE (B1) shows 
mural thickening and enhancement in the distal ileum in a patient with active CD (T1 weighted 
imaging with fat saturation after injection of gadolinium chelates). The middle MRE panel (B2) 
shows a narrowed luminal segment with thickened wall and upstream dilation suggesting the 
presence of a stricture (T2 weighted imaging). The right MRE panel (B3) shows multiple converging 
enhancing loops of small bowel suggestive of entero-enteric fistulae (arrows) (T1 weighted imaging 
with fat saturation after injection of gadolinium chelates); in the lower illustration, a deep and 
transmural fissure/ulcer leads to the formation of an abscess. Reproduced with permission from 
Torres J et al. (2017) Crohn´s disease. The Lancet. doi: 10.1016/S0140-6736(16)31711-11. 
 
 
In UC, inflammation is usually restricted to the colon only, involving only the mucosa and 
sometimes the sub-mucosal layers; usually the inflammatory process starts in the anal canal 
and extends proximally. Patients may have disease limited to the rectum (proctitis), up to the 
splenic flexure of the colon (left-sided colitis) or beyond the splenic flexure (extensive 





forms of disease (left-sided colitis, pancolitis) are usually associated with higher need for 
steroids, hospitalization and surgery4, 5. 
 
Figure 2 – Ulcerative colitis classification based on disease extent. The figure depicts the 3 types 
of mucosal involvement usually seen in ulcerative colitis, as per the Montreal classification. This 
classification has prognostic and therapeutic implications, since proctitis is usually associated with a 
milder disease course, lower therapeutic requirements, less need for hospitalizations and surgery4, 5. 




Occasionally mild inflammation can be seen in the terminal ileum, a process known as 
backwash ileitis. Typical symptoms in UC include rectal bleeding, bloody diarrhea, fecal 
urgency and incontinence, mucus discharge, and abdominal pain. Clinical presentation 
might vary based on disease extent. Patients with proctitis might predominantly have 
urgency and tenesmus (sensation of incomplete evacuation), while in pancolitis, bloody 
diarrhea and abdominal pain might be more prominent. 
 
The diagnosis of IBD relies on a combination of clinical, laboratorial, endoscopic, 
histological, and radiological findings after exclusion of alternative diagnosis1. Endoscopy 
with biopsies is required to establish the diagnosis. Typical endoscopic findings in CD are 
ulcerations interspersed with areas of normal mucosa, cobblestoning, and rectal sparing. 
Focal, discontinuous and segmental chronic inflammation is the key pathological finding. 
Non-caseating granulomas can sometimes be found1, 7 . In UC, typical endoscopic findings 





ulcerations. The typical histologic findings are distortion of crypt architecture, increased 
lymphocytes and plasma cells in the lamina  propria, basal plasmocytosis, mucin depletion, 
and  Paneth cell metaplasia67. 
 
IBD is a multisystemic disease, and multiple other organs can be affected, including the 
bones, joints, mouth, skin, eyes, hepatobiliary system, lungs and kidneys8-10. The overall 
prevalence of these extra-intestinal manifestations (EIM) ranges from 20-50%, and they may 
present prior, in conjunction or following the diagnosis of the bowel disease8. Some EIM 
run in parallel with the bowel disease activity while other have an independent course. One 
of such EIMs is Primary Sclerosing Cholangitis (PSC), described for the first time in 




IBD is a chronic disease that can affect all ages. There is no sex-specific distribution in adult 
IBD, and the onset of the disease usually occurs in the 2nd- 4th decade of life, with the highest 
incidence reported among 20 to 29 year-old individuals; a second and smaller peak has been 
described inconsistently between 50-60 years12. There has been a steady increase in IBD 
frequency in most regions of the world12. Usually there is a rise in the incidence of UC, 
followed by a rise in the number of new cases of CD12. The incidence and prevalence of IBD 
is highest in westernized nations, and in urban compared to rural areas. The highest reported 
incidence rates come from Canada (20.2/105), Northern Europe (10.6/105), New Zealand 
(16.5/105) and Australia (29.3/105)12. Prevalence rates are highest in Europe (322/105)9, 
Canada (319/105)4 and United States (214/105)1, 13-16. Portugal is considered to be an 
intermediate incidence and prevalence region, with a growing number of new cases16. 
 
Etiology and pathophysiology  
Genetics and family history 
Several lines of evidence link genetics to the risk of IBD. First, around 12% of patients have 
a family history of IBD, with the risk being higher if first-degree relatives or multiple family 
members are affected17, 18. Second, concordance rates in monozygotic twins range from 20–
50%, with higher concordance rates for CD than UC19. Third, certain ethnic groups are 





African-American and Asian ancestry is associated with the lowest risk19. Finally, Genome-
wide association studies (GWAS) have identified more than 200 risk alleles associated with 
IBD, of which 37 are specific for CD and 32 for UC20. Interestingly, 70% of the loci are 
shared with other diseases, such as type 1 diabetes, ankylosing spondylitis and psoriasis20. 
Furthermore, there is a striking overlap between loci for IBD and primary 
immunodeficiencies and mycobacterial infection. Among the identified genes, notable 
examples include mutations in genes associated with bacterial sensing and innate immunity 
(NOD2, ATG16L1, LRKK2, IRGM, Il23R, HLA, STAT3, JAK2 and Th17-pathway) and 
altered mucous layer (MUC2)21. However, only 13.1% of disease heritability is explained 
by genetic variation, highlighting the importance of epigenetic and other non-genetic 
environmental factors1.  
 
Environmental factors 
In the past years, areas of the world where IBD was previously considered to be very rare, 
have witnessed a sharp increase in their incidence rates, almost in parallel with the fast 
industrialization rates ongoing in these areas1 22. Changes in lifestyle, diet, better sanitation 
and Westernization” of lifestyles has been proposed as a potential explanation to the rise of 
allergic and immune-mediated disorders, including IBD over the past few decades (‘hygiene 
hypothesis’). However, breastfeeding, living in rural environments, contacting with animals 
in childhood, etc, have been only inconsistently identified as being “protective” for IBD1, 23, 
24. Cigarette smoking is the best studied environmental factor; it is associated with twofold 
increase in risk for developing CD (OR, 1.76; 95% CI 1.40-2.22), while it is protective from 
developing UC1, 6, 25-27. Appendectomy performed before the age of 20 years confers 
protection against ulcerative colitis28. Antibiotic exposure in early childhood, and during 
pregnancy has been shown to increase the risk of IBD29, 30, again highlighting a putative role 
for the microbiota in disease pathogenesis. Other medications potentially associated with 
higher risk of developing IBD include oral contraceptives, aspirin and nonsteroidal anti-
inflammatory drugs, while statins have been linked with a decrease in the incidence of IBD, 
especially in the elderly31, 32. A reduction in dietary fiber and an increase in saturated fat 
intake have also been associated with increased risk33-35. Micronutrients such as zinc or iron, 





to be proven for many environmental factors, as only association studies with major 
methodological limitations have been conducted.  
 
Microbiota  
The role and involvement of the gut microbiota in the pathogenesis of IBD has long been 
supported by many clinical observations, such as disease location in areas of highest 
bacterial population, the positive role of antibiotics for inducing remission and for preventing 
post-operative recurrence, and remission of disease upon diversion and recurrence upon re-
anastomosis36. The advent of next-generation sequencing, allowed the characterization of an 
abnormal composition of commensals called “dysbiosis”. Generally, IBD is characterized 
by a decrease in species diversity, namely in Bacteroides and Firmicutes, and specifically in 
bacteria from the Clostridium cluster XIVa and IV, and an increase in 
Gammaproteobacteria37 and Actinobacteria38, 39. Faecalibacterium prausnitzii, a butyrate-
producing commensal with anti-inflammatory properties, has been shown to be reduced in 
mucosal samples from patients with CD and UC38, 39. Approximately 1/3 of CD patients 
display in ileal biopsies increased numbers of mucosa-associated Escherichia coli, 
designated adherent-invasive E. coli (AIEC)30,31 . These E.coli strains are able to cross the 
mucus barrier, adhere and invade intestinal epithelial cells (IEC), and survive and replicate 
within macrophages, provoking the secretion of high amounts of TNF-α30,31. The potential 
causative role of the gut microbiota in disease pathogenesis, had led many investigators to 
seek a microbial-derived therapy. So far the experience with antibiotics and probiotics has 
been disappointing40, but the recently published results showing a promising role for fecal 
transplant in the setting of ulcerative colitis has again led to very active investigation in this 
area41.   
 
Intestinal immune system in IBD 
IBD is a complex disease with a complex ethiopathogenesis. It is commonly accepted that 
IBD results from the interplay between environmental factors, genetic susceptibility, and 
intestinal microflora resulting in an abnormal mucosal immune response and compromised 
epithelial barrier function. Multiple and overlapping pathways of the intestinal immune 
system are dysregulated in IBD (Figure 3). 
The mucous barrier and epithelial barrier defects are strongly implicated in the pathogenesis 





luminal contents and itself42. Defects in the barrier function of the intestinal mucosa can 
prime increased microbial and antigen presentation and lead to immune activation. After 
triggering by antigen presentation, both innate and acquired immune responses are activated 
with subsequent loss of tolerance to enteric commensal bacteria. This results in sustained 
Th1 and/or Th17 responses and production of pro-inflammatory cytokines (Il1, Il2, Il6, INF-
γ, TNF-α, Il17, etc.). TNF-α is one of the most relevant mediators in intestinal inflammation. 
Together with Il1 and Il6 it also contributes to symptoms such as fever, anorexia and weight 
loss. Disruption of this buffer zone by emulsifiers, ubiquitous in western diet43 or by 
mutations in MUC2 gene44 are associated with IBD. Further, epithelial cells are armed with 
an evolutionarily conserved process called autophagy, in which unwanted cytoplasmic 
contents are targeted to the lysosome for degradation, preventing the dissemination of 
invasive bacterial species. Notably, defects in autophagy-related genes such ATG16L1 and 
IRGM have been identified as further important risk factors for the development of CD45. 
Finally, defects in intestinal tight junctions, comprising members of the claudin and occludin 
families,  are associated with IBD3. Many studies performed in patients with IBD have 
shown that intestinal barrier function is disrupted both in active and in quiescent disease 
states. Indeed, several studies have shown that increased intestinal permeability to inert 
tracer molecules such as PEG molecules or 51Cr-EDTA occurs before inflammation and can 
predict disease relapse in patients with CD46. Interestingly, increased permeability has also 
been documented in first-degree relatives of patients with CD, underlining possible shared 
genetic susceptibility to disease17.   
An array of innate immune mechanisms coordinates to preserve mucosal function and 
integrity. The NOD-like receptors (NLRs) are one such class of innate immune proteins that 
mobilize host defense to intracellular fragments of bacterial peptidoglycan, by initiating 
nuclear factor !B (NF!B)-dependent and mitogen-activated protein kinase (MAPK)-
dependent gene transcription, producing multiple protective cytokines. NOD2 was the first 
gene to be associated with CD47 and it remains a prominent genetic risk factor for CD. 
Dendritic cells (DCs), key antigen-presenting cells, are tolerogenic at steady state. However, 
under inflammatory conditions they transform into cells with inflammatory potential. In 
patients with IBD, intestinal DCs have enhanced expression of TLR2, TLR4, and co-
stimulatory molecules, and they secrete increased pro-inflammatory cytokines compared to 
healthy controls. Intestinal macrophages, play essential housekeeping functions, such as the 





neutrophils choreograph the early response to microbial stimuli and likely modulate the 
adaptive responses beyond the acute state by the production of cytokines and reactive oxygen 
species (ROS). Adaptive immune cells have long been implicated in the pathogenesis of 
IBD. CD4+ T helper (TH) cells can be functionally compartmentalized into TH1, TH2, TREG, 
TH17, TFH and TH9 cells49. Broadly, ulcerative colitis is a modified T-helper-2 (Th2) disease, 
while Crohn’s disease is Th1 driven disease. Intestinal inflammatory infiltrate in CD 
contains both TH1 and TH17 cells. Such effector T cell responses to bacteria or fungi are 
implicated in the pathogenesis of CD49. In addition, impaired functional activity of  intestinal 
TREG has been reported in CD patients50. The colonic lamina propria cells from patients with 
ulcerative colitis contains Th2-T cells that produce interleukin-5 (IL5) 49. Il4 and IL13 have 
also been implicated in the pathogenesis of ulcerative colitis. IL13, produced by non-
classical natural killer T cells is a key mediator of epithelial cytotoxicity and barrier 




Figure 3 - Overview of the intestinal immune system in health and IBD. During the healthy state 
(left side of the figure), the intestinal epithelium and IgA dimers work in concert to regulate and 
separate the luminal microflora from the mucosal immune system. During the healthy state, barrier 
function is maintained by the mucus layer and epithelial cells bound across tight junctions The 
intestinal epithelium also contains specialized cells such as Paneth cells (that produce antimicrobial 





presenting cells such as dendritic cells (DC). Contact with the antigen leads to DC maturation and 
antigen presentation to T and B cells. DCs default to inducing a “tolerizing” phenotype in the mucosa 
unless danger signals such as bacterial LPS induce the switch to an inflammatory/immunizing DC 
phenotype. Intestinal DCs also imprint T and B lymphocytes to express gut homing molecules α4β7 
and CCR9. Lymphocytes thus imprinted within the GI tract enter the systemic circulation and upon 
reaching intestinal high endothelial venules, the gut-imprinted, α4β7-expressing lymphocytes engage 
locally expressed MAdCAM and egress the circulation to enter the intestinal lamina propria. The 
intestinal lamina propria has multiple families of T cells. These include TH1, TH17 and TREG 
subtype. At steady state TREG regulate the activity of TH1 and TH17 cells and prevent unchecked 
inflammation. During mucosal injury and inflammation such as seen in Crohn’s Disease (right side 
of the figure), the epithelial barrier is breached as a primary or secondary event and the luminal 
microflora stimulates a pro-inflammatory immune response by DCs and inflammatory macrophages 
(Mφ). The regulatory ability of TREG is outstripped by inflammatory activity of TH1 and TH17. 
Additionally, innate lymphoid cells (inset), homeostatic at steady state contribute to the cytokine 
production, perpetuating inflammation. Mucosal injury and damage is associated with dysbiosis, 
which perhaps perpetuates the inflammatory cascade. Increasing understanding of the mucosal 
immune system has led to an expanding array of therapeutic targets. Of these, TNF-α antagonists 
and homing inhibitors are currently in clinical practice while the others are in early to advanced 
stages of clinical development. DC= dendritic cell, MAdCAM=Mucosal addressin Cell Associated 
Molecule, IL=interleukin, TH= T helper cell, TREG= Regulatory T cell, IFN= interferon, Mφ= 
macrophage, TGF= transforming growth factor. Illustration by Jill Gregory. Reproduced with 




The management of IBD 
The enormous advances in the knowledge about disease pathogenesis, resulted in the 
development of new targeted therapies directed at specific cellular processes, that led to 
major improvements in the care of patients. This resulted in a treatment paradigm change 
that evolved in from mere control of symptoms and improved quality of life towards 
attaining deep remission (absence of symptoms and endoscopic healing), with the goal of 
blocking the natural progression of disease and avoiding complications, bowel damage and 
disability5, 51.  However, there is no cure for disease, and medical-free remission is not 





The choice of medication depends on disease location, behavior, and severity and response 
to previous therapies, and considers prognostic factors that are known to be associated with 
higher probability of complicated disease41. The treatment of IBD involves an induction and 
maintenance regimen. The most widely used drugs in IBD currently are corticosteroids, 5-
aminosalicilates, immunosuppressants (IM) [thiopurines (azathioprine, mercaptopurine), 
and methotrexate], biologics [(anti-TNF (infliximab, adalimumab and golimumab), anti-
adhesion molecules (vedolizumab) and anti-IL23 (ustekinumab)]1, 3, 6. Corticosteroids are 
potent anti-inflammatory drugs that are used to rapidly induce clinical remission; they should 
never be used as maintenance therapy, since they have multiple side-effects. Patients who 
are dependent on steroids to maintain clinical remission have indication to start steroid-
sparing agents such as immunomodulators or biologic drugs1, 3, 6. The 5-aminosalicylates 
drugs are not effective in the treatment of Crohn´s disease but are usually the first-line 
therapy for the treatment of mild UC (administered as suppositories, enemas, or oral 
formulations). Antibiotics use should be restricted to CD complicated by fistulas and/or 
abscesses. Biological drugs are usually reserved for patients with moderate-severe UC. 
There is an increasing tendency to consider early aggressive therapy (IM and/or anti-TNF) 
in the subgroup of patients with poor prognostic factors (perianal disease, extensive small 
bowel disease, young age at diagnosis, deep ulcers in endoscopy, penetrating disease) 
complicated and/or severe disease (top-down therapy)1, 3, 5, 6. Patients with refractory medical 
disease, who develop complications (abscesses or malignancy), and/or do not tolerate 
medical therapy are candidates for surgery1, 3, 6. The decision to advance for surgery should 
always be discussed in the context of a multidisciplinary team involving dedicated surgeons 
and gastroenterologists, and should include appropriate pre-operative imaging, patient 
counselling, optimization of nutritional status of the patient, and reduction in the 
thromboembolic risk1, 6.  
 
 
PRIMARY SCLEROSING CHOLANGITIS 
 
PSC is a chronic and progressive cholestatic disease, characterized by inflammation and 
fibrosis of the intrahepatic and/or extrahepatic ducts53, that may result in liver cirrhosis and 
eventually end-stage liver disease53. Orthotopic liver transplantation (OLT) is the only 





respectively53. Without OLT, half of symptomatic patients die within 12-15 years. In 
Western countries, the reported incidence of PSC is 0.07-1.3 per 100.000/year, and the 
prevalence is 8.5-13.6 per 10.00054,55. There is no epidemiological data available in Portugal 
for PSC, but it is generally considered a very rare disease. 
 
Having a diagnosis of IBD is the strongest risk factor for PSC development, since 70% of 
patients with PSC have underlying IBD, most frequently ulcerative colitis (UC) in over 56-
72%% of cases56, 57. Conversely, in patients with known IBD, PSC is found much less 
commonly, occurring in about 2-8% of UC patients and 3% of Crohn’s disease (CD) cases58.  
 
Although there may be a possible common pathogenesis between PSC and IBD, the two 
disorders can occur at different times. PSC may be diagnosed many years after 
proctocolectomy for colitis, and conversely IBD can appear many years after the initial 
diagnosis of PSC or even after OLT altogether59. In most reports, IBD diagnosis precedes 
the diagnosis of PSC60, 61. In patients with known IBD, the presence of persistent of 
unexplained cholestasis obliges one to exclude concurrent PSC through magnetic resonance 
cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography 
(ERCP). When PSC is diagnosed first, half of the cases have only abnormal laboratory tests; 
the typical diagnostic hallmarks of fever, itching, and jaundice are rarely seen nowadays53. 
Symptomatic patients usually present with fatigue and pruritus and can also exhibit jaundice, 
hepato-splenomegaly or scratching injuries. Recurrent episodes of bacterial cholangitis with 
fevers, chills, right upper quadrant pain and jaundice can also be a part of the clinical 
presentation, and usually develops in about 10–15% of patients during the course of their 
disease62. The diagnosis of PSC is based on the findings of diffuse multifocal strictures and 








Figure 4 – Typical findings of Primary Sclerosing Cholangitis. Diagram (left) and magnetic 
resonance cholangiopancreatography imaging (right) showing the typical findings of primary 
sclerosing cholangitis. Several strictures with intervening saccular dilatations of both the intrahepatic 
and the extrahepatic bile are seen conferring a beading aspect to the intra-hepatic biliary tree. 
Diagram in the left reproduced with permission from Hirschfield G et al. (2013) Lancet. Primary 
Sclerosing Cholangitis. doi: 10.1016/S0140-6736(13)60096-363. Cholangiogram-MRI image 
courtesy of Afonso Gonçalves, MD 
 
 
Patients with a confirmed diagnosis of PSC should undergo colonoscopy with biopsies to 
exclude concomitant IBD or any malignancy53, even if they report no gastrointestinal 
symptoms. As most of PSC-IBD patients have mild colonic disease activity and even 
possible normal endoscopic appearances, histological sampling is crucial to avoid 
underdiagnosis58. Although no evidence-based guidelines are available, if the index 
colonoscopy is negative for IBD, a repeat colonoscopy every 3-5 years should be performed 
to monitor for possible onset of IBD64. 
 
The pathogenesis of PSC-IBD – what is known 
PSC is likely to have an underlying multifactorial etiology, with a predominant immune-
mediated process53, 65. PSC and IBD are interrelated conditions that may share an underlying 
predisposition. Both diseases share common antibodies, such as those directed against 
cytoplasmic and nuclear antigens of neutrophils with a characteristic perinuclear staining 





and in up to 68% of patients with UC53. The available evidence points towards a complex 
interaction between genetic, immunologic and environmental factors (Figure 5). 
 
 
Figure 5 - Possible hypothesis linking PSC and IBD pathogenesis, including genetic 
predisposition, immune-mediated processes, altered gut microbiota and altered bile acids (BA) 
metabolism. Reproduced with permission from Palmela C. et al (2017). Gut Liver. Inflammatory 
Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated 




From a genetic standpoint, there is increasing evidence that PSC is distinct from UC and 
CD. Large-scale genome-wide association studies (GWAS) have identified close to 200 
independent loci associated with IBD20, 65, 66. Most of these loci are shared between UC and 
CD20. Genome-wide association studies (GWAS) have allowed for the identification of 23 
genetic risk loci associated with PSC.67 Most of these genetic risk loci play an important role 
in the immune system, such as the HLA complex, IL2, or PRDX5, suggesting that PSC may 
be an immune-mediated disorder. Furthermore, there is some overlap between some genetic 




























of PSC disease predisposition68, pinpointing the possible importance of the environment in 
the pathogenesis of the disease. Genetic predisposition to autoimmune bile duct injury 
triggered by toxic or infectious agents that may gain access through the diseased colon is 
potentially a major mechanism leading to PSC in IBD patients65.  
 
Gut microbiome 
Several lines of evidence support the involvement of gut microflora in PSC´s pathogenesis. 
Bacteria and fungi are more frequently found in the bile ducts of patients with PSC, as 
compared to patients with other cholestatic liver diseases69, 70. Several reports and case series 
of pediatric patients with PSC treated with vancomycin with positive results further suggest 
a role for the gut microbiome, and have paved the way for the trial of antibiotics in PSC71. 
Indeed, in a pilot small randomized controlled trial where patients were allocated to 
vancomycin high or low doses, or metronidazole, high or low doses, it was shown that 
patients receiving vancomycin reached the primary endpoint of decrease in alkaline 
phosphatase at 12 weeks72. Moreover, addition of metronidazole to ursodeoxycholic acid 
(UDCA) showed some beneficial effects in biochemical test results and liver histology73. 
The “leaky gut” hypothesis suggests that increased intestinal permeability may lead to 
translocation of bacterial metabolites from the gut74 (Figure 5). The liver receives 
approximately 75% of its blood supply from the splanchnic circulation and is constantly 
exposed to both beneficial and noxious molecules from the intestinal microbiome75. This so-
called ‘gut-liver axis' is essential for the maintenance of health but may also play an 
important role in pathogenesis of liver and intestinal diseases75,76. This dysbiosis may be 
associated with mucosal immunity dysregulation by modulating intestinal permeability and 
altering homing of gut-specific lymphocytes77. Recently, evidence for an etiologic role of 
the intestinal microbiome in PSC has been provided by animal model studies. Multidrug 
resistance gene 2 knockout (Mdr2-/-) mice, a murine model for PSC, exhibited a more severe 
phenotype when maintained under germ-free conditions.78 However, NOD.c3c4 mice, a 
murine model for biliary inflammation, exhibits a less severe phenotype when maintained in 
germ-free conditions.79 These contradictory findings probably result from the different 
murine models used and the different intestinal microbiota of these mice, highlighting the 
complex interaction between the intestinal microbiota and the liver. 
The interaction between microbiota and bile acid (BA) metabolism may also play an 





between the microbiome and BA pool. Reduced BA in the gut (such as in situations of 
obstructive cholestasis like PSC) leads to bacterial overgrowth and inflammation. In the 
other way around, BA metabolism is a property of the gut bacteria80. 
Recent evidence supports the existence of BA (dys)metabolism in IBD patients due to 
impaired microbiota enzymatic activity81. One of the contributing factors for the difference 
in phenotype between PSC-IBD patients and IBD controls could potentially be altered 
concentration and/or composition of colonic bile acids impacting on gut microbiota and stool 
BA metabolism. 
 
Gut lymphocyte homing 
Activated T lymphocytes from the inflamed and permeable gut may enter the enterohepatic 
circulation and persist as memory cells that cause hepatic inflammation82, 83. Some molecular 
features, such as chemokines and adhesion molecules, are shared by the liver and intestine 
and could contribute to lymphocyte binding at both sites82. T cells activated in the gut during 
active inflammatory bowel disease could differentiate into effector cells with the ability to 
bind to both hepatic and mucosal endothelium. The activation and expansion of these 
memory cells in the liver could eventually lead to the induction of MAdCAM-1 and CCL25 
in the liver, promoting the recruitment of CCR9+ α4β7+ mucosal T cells and the development 
of inflammation84. The enterohepatic circulation of lymphocytes may explain the interaction 
between the colonic immune system triggered by dysbiotic intestinal microbiota and biliary 
inflammation. This theory is further supported by the finding of memory T-cells with 
common clonal origin in both the gut and the liver of patients with PSC-IBD.85 
Findings such as PSC development after colectomy for IBD, or the development of IBD 
after OLT for PSC, have led some investigators to suggest that aberrant homing of 
lymphocytes between the intestine and liver could be involved in the pathogenesis of the 
PSC-IBD phenotype82.  
 
Environment 
Very little is known about the impact of environment in the pathogenesis of PSC. Smoking 
has been repeatedly associated with a lower risk for developing PSC, independently of the 
protective effect of smoking in UC.86-88 Coffee consumption also seems to be associated with 





recurrent urinary tract infections88. There is a clear need for further studies exploring the 
impact of environmental factors in the genesis of disease. 
 
 
The special phenotype of PSC-IBD 
The co-occurrence of PSC with IBD is associated with a distinct IBD phenotype (Figure 6).  
 
 
Figure 6 - The special phenotype of PSC-IBD. Patients with PSC-IBD present more often extensive 
but mild colitis, backwash ileitis, rectal sparing, and right-sided colorectal neoplasia. Reproduced 
with permission from Palmela C. et al (2017). Gut Liver. Inflammatory Bowel Disease and Primary 




Both sex and all age groups can be affected, but PSC is more common in men (65.5%), and 
the mean age of diagnosis is 38.5 ±15.5 years.56 Patients with PSC-IBD tend to have a PSC 





years versus 58.9 ± 18.2 years; p < 0.001)89. Some studies indicate that the mean age for 




The impact of the PSC on the IBD 
PSC-IBD patients typically have extensive colonic involvement, irrespective of the IBD sub-
type. In a population-based cohort pancolitis was observed in 83% of PSC-UC patients90, 
although lower rates have also been reported65. In PSC-CD colonic involvement is the most 
often reported (37-82%), followed by ileo-colic (22-58%), and rarely isolated ileal 
involvement (2-5%)58. Ulcerative proctitis or Crohn’s ileitis are very rarely associated with 
concomitant PSC90, 91. The frequency of rectal sparing ranges from 6% to 66% (versus 2-
25% in UC without PSC). Backwash ileitis, a mild inflammation occasionally seen in the 
terminal ileum in patients with UC, has been reported in up to 46% of patients (as compared 
to 3-24% in UC without PSC)58.   
Despite the higher prevalence of extensive colitis, the intestinal inflammation in PSC-
IBD patients is usually quiescent leading to mild symptoms and milder disease course59, 
89. Typically, the endoscopic and histologic inflammatory activity is highest in the right 
colon and lowest towards the distal colon58, 61, 89,92, and on histopathology, the colonic 
inflammation is mild59, 93. 
There may exist an inverse relationship between PSC disease severity and IBD activity. 
PSC-IBD patients with more severe liver disease requiring OLT (orthotopic liver 
transplantation), have less severe UC, with fewer flares and lower steroids and 
immunosuppressive requirements94. In contrast, those not requiring OLT, and therefore 
with presumably less aggressive liver disease, showed an increased need for intestinal 
surgery and more frequent colorectal neoplasia94. These data are in a certain way 
supported by a recent study where patients with long-standing IBD were screened with 
magnetic resonance cholangiopancreatography (MRCP) for PSC95. Those with 
subclinical PSC, were found to have a higher risk of IBD disease progression (with 
extensive colitis, persistent symptoms and even colectomy). Although not universally 
confirmed, studies have reported that IBD may worsen after OLT in approximately 30% 
of patients53, 96-98. De-novo IBD after OLT has also been reported and it may develop in 14-






The impact of IBD on the PSC 
The effect of the IBD on the PSC phenotype is less well defined. Combined intrahepatic and 
extrahepatic biliary involvement has been described to be more common in PSC-IBD 
patients compared to PSC patients alone (81.5% vs. 46.2%; p<0.05)100, but not universally 
confirmed56, 101, 102. Some studies have suggested that there is an increased prevalence of 
small-duct PSC in PSC-CD patients as compared to PSC-UC.103 PSC-UC is more often 
associated with large-duct PSC as compared to other phenotypes such as small-duct 
PSC(sdPSC), or PSC associated with auto-immune hepatitis (AIH) (frequency of UC in 
patients with classical PSC: 58.1% vs 33.5% in sdPSC, and vs 47.7% in PSC-AIH; P < 0.001 
for both comparisons)56.  
Conflicting data exists on the impact of concomitant IBD on liver-related outcomes91, 104-106; 
however, a recent large multicentric study showed that PSC-UC is associated with a greater 
risk of progressing to OLT or death by 56% in comparison to PSC-CD and by 15% in 
comparison to PSC-alone. It has been postulated that the more benign phenotype of PSC-
CD may be explained by the increased prevalence of sdPSC. However, in a retrospective 
study, even large duct PSC-CD patients had less liver-related morbidity and mortality as 
compared to PSC-UC patients and PSC-alone103, 107.  
Patients in whom colectomy occurs before PSC is diagnosed may have a lower risk of OLT 
or death (HR 0.71, 95%CI 0.53-0.95), as opposed to those with colon in situ at the time of 
PSC diagnosis108. Additionally, several publications have suggested that an intact colon at 
the time of liver transplant is a strong predictor of PSC recurrence in the allograft109-111, 
although not universally confirmed112.  
Altogether these data suggest that PSC severity may have a ‘protective’ effect on UC´s 
activity, and on the other hand, that colonic disease may have the opposite effect in the 
liver disease. 
 
Increased colorectal dysplasia and cancer in PSC-IBD patients 
Since its initial description by Broomé et al.113, plenty of studies have now confirmed that 
patients with PSC-IBD have an increased risk of colorectal neoplasia (CRN, colorectal 
dysplasia and colorectal cancer)114-122. A large meta-analysis evaluating 13,379 patients with 
IBD, 1,022 (7.63%) of whom had concomitant PSC, showed that there was a three-fold 





population (odds ratio (OR) 3.24 [95% CI 2.14-4.90])123. This trend persisted even after 
evaluating colorectal cancer (CRC) risk alone (OR 3.41 [95% CI 2.13-5.48]). In a subgroup 
analysis, PSC-UC patients were found to have a higher risk of both dysplasia (OR 2.98 [95% 
CI 1.54-5.76]) and cancer (OR 3.01 [95% CI 1.44-6.29]) compared to UC-only patients, 
although there was high heterogeneity among the studies. Particularly, the PSC-CD 
population had a non-statistically significant higher risk of CRN and cancer (OR 2.32, 
p=0.133 and OR 2.91, p=0.388 respectively). Interestingly, in one large cohort describing 
the risk of cancer in PSC patients, CRN risk was only increased when IBD was also 
present124.  
All major guidelines consider PSC-IBD patients to be a group for high risk of developing 
aCRN and thus, routine endoscopic surveillance (preferably using chromoendoscopy) every 
year, starting from the moment PSC is diagnosed, is strongly advised7, 125.  
 
Increased hepatobiliary malignancy 
PSC is associated with an increased risk of hepatobiliary malignancy, especially of 
cholangiocarcinoma (CCA).126 Risk estimations for CCA vary, but highest estimates reach 
up to a 20% cumulative 30-year risk for PSC patients56, 127, while the risk of hepatocellular 
carcinoma or gallbladder carcinoma is far lower.56 Some centers perform annual imaging 
studies (either MRCP or ultrasound) together with a serum CA 19-9 for the early detection 
of CCA,126, 128 although  there are no evidence-based recommendations.129  When a suspicion 
of CCA is raised, ERCP with ductal sampling (brush cytology or endobiliary biopsies) is 
recommended. Although the increased risk of increased CCA risk is independent of 
concurrent IBD diagnosis, work has shown that prolonged duration of IBD may be 
associated with a further increased risk.130 Furthermore, in a large cohort, patients with PSC-
UC had a 45% and 35% higher risk of developing hepatobiliary malignancy as compared to 
PSC-CD and PSC-alone, respectively56. 
 
The management of PSC 
Despite all the advances in the knowledge about disease pathogenesis and management of 
IBD, PSC remains a disease with a dismal prognosis due to the absence of effective medical 
therapies, and the progressive nature of disease often resulting in liver cirrhosis and 





or death usually take place within 13.2-21.3 years after the initial diagnosis of PSC, 
depending on severity of disease.131  
Patients with PSC-IBD should be managed according to the general IBD guidelines. 
However, as noted earlier, there are several differences in the IBD disease phenotype of PSC 
patients (pancolitis, rectal sparing, mild symptoms) that may lead to different management 
decisions. Close articulation with a specialized hepatologist is warranted when considering 
treatment options for PSC, such as UDCA. When somewhere in the course of PSC-IBD a 
colectomy is necessary, both an ileal-pouch anal-anastomosis (IPAA) or proctocolectomy 
and ileostomy can be performed. In case of a colectomy with ileostomy, there is a risk of 
parastomal varices. In addition, this procedure often results in a rectal remnant remaining in 
situ, which is at risk of developing rectal stump cancer.132 Therefore, endoscopic rectal 
stump surveillance should be performed. There is a higher risk of developing pouchitis after 
IPAA, affecting 14-90% of cases (versus 33% in patients with conventional IBD)58, 64, 65, 133. 
Furthermore, there may be an increased risk of developing pouch dysplasia in PSC-IBD 
patients134. Nonetheless, the incidence of pouch failure in PSC-IBD seems to be similar to 
IBD-alone patients58, 135.  
 
The therapeutic approach to PSC is the same, whether there is concomitant IBD or not. 
Unfortunately, there is currently insufficient evidence to show differences in effectiveness 
measures such as mortality, health-related quality of life, cirrhosis, or liver transplantation 
between any active pharmacological intervention and no intervention136.  
Ursodeoxycolic acid (UDCA) is used extensively, leading to an improvement in liver 
biochemistry results, but not on important liver-related outcomes.137 Experimental and 
animal-model studies have suggested a possible suppressive effect of UDCA on colonic 
tumor formation138. Results on a possible chemopreventive effect of UDCA are conflicting 
and most studies did not incorporate findings on dosage and treatment duration. A recent 
meta-analysis found a significant chemopreventive effect of UDCA on the risk of aCRN.139 
Specifically, the risk of all colorectal neoplasia was decreased for low-dose (8-15 
mg/kg/day) UDCA use. Notably, a recent study found an increased risk of CRC for patients 
treated with high doses of UDCA (28–30 mg/kg/day).140 While high-dose UDCA as a 
chemoprotective agent or as a maintenance treatment in PSC is discouraged, many 






Vedolizumab, a biologic drug approved for the treatment of IBD, blocks gut leukocyte 
trafficking by preventing the α4ß7 subunit from binding to mucosal addressin cell adhesion 
molecule-1 (MAdCAM-1). Aberrant expression of these gut adhesion molecules in PSC has 
opened the possibility of exploring vedolizumab as a potential therapy142, although no RCT 
results are available and preliminary results don´t look positive.  
The potential role of microbiota in disease pathogenesis is supported by positive results from 
trials exploring the use of antibiotics in the treatment of PSC. Vancomycin, particularly, has 
shown promising results72, and further trials are ongoing. 
It is evident that there is an urgent need exists to identify an effective medical treatment for 
primary sclerosing cholangitis through well-designed RCTs with adequate follow-up that 
aim to identify differences in outcomes important to people with primary sclerosing 
cholangitis136. 
Liver transplantation is the only curative option for patients with PSC, although PSC can 
recur in roughly 25% of the transplanted patients.143 Although not unanimously shown, a 
range of studies suggests a persistence or increase in IBD activity after OLT.144-146 
Unfortunately, the evidence on colonic neoplasia risk after transplantation is scarce. While 
early reports may have suggested an increase in CRC risk post-OLT, more recent evidence 
did not find such an effect.147-150 Interestingly, a recent study comparing dysplasia 
progression rates between transplanted and non-transplanted patients found a longer time to 







RATIONAL TO CONDUCT RESEARCH PRESENTED IN THIS THESIS 
 
There are multiple aspects of PSC-IBD that remain to be solved. Despite all the advances in 
the knowledge about disease pathogenesis and management of IBD, the special PSC-IBD 
phenotype remains unexplored and in that sense, PSC can be considered an orphan disease.  
Investigators have speculated about possible alterations in the concentration and/or 
composition of colonic bile acids (BA), especially as a justification for the increased risk of 
CRN118. Notably, patients with PSC alone, without IBD do not have an increased risk of 
developing CRN124, suggesting that additional factors besides BA must be involved. The 
recent discovery of receptors implicated in BA homeostasis and their correlation with gut 
inflammation and carcinogenesis, as well advances in our knowledge about intestinal 
microflora, offer new insights into this subject.  
BA homeostasis is tightly regulated by the activation of Farnesoid X Receptor (FXR), a 
nuclear BA receptor, expressed at high levels in liver and intestine 152. BA act as ligands for 
FRX, which in turn serves as a biological sensor for BA 153. The interaction between BA and 
FXR has been shown to play a key role not only in the enterohepatic circulation, but also in 
regulation of inflammatory liver and intestinal responses, intestinal barrier function and 
antibacterial defense 154. Additionally, this bile acid receptor has also been shown to be 
involved in colorectal cancer. 
The consequences of cholestasis and of a BA pool altered by the diverse bacteria in the 
inflamed colon are not fully known, but we can hypothesize that a specific alteration of the 
microbiome in PSC-IBD patients could participate in the special phenotype, including in 
colorectal carcinogenesis either directly or through BA transformation. Indeed, several lines 
of evidence suggest a role for the gut microbiome in the pathogenesis of PSC associated with 
IBD. Alternatively, changes in BA composition due to the liver disease could also participate 
and lead to the selection anti-inflammatory or more pro-carcinogenic strains of bacteria in 
the gut, that could be associated with this phenotype. 
 
Herein we plan to explore the interactions between gut dysbiosis, BA metabolism, and 
expression of BA receptors in the inflamed colon that may contribute to the special 
phenotype observed in PSC-IBD patients. Additionally, we plan to further explore clinical 





literature does not provide and answer, specifically the management and follow-up of low-
grade dysplasia in PSC-IBD. 
 
 
Figure 7 - Proposed interaction between colonic inflammation, microbiome and altered bile 
acid pool and bile acid metabolism through FXR, that could explain the special phenotype 
primary sclerosing cholangitis and inflammatory bowel disease (PSC-IBD). Adapted from 
Torres J et al. (2011). APT 2011. Review article: colorectal neoplasia in patients with primary 




PSC associated with IBD represents, therefore, a unique model in which to study bile acid 
metabolism, inflammation and interactions with gut flora. A better understanding of these 
processes might provide new insights into the pathogenic mechanisms involved in this 












































THE ROLE OF BILE ACID RECEPTORS IN THE SPECIAL PSC-IBD 


















Bile acids (BA) are important signaling molecules, acting in inflammation and metabolism, 
through activation of BA receptors such as the nuclear BA receptor Farnesoid X receptor 
(FXR).  
FXR, is a nuclear receptor, recently discovered and characterised156. FXR is the main BA 
receptor, regulating virtually every aspect of bile acids metabolism157, the entero-hepatic 
circulation and the cross-talk between the liver and colon (Figure 8)158. 
 
 
Figure 8 - Illustration of the role of FXR in entero-hepatic circulation. Primary Bile acids 
[chenodeoxycholic acid (CDCA) and cholic acid (CA)] are produced in the liver by the conversion 
of cholesterol into primary bile acids, a reaction mediated by the enzyme cholesterol 7-α-
monooxygenase (CYP7A1), and then conjugated with glycine or taurine becoming water-soluble. 
After a meal, bile containing bile acids (BA) is secreted into the intestine. Normally, most of the BA 
secreted by the liver are efficiently reabsorbed in the terminal ileum, through an active process carried 
out by the apical sodium-dependent BA transporter (ASBT), leaving only approximately 5% of the 





transformed into secondary BA by bacterially-mediated processes. In the terminal ileum FXR 
induces synthesis of fibroblast growth factor-19, which is then secreted into the portal circulation. In 
the liver, FGF19 binds to its receptor, fibroblast growth factor receptor 4 (FGFR4), which will 
eventually signal to the liver the end of the entero-hepatic circulation and inhibit the CYP7A1, thus 
downregulating bile acid synthesis159. Reproduced with permission from Schaap, F. G. et al. (2013) 




It is expressed at high levels in liver and intestine, especially in the terminal ileum and 
proximal colon152. In enterocytes, BA-dependent FXR activation results mainly in two 
events. First, FXR induces synthesis of fibroblast growth factor-19 (FGF19), which is then 
secreted into the portal circulation and acts on hepatocytes to suppress the enzyme 
cholesterol 7-α-monooxygenase (CYP7A1), the rate-limiting enzyme responsible for BA 
synthesis160. Second, FXR-activation increases expression of ileal BA-binding protein 
(IBABP) and basolateral organic solute transporter (OST) and is coupled to reduced apical 
sodium-dependent BA transporter (ASBT) expression, resulting in decreased BA intestinal 
absorption and prevention of intracellular BA accumulation161. Therefore, FXR-mediated 
mechanisms prevent the noxious effects of BA accumulation on hepatocytes and on the cells 
lining the intestinal and biliary tract154, playing a key role not only in the enterohepatic 
circulation, but also in the regulation of inflammatory responses in the liver and intestine154.  
Several work has demonstrated that besides its role on bile acid and lipid metabolism, this 
receptor is also involved in mucosal immune response. FXR exerts a number of modulatory 
and immune-regulatory effects on ileal and colonic epithelial cell lines162: 
1.! FXR has anti-inflammatory properties 
FXR is expressed in macrophages, and its activation results in the robust down-regulation of 
the expression of several IFNγ regulated genes and several inflammatory signaling 
pathways, such as the STAT3 (signal transducers and activators of transcription 3) pathway; 
however, in the setting on inflammation, FXR is down-regulated  through IFNγ (Interferon 
gamma) mediated repression mediated by STAT1 activation163. FXR-knockout mice are 
more susceptible to a model of chronic induced intestinal inflammation and present 
increased chemically-induced [trinitrobenzensulfonic acid (TNBS) or dextrane sodium 
sulfate (DSS) models)] colitis severity; conversely, the administration of an FXR agonist 





data showing that colonic inflammation down-regulates colonic FXR-expression, since 
patients with IBD present lower expression of this receptor in areas of inflamed mucosa164, 
and FXR mRNA expression was almost undetectable in colon biopsies from 
macroscopically-inflamed areas in patients with Crohn’s disease164. 
2.! FXR has a role in barrier function by regulating antibacterial growth 
FXR knockout mice (FXR-/-) mice display dysregulated immune response, compromised 
epithelial barrier, increased intestinal permeability, and increased levels of bacteria in the 
ileum and mesenteric lymph nodes. Conversely, in a model of bile duct ligation (a model of 
obstructive cholestasis similar to PSC), the resulting small intestine bacterial overgrowth, 
can be reversed by FXR agonist or by administering BA that leads to FXR activation165.  
3.! FXR may be involved in colorectal carcinogenesis 
FXR has an important role in maintaining BA concentration, thereby preventing BA-
cytotoxicity. FXR-knockout mice have an increased colorectal carcinogenesis (increased 
number of tumors and tumors size) in murine intestine tumorigenesis models: APCmin mice 
(adenomatous polyposis coli) and azoxymethane (AOM)-induced colon cancer166, through 
increased cell proliferation via promotion of Wnt signaling, and up-regulation in the 
expression of genes involved in cell cycle progression and inflammation, such as cyclin D1 
and interleukin-6166. In humans, it has been shown that FXR is down-regulated with a 
reciprocal relationship between the degree of expression and tumor stage167, 168.  
 
These data suggest that in PSC-IBD patients, colonic inflammation, in part by inactivating 
FXR-mediated mechanisms, could exacerbate the toxic effects of secondary BA on colonic 
cells. The involvement of the FXR receptor in both intestinal inflammation and 
carcinogenesis makes it an interesting target to study in colitis as well in colitis-associated 
neoplasia.  Furthermore, being the major regulator of the entero-hepatic circulation of bile 
acids, the influence of concomitant PSC in FXR’s colonic expression is of interest to study. 
 
 
RATIONAL AND AIMS 
 
Rational: The expression of FXR has been reported to be downregulated in the setting of 
colonic inflammation169, 170 and in colon adenomas and cancers of the colon162. However, 





inflammation of the colon, such as UC, and moreover in PSC-IBD; specifically, nothing is 
known about the expression of FXR with respect to the degree of inflammation (active vs. 
quiescent; mild versus severe), the location in the colon, or whether there might be 
differences between IBD and PSC-IBD patients.  Likewise, this receptor has never been 
studied in the setting of colitis-associated neoplasia (dysplasia or cancers). We hypothesized 
that the expression of FXR would be lower in mucosa that is involved with active 
inflammation, but not in mucosa with only quiescent inflammation and that FXR´s 
expression would be lower in mucosa that is involved with dysplasia and cancer compared 
to background mucosa with quiescent inflammation.   
Aim: To analyze the expression of the nuclear receptor FXR in non-neoplastic and neoplastic 
tissue of patients with IBD with, and without, PSC. 
Approach: Patients with UC, and PSC-IBD were identified from the UC-Surveillance 
Database, and from the GI Pathology database, at Mount Sinai Hospital, New York. 
Archived paraffin embedded tissues taken during surveillance colonoscopy were retrieved, 
sectioned and stained for FXR by immunohistochemistry. Expression was correlated with 
degree of inflammation, degree of dysplasia, location in the colon and disease state.  
 
Contribution of the PhD candidate: 
The candidate had the idea to study this receptor in biopsies from PSC-IBD and IBD alone 
patients. She wrote the protocol, selected samples from the pathology repository at Mount 
Sinai and performed the immunohistochemistry in collaboration with Xiuliang Bao at Mount 
Sinai. She had the idea to study methylation in cancer cell lines in relation to FXR, which 
was performed by Xiuliang Bao. She read the slides in collaboration with Professor Noam 
Harpaz, an expert GI pathologist and Dr. Alina Iuga, also a GI pathologist at Mount Sinai. 
The PhD candidate performed the statistical analysis for the project, presented the work in 
international meetings and finally wrote the paper that was published in Inflammatory Bowel 
Diseases (Impact factor: 4.5): “Farnesoid X receptor expression is decreased in colonic 
mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. 
Torres J, Bao X, Iuga AC, Chen A, Harpaz N, Ullman T, Cohen BL, Pineton de Chambrun 
G, Asciutti S, Odin JA, Sachar DB, Gaskins HR, Setchell K, Colombel JF, Itzkowitz SH. 







MATERIAL AND METHODS 
 
Case Selection 
Following approval by the Mount Sinai School of Medicine Institutional Review Board, 
patients were identified using the Mount Sinai Gastrointestinal Pathology and UC-
Surveillance databases described in previous studies171. Besides demographic information, 
clinical information and pathologic findings from colonoscopies and operations, including 
anatomic extent of disease at diagnosis, presence and grade of any dysplasia, and presence 
and severity of inflammation at each biopsied segment of colon, were recorded. Additionally, 
for the measurement of FXR expression in colitis-associated neoplasms, we analyzed 
samples in two tissue microarrays (TMAs) containing samples of colorectal neoplasia (CRN) 
from IBD patients (colorectal cancer, low and high-grade dysplasia). 
Patients with extensive UC at diagnosis, with or without PSC, were identified and their 
pathology blocks retrieved. The presence or absence of PSC was based on the results of 
serum biochemical tests and cholangiography and/or hepatic biopsy. Patients with Crohn’s 
disease and indeterminate IBD were excluded. From each patient, whenever available, 
samples from the right colon (RC) and left colon (LC) were recovered. An attempt was made 
to have samples representative of different degrees of histological inflammation.  
One hundred and twelve patients (84 males, median age 51y) were included in this study. 
There were 24 patients with concomitant PSC. All patients had extensive UC at diagnosis 
(defined by greatest microscopic extent proximal to the splenic flexure). Median disease 
duration for the patients in whom that information was available was 20±13 years (range 1- 
60y). From all these patients, 231 colonic samples (biopsy specimens, surgical samples, and 
tissue microarrays) were obtained: 155 from UC patients (62 from the RC) and 76 from PSC-
UC (39 from the RC). From 9 PSC-UC and 62 UC patients, 79 samples of CRN (19 






Figure 9 – Distribution of patients and samples per group. Samples correspond to either biopsies, 
tissue microarrays or surgical specimens. 
 
 
Histologic grading of inflammation and neoplasia  
For each non-dysplastic sample, the severity of histologic inflammation was taken from the 
pathology report. These specimens had been scored according to the histologic activity index 
(HAI) that we have previously validated and described171. The histological criteria for 
grading severity of inflammation was developed by one of the authors (N.H.) and placed 
into routine use at The Mount Sinai Hospital in 1988. These criteria have remained 
unchanged since their introduction. All reports had been issued by one of a small group of 
gastrointestinal pathologists, trained by N.H., using the narrative equivalent of a 
standardized histological activity index (HAI)172. The degree of inflammation for each 
biopsy site was scored as follows: (0) inactive/absent, (1) mild, (2) moderate or (3) 
severe171. An HAI of 0 (inactive) corresponds to inactive colitis with no cryptitis or crypt 
abscesses; an HAI of 1 (mild) corresponds to mildly active colitis with one crypt abscess; an 
HAI of 2 (moderate) corresponds to moderately active colitis with cryptitis involving >50% 
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Dysplasia was diagnosed initially as log-grade or high-grade dysplasia, by one of the authors 
(N.H.) using the criteria of the IBD Dysplasia Morphology Study Group173 and confirmed 
as a part of this study by a second GI pathologist (A.I.).  
 
Immunohistochemistry 
Immunohistochemistry for FXR was performed manually on samples and tissue microarrays 
(TMAs), using a mouse anti-human FXR monoclonal antibody (Perseus Proteomics, Tokyo, 
Japan). This antibody specifically recognizes human FXR and cross-reacts with mouse and 
rat FXR. From the formalin-fixed, paraffin-embedded tissue blocks of biopsies and 
colectomy specimens, sequential sections were cut at 4-µm thickness and mounted on 
adhesive slides. Slides were de-parafinnized in xylene and subsequently washed in graded 
ethanol (100%, followed by 95%) and re-hydrated in distilled water. For antigen retrieval, 
sections were incubated in a microwave for 30 minutes using a 0.1% sodium citrate buffer 
and subsequently washed in PBS at room temperature. Endogenous peroxidase activity was 
blocked by incubating the slides with 3% H2O2 for 10 minutes and then rinsed three times 
with PBS (Phosphate Buffered Saline). Sections were incubated for 60 minutes at room 
temperature in 2% BSA (bovine serum albumin) to avoid nonspecific signal, and then 
overnight at 4oC with the primary anti-FXR antibody. Subsequently, slides were rinsed 3 
times in PBS and treated for 30 min at room temperature with a polyclonal anti-mouse 
secondary antibody (EnVision+ System-HRP Labelled Polymer Anti-mouse - Dako, 
Denmark), and again washed three times with PBS. Slides were then incubated with 
diaminobenzidine (DAB) using the Peroxidase substrate DAB kit TM (Vector Laboratories). 
After cleansing with water, slides were counterstained with Harris modified Hematoxylin 
solution for 50 seconds, dipped in ethanol and in ammonia water, with rinse in tap water in 
between. Finally, sections were de-hydrated in 95% and 100% alcohol consecutively, 
washed with xylene and mounted with VectaMount TM (Vector Laboratories). At least one 
section with normal small intestinal mucosa was included for each run as a positive control.  
 
Evaluation of immunohistochemistry 
FXR nuclear expression was scored by two independent, experienced observers (S.I. and 





was scored as absent (0), weak (+) and strong (++). There was a 95% concordance between 
the two observers. Differences were resolved by consensus evaluation of the slides.  
 
FXR gene de-methylation experiments 
Cell Culture: 
Human liver cell line HepG-2 cells were cultured in RPMI-1640 medium (Invitrogen, CA) 
with 10% FBS (fetal bovine serum) Cell at 37°C in 5% CO2 atmosphere. Human colorectal 
cancer cell lines were cultured in DMEM (Dulbecco's Modified Eagle's medium) 
(Invitrogen, CA) with 10% FBS Cell at 37°C in 5% CO2 atmosphere. HepG-2, Caco-2, 
HCT-116, HT-2 and SW-480 cells were seeded at a concentration 1x104 cells/ml in 6-well 
cell culture plate, 2 ml/well and the following day, were treated with 0, 1 and 10 µM 5-Aza-
2’-deooxycytidine (5-Aza) (Sigma-Aldrich, MO) in fresh culture medium. 5-Aza was 
removed by replacing the medium 24 hours later. The cells were harvested 4 days after 
removal of 5-Aza for RNA extraction. 
 
Quantitative real –time PCR analysis of FXR mRNA expression: 
Total RNA was extracted using RNeasy Mini Kit (Qiagen, CA). One µg total RNA was used 
for cDNA synthesis in RNA to DNA EcoDry Premix (Double Primed) (Clontech, CA). FXR 
mRNA levels were evaluated by SYBE Green assay using advantage qPCR premix 
(Clontech, CA) and primers: 5’-GCCTGTCTCCTGGGTCGCCT-3’ (forward) and 5’-
TCCCCATCACTGCACGTCCCA-3’ located in exon 11. The mRNA level of the target 
genes was normalized to GAPDH mRNA. Primers of GAPDH as: 5’- 
ACCACAGTCCATGCCATCAC-3’ and 5’- TCCACCACCCTGTTGCTGTA-3’. All 
samples were analyzed in triplicate. 
 
Statistical analysis 
Data analysis was performed using the computer software Statistical Package for Social 
Sciences - SPSS for Mac (version 19.0). When appropriate, Fischer’s exact test, Student’s t 










FXR expression in non-neoplastic mucosa 
There were 152 samples without dysplasia from 62 patients: 66 from 22 PSC-UC patients, 
and 86 from 40 UC patients. Among the non-dysplastic samples, 70 were from 21 patients 
who had no neoplasia in the colon at the time of sampling or surgery; 82 samples were from 
patients that displayed with neoplasia elsewhere in the colon. Seventy-two samples were 
from the RC (mostly ascending colon and proximal transverse) and 80 from the LC (mostly 
sigmoid colon).  
We observed that FXR expression was higher in the RC than the LC. Overall, 32% of the 
samples from the RC demonstrated strong expression, compared to only 14% in the LC (p= 
0.011). When stratified by disease type, this difference remained statistically significant only 
for UC samples: 39.5% of the samples from the RC versus 16.7% had strong FXR expression 
(p= 0.017). In PSC-UC samples, while there was also a trend towards stronger FXR 
expression in the proximal colon (strong FXR expression in 23.5% of samples from RC 
versus 9.4% from LC), this did not reach significance (p= 0.11). Thus, FXR expression 
seems to be weaker in the left colon of patients with UC and PSC-UC. FXR expression did 
not differ according to location or disease type in samples from patients without neoplasia 
compared to those with neoplasia somewhere in the colon (data not shown). 
When we compared FXR expression to the degree of inflammation, samples with the highest 
degrees of inflammation (moderate or severe inflammation) demonstrated FXR expression 
that was almost always absent or weak in both UC and PSC-UC, regardless of colonic 


















PSC-UC (29) 22 (75.9) 7 (24.1) 
0.017 






PSC-UC (29) 26 (89.7) 3 (10.3) 
0.52 




PSC-UC (5) 4 (80) 1 (20) 
0.49 
UC (13) 12 (92.3) 1 (7.7) 
LC 
PSC-UC (3) 3 (100) 0 (0) 
0.51 
UC (18) 14 (77.8) 4 (22.2) 
 
Table 1 - Relationship between degree of FXR expression and the degree of inflammation 
according to colonic location and disease type.  
 
 
Very few of the highly-inflamed samples demonstrated strong FXR expression. With 
quiescent or mild inflammation, FXR expression was almost always absent or weak in the 
LC (87% in UC, 90% in PSC-UC), reflecting the normal distal decrease in FXR expression 
(Figure 10, E and F). In samples from the RC of UC patients, FXR expression decreased 
with higher degrees of inflammation: 56% of specimens with quiescent/mild inflammation 
had strong FXR expression, compared to 7.7% (1/13) with moderate/severe inflammation 
(p=0.005). Unexpectedly, the same pattern of FXR expression was not observed in the RC 
of PSC-UC patients: 24% of the RC samples displaying quiescent-mild inflammation had 
strong FXR expression compared to 20% of samples with moderate/severe inflammation 
(Figure 10, B and C). Indeed, the main difference between PSC-UC and UC was the finding 
that in the RC, with quiescent or mild inflammation 56% of UC samples retained strong 
FXR expression, compared to only 24% of PSC-UC samples (p= 0.017) (Table 1; Figure 
10).  
Similar to previous observations in normal colon174, we observed that FXR 
immunoreactivity presented a gradient of expression throughout the crypts, which was 
especially evident in the RC. Thus, FXR expression was stronger at the crypt surface and 







Figure 10 – FXR immunohistochemical staining of non-neoplastic mucosa.  A) Normal terminal 
ileum from patient with UC: there is strong nuclear staining in villi with gradual decrease towards 
the crypts (10x) B) RC biopsy of a patient with UC and quiescent inflammation; a strong nuclear 
positivity at the surface and upper part of the colonic glands with a gradual loss of expression in the 
crypts is seen (20x). C) RC biopsy of patient with PSC and quiescent inflammation displaying 
diminished FXR nuclear expression (20x). D) RC of a patient with UC and moderate inflammation:  
decreased FXR nuclear expression compared to uninflamed mucosa in B (20x). E) Uninflamed LC 
in a patient with UC lacking strong FXR staining (20x) F) Uninflamed LC of patient with PSC-UC 






FXR expression in neoplastic mucosa  
There were 52 colorectal cancers (CRC) (15 well differentiated; 14 moderately 
differentiated; 23 poorly differentiated), 6 high-grade dysplasia (HGD) and 21 low-grade 
dysplasia (LGD).  
Overall, FXR expression was absent in most (57/79; 72.2%) of the dysplastic and CRC 
samples. Among the samples maintaining any FXR expression, there was an inverse 
correlation with the degree of neoplasia (Figure 11). 
FXR was expressed in LGD (13/21; 61.9%), HGD (3/6; 50%), and CRC (6/52; 11.5%), 
although the difference was significant only between dysplastic samples versus cancer 














LGD (n=21) 8 (38.1%) 13 (61.9%) 0 
ns 
HGD (n=6) 3 (50%) 2 (33.3%) 1 (16.7%) 
CRC (n=52) 46 (88.5%) 6 (11.5%) 0 < 0.001 0.003 
 




No significant differences were observed according to colonic location of the neoplasm, or 
between UC and PSC-UC patients (data not shown). In the CRC samples that retained some 







Figure 11 - Examples of FXR staining in colitis-associated neoplasia. A) LGD showing retained 
FXR nuclear expression (20x) B) High power image of a focus of LGD highlights nuclear FXR 




In Vitro Studies with Colon Carcinoma Cell Lines 
Hep2G cell line is a human liver cancer cell line, while Caco-2, SW480, HT-29, and HCT-
116 are CRC cell lines. We wanted to assess FXR expression in colon versus liver cancer 
cell lines, and also to study the potential effect of DNA methylation as mechanism for FXR 





demethylation agent. We found that, compared to HepG2 cell line, FXR expression at the 
mRNA level was very low, and was undetectable by western blot in all 4 CRC cell lines. 
While there were no significant changes in FXR mRNA expression in Caco-2, SW480 and 
HepG2 cells after treated with 5-aza (Figure 12), in HCT-116 and SW480 cells, 5-aza 









The involvement of the FXR nuclear bile acid receptor in both intestinal inflammation and 
carcinogenesis makes it an interesting target to study in colitis and in colitis-associated 
neoplasia.  Furthermore, being the major regulator of the entero-hepatic circulation of bile 






A recent study showed that there was no difference in ileal and ascending colon FXR mRNA 
expression between controls, CD, and UC patients in remission175.  However, the distribution 
of FXR throughout the colon of patients with UC, or the regional distribution and relation to 
inflammation in PSC-UC patients had not previously been reported. In UC patients, we 
observed a distal decrease in FXR expression, with a stronger expression in the RC samples 
as compared to the LC samples. This pattern of distribution had already been described in 
normal subjects, and proposed to occur in parallel with the proximal-distal gradient of bile 
acid flow along the colon174. However, when we stratified by disease type, we observed 
decreased FXR expression in samples from the RC of PSC-UC patients.  
Since FXR has been shown to be down-regulated in the presence of intestinal inflammation, 
we also analyzed results according to the degree of histologically active inflammation. 
Perhaps not unexpectedly, we observed that with more severe inflammation, FXR expression 
was usually absent or weak, independent of location or disease type. With quiescent/mild 
inflammation, FXR expression was also typically weak/absent in both UC and PSC-UC 
patients if the tissue sample was from the LC, reflecting the normal distal decrease in FXR 
expression. Interestingly, with little or no inflammation, the RC of UC patients retained the 
normal pattern of rather high expression of FXR, but the RC of PSC-UC patients did not. 
Thus, PSC-UC patients appear to lose FXR expression in the RC even without much 
inflammation.  
There are data implicating FXR as a tumor suppressor gene176. FXR is decreased in human 
sporadic CRC with an inverse correlation between the degree of expression and tumor stage 
162, 174. Furthermore, FXR-/- mice have been shown to have increased intestinal 
carcinogenesis, increased cell proliferation via promotion of Wnt signaling and up-regulation 
in the expression of genes involved in cell cycle progression and inflammation, such as 
cyclin D1 and interleukin-6166. The expression of FXR in the different stages of colitis-
associated neoplasia had not yet been described. We herein observed that there was an 
inverse correlation within the neoplastic sequence in colitis-associated carcinogenesis, with 
complete loss of FXR expression in 38%, 50%, and 88.5% of LGD, HGD and colitis-
associated cancers, respectively. FXR expression in the non-neoplastic adjacent mucosa did 
not present a similar pattern of expression (data not shown) and therefore, it is likely that 
FXR down-regulation occurs during neoplastic transformation from LGD, to HGD and 





We additionally sought to explore the potential role of DNA methylation as a molecular 
mechanism of down-regulation of FXR mRNA expression in colorectal cancer cell lines. 
DNA methylation is associated with histone modifications and the interplay of these 
epigenetic modifications is crucial to regulate the functioning of the genome by 
changing chromatin architecture177. The covalent addition of a methyl group occurs 
generally in cytosine within CpG dinucleotides which are concentrated in large clusters 
called CpG islands in the promoter region of some genes177.  It is commonly known that 
inactivation of certain tumor-suppressor genes occurs as a consequence of hypermethylation 
within the promoter regions. Indeed, DNA methylation is a common mechanism occurring 
in the development and progression of sporadic CRC, which may also have a role in colitis-
associated neoplasia178. Putative CpG islands within the promoter and the fourth exon of the 
human FXR gene have previously been described179. We observed that while in Caco-2, HT-
29 and HepG2 cell lines there were no changes in FXR mRNA expression after 5-aza 
treatment, in HCT-116 and SW480 cells, 5-aza treatment resulted in dose-dependent 
increases in FXR mRNA expression. This suggests that loss of expression of FXR in colonic 
cells may be regulated, at least in part, by gene silencing by DNA hypermethylation. 
Bearing in mind the role of FXR in colorectal carcinogenesis, it is tempting to suggest that 
FXR’ down-regulation observed in PSC-UC samples could explain, in part, the high risk of 
right-sided CRN in these patients, even in the presence of quiescent to mild inflammation.  
There are data suggesting that during cholestatic liver disease, such as PSC, intestinal BA 
absorption is reduced which could lead to a relative increase of BA in the proximal colon, in 
turn producing heightened conversion of primary bile acids into secondary, more 
carcinogenic, bile acids 180, 181. Down-regulation of FXR could therefore expose colonocytes 
to high levels of secondary bile acids or other toxic products, increasing carcinogenesis risk.  
 
Our study had some limitations. Although a large number of samples were studied overall, 
the difference of FXR expression in the RC of PSC-UC patients was based on a somewhat 
small sample size. These findings should be confirmed in other studies. In addition, as a 
descriptive, retrospective immunohistochemical study on archival tissue, our study does not 
allow us to draw any mechanistic conclusions, such as whether low FXR expression results 
from FXR down-regulation or from post-transcriptional events modulating FXR expression.  
Further research is required to elucidate the underlying mechanisms for FXR down-





the terminal ileum occurring during cholestasis or the reduced bile acid secretion occurring 
in PSC, could lead to a secondary feedback down-regulation of colonic FXR; this would 
make more sense in advanced disease but unfortunately no data about PSC stage or serum 
bilirubin levels amongst the UC-PSC group was available.  
Recent animal experiments have shown that activation of FXR in the intestine protects the 
liver from cholestasis by reducing the hepatic pool of bile acids182. Failure to activate FXR 
or constitutive down-regulation of FXR could therefore exacerbate PSC and hepatic 
cholestasis by increasing bile acids levels within hepatocytes. In a recent study, 2,355 IBD 
patients (1,193 with UC) and 853 controls were genotyped with seven tagging SNPs and two 
functional SNPs for FXR. None of the SNPs was associated with the presence of IBD; 
however, no information or sub-analysis for patients with PSC-UC was provided175. 
Ongoing183 and future GWAs in PSC will probably shed some light on the role of FXR and 
other nuclear receptors and their role for PSC development and progression. It is apparent 
that the cross talk between the liver and the colon in PSC-UC patients has yet to be explored 




































THE FEATURES OF MUCOSA-ASSOCIATED MICROBIOTA IN 
 PRIMARY SCLEROSING CHOLANGITIS ASSOCIATED WITH 















The human microbiome is defined as the collection of organisms and their genomes 
inhabiting different locations and habitats, and includes not only bacteria but also viruses, 
archaea and fungi184. It is now known that our microbiome is crucial to our health and well-
being185. The number and variety of bacteria exponentially increase from the proximal to the 
distal gastrointestinal tract, with the colon harboring most of the gut microbiota185.  The 
human colon alone contains around 1011-1012 different bacterial species, with anaerobic 
bacteria contributing 99% of the total diversity186. It is estimated that there are 100 times 
more bacterial genes in our body than human genes.  
Colonization with commensal organisms begins shortly after birth on exposure to vaginal 
microbiota, and some authors have even hypothesized that bacterial colonization may start 
in utero185, 187. During the first years of life the developing microbiome is very dynamic and 
sensitive to environmental incursions, being formed as infants are introduced to new flora 
through breastfeeding, introduction of solid food, etc. After the first 2 to 3 years of life the 
microbiome acquires an adult-like configuration and it becomes more resilient to change and 
more stable188. Several factors are known to influence the gut microbiome composition such 
as antimicrobials, sanitation, vaccination, diet, and disease186.  
Intestinal microflora is essential for host wellbeing by virtue of their participation in immune 
and metabolic functions. For example, our gut bacteria are responsible for degradation of 
complex polysaccharides with subsequent production of short-chain fatty acids, which 
contribute to salvage of nutrients and to the integrity of the epithelial layer. The flora also 
have a role in preventing colonization of harmful pathogenic species, and they can 
participate in the detoxification of various carcinogens such as heterocyclic aromatic amines 
and polycyclic aromatic hydrocarbons189. Importantly, our gut flora has a major role in the 
mucosal immune system development and maturation. Indeed, while our immune system 
impacts microbiome composition and activity, the microbiome itself also modulates both 
innate and adaptive immune responses at the mucosal interfaces190. The interaction of our 
microbiome with the immune system results in several processes such as the as the secretion 
of secretory IgA and the release of endogenous antimicrobial peptides, as well the 
differentiation of T helper cells, especially TREG (T regulatory cells) and Th17 cells (T helper), 
among others190186.  Changes in the bacterial communities in the gut have been associated 





bowel diseases184, although it is not clear whether these changes are cause or consequence 
of disease status. 
 
The 4 predominant bacterial phyla in our gut are Firmicutes, Bacteroidetes, Actinobacteria, 
and Proteobacteria, followed by archaea, viruses, and fungi185. Most the bacteria present in 
our gut are non-cultivable or slow-growing, and therefore, for many years our knowledge 
about the microbiota was hampered by the limitation of traditional microbiological 
techniques in defining its complexity and diversity. However, in the last years the field of 
microbiome has witnessed major advances due to the development of high-throughput next-
generation sequencing (NGS). One of the most commonly used NGS methods is the 
sequencing of 16s rRNA gene. The 16s rRNA gene is an evolutionary conserved gene 
amongst all bacterial species. It has hypervariable (the most commonly used being the 
V1–V3, V4, and V4–V5 regions) and conserved regions.  Polymerase chain reaction (PCR) 
primers targeting broadly conserved regions of the 16S gene are used to amplify the 
microbial species, distinguishing  bacterial from human DNA, while the sequencing of the 
hypervariable regions can be used to distinguish among bacterial genus/species191. After 
sequencing, the analysis of the 16S data involves assigning the DNA sequences to a given 
species, using the reference data from available libraries (eg: Greengenes, RDP, SILVA). 
The sequencing of the 16s rRNA gene generates usually thousands of reads.  However, it 
is incorrect to assume that each unique read represents a different species: mutations and 
sequencing errors can lead to slightly different amplicon sequences within a species. 
Because not all DNA sequences match 100% the genomic sequencing and therefore can 
be confidently assigned to a given species, a new term has become common in taxonomy—
the operational taxonomic unit (OTU)—which is used to characterize a group of microbes 
that share a certain level of 16S rRNA sequence homology191, 192. Generally, a 97% identity 
cutoff is typically used as an approximation of genus/species-level resolution; that is, 
sequences that share more than 97% similarity are assigned to an operational taxonomic unit 
(OTU) that is then classified to known bacteria193. After assigning reads to a taxonomic 
classification, several pipelines for data analysis exist, allowing the ecological 
characterization of a microbial community. 
 
Multiple clinical and experimental observations, support a central role for the gut microbiota 





characterized by a decrease in species diversity, altered bacterial function and aberrant 
bacterial communities in the gut, with a decrease in beneficial taxa namely in Bacteroides 
and Firmicutes (and specifically in bacteria from the Clostridium cluster XIVa and IV), and 
an increase in Proteobacteria195. The descriptions of dysbiosis in first-degree relatives of 
IBD patients or in unaffected twins of IBD probands196, 197, and the presence of circulating 
antimicrobial antibodies in the blood of patients many years before diagnosis17, 198, further 
suggest a primary role for the gut microbiota in determining disease risk; however, whether 
IBD gut-associated dysbiosis has a primary role in disease initiation and expansion, or 
merely reflects chronic inflammation, has so far been difficult to prove in humans194. 
Interestingly, it has been demonstrated that IBD patients present altered BA metabolism 
(dysmetabolism): patients with IBD present lower fecal and serum secondary BA 
proportions in comparison to healthy controls, due to a dysbiosis with a decrease in bacteria 
bearing BA hydrolase activities199.  
 
PSC could also potentially be associated with a specific gut flora. Some data from basic and 
clinical studies support the hypothesis that the intestinal microbiota may have a role in 
disease pathogenesis200, 201. For example, animal models of surgically-induced small 
intestinal bacterial overgrowth develop abnormalities in the intra- and extra-hepatic bile 
ducts that resemble PSC by cholangiography and histology200. The improvement of liver 
enzymes following a trial of antibiotic therapy, and a recent case reporting laboratorial and 
histological abnormalities reversal following vancomycin treatment in a liver transplant PSC 
recurrence, also suggest a role for the gut flora in disease pathogenesis72, 202, 203. With the 
advent of culture-independent techniques, a better understanding of how the gut microbiome 
can affect and modulate the development of liver diseases has emerged. Indeed, microbiota 
alterations in cirrhosis are now well-documented204. Being a cholestatic liver disease with 
profound alterations in bile acid pool205, and acknowledging the reciprocal relationship 
between gut flora and bile acid metabolism80, 206-208, it is very likely that patients with PSC-










RATIONAL AND AIMS 
 
Rational: It is plausible that different microbial communities could be associated with PSC-
IBD as compared to IBD, and that this altered mucosal microbiome could contribute to their 
specific phenotype. 
Aim: To explore whether different microbiomes across different colonic locations could be 
associated with the special phenotype of PSC-IBD, including more right-sided 
inflammation. 
Approach: Patients with IBD and with PSC-IBD ongoing colonic surveillance at Mount 
Sinai Hospital and Chicago University were recruited and consented for biopsy collection 
for microbiome study.  
 
Contribution of the PhD Candidate 
The PhD candidate wrote the protocol and applied for funding while she was at Mount Sinai 
in 2011. She developed the standard operating procedures for the protocol, recruited patients 
and samples. When she came back to Portugal in 2012 the protocol was integrated in the 
SHARE (Sinai-Helmsley Alliance for Research Excellence Network) research alliance and 
the recruitment of patients and samples continued up to 2015 which coincided with the 
candidate´s return to Mount Sinai. She was therefore able to go on with the protocol and 
finalize the study. She participated in the DNA extraction from the samples; supervised by 
Professor Hu she learned how to handle the data analysis, calculate diversity analysis and 
other metrics in microbiome analysis, and therefore participated in the bioinformatics 
analysis. In conjunction and with the supervision of Professor Jianzhong Hu and Professor 
Steven H. Itzkowitz she wrote and published the paper which was published in Alimentary 
Pharmacology and Therapeutics journal (Impact Factor: 7.286): “The features of mucosa-
associated microbiota in primary sclerosing cholangitis. Torres J, Bao X, Goel A, Colombel 
JF, Pekow J, Jabri B, Williams KM, Castillo A, Odin JA, Meckel K, Fasihuddin F, Peter I, 










MATERIAL AND METHODS 
 
Subjects and sampling 
Between November 2011 and November 2014, patients with PSC, patients with IBD and 
healthy controls undergoing colonoscopy at the Mount Sinai Medical Center and at the 
University of Chicago, were prospectively recruited, within a collaborative multicenter 
program for integrated studies in IBD (Sinai-Helmsley Alliance for Research Excellence 
(SHARE) Network). Sample collection protocol was standardized across two institutions to 
avoid possible bias during sample collection and processing. The inclusion criteria were age 
greater than 18 years, confirmed diagnosis of PSC based on histology and/or abnormal 
cholangiogram (ERCP or MRCP), and confirmed diagnosis of IBD by conventional 
endoscopic and histological criteria209. Patients with a personal history of colectomy, a 
diagnosis of secondary sclerosing cholangitis, or concomitant infectious colitis at the time 
of colonoscopy were excluded. Patients with newly diagnosed PSC, who were scheduled for 
their initial colonoscopy to screen for IBD, and healthy controls undergoing screening 
colonoscopy, were also recruited.  
Demographical and clinical information were recorded for every patient. During 
colonoscopy, disease severity was recorded [Mayo score for UC and SES-CD (simple 
endoscopic score for CD) for CD], and biopsies for colorectal neoplasia screening were 
obtained, according to current guidelines. On all subjects, biopsies were collected from the 
left colon (LC) for microbiota analysis, and in a subset of patients, biopsies were also 
collected from the terminal ileum (TI) and right (RC) for comparison of the microbiota 
features across different colonic locations. Biopsies were either snap frozen or stored in 
RNAlater® (Qiagen, Valencia CA) for subsequent analysis. All samples were analysed at 
Icahn School of Medicine at Mount Sinai, New York. 
 
Tissue DNA extraction and 16S ribosomal RNA (rRNA) amplification 
Tissue samples were transferred into bead tubes (MO-BIO, Carlsbad, CA) and homogenized 
using bead beating method. Homogenized tissue samples were further processed using the 
Qiagen DNeasy Blood & Tissue Kit following the manufacturer’s protocol (Qiagen, 
Valencia, CA). Total DNA concentration was determined with Qubit 2.0 Fluorometer (Life 
Technologies, Norwalk, CT). The phylogenetically informative V3-V4 region of 16S 





primers were synthesized by IDT (Integrated DNA Technology, Coralville, IA). We used a 
dual-barcoding approach to label the 16S rRNA amplicons from each sample as described 
previously. Briefly, the 6-mer barcodes were attached on the 5’ ends of both forward and 
reverse PCR primers so that 16S rRNA PCR amplicons from each sample contained a unique 
dual barcode combination. The 16S rRNA amplicons were further pooled with equal 
molarity and submitted for MiSeq 2x300 pair-end sequencing at high depth. The paired 
sequence readings were merged and filtered by size (>400bp) and quality score (>Q30) using 
CLC genomics workbench version 7. The processed readings were further split by dual 
barcode for each sample and assigned taxonomic classification using QIIME (quantitative 
insights into microbial ecology) pipeline 1.8.0211. Repeated measurements of the same 
sample were made to assess sequencing reproducibility. After processing, QIIME provided 
detailed operational taxa unit (OTU) tables containing the microbiota composition and 
abundance for each individual sample. 
 
Metagenomic 16S rRNA data analysis 
Microbial diversity is usually described in terms of within (alpha-diversity) and between 
(beta-diversity) samples diversity. Both terms were introduced by Whittaker in 1972 to 
describe ecological metrics in a community212. Broadly speaking the alpha-diversity can be 
defined as the species richness212. It can be characterized using the total number of species 
[(species richness: eg. Chao1 index, OTU total abundance, or Phylogenetic Diversity (PD)] 
or the relative abundances of the species (species evenness: eg. Shannon index), or indices 
that combine these two dimensions212. The beta-diversity metrics provides a measure of the 
degree to which samples differ from one another, or in another words, the overall bacterial 
composition of a bacterial community. It can reveal aspects of microbial ecology that are not 
apparent from looking at the composition of the individual samples. Beta-diversity measures 
can be quantitative (using sequence abundance, e.g., Bray-Curtis or weighted UniFrac) or 
qualitative (considering only presence-absence of sequences, e.g., binary Jaccard or 
unweighted UniFrac) 213. Second, they can be phylogeny based (the UniFrac metrics) or not 
(Bray-Curtis, etc)213. Usually beta-diversity measures are visualized using ordination 
techniques, in non-metric multiple dimensional scaling (nMDS) plots or in principal 
component analysis (PCA) or principle coordinates analysis (PCoA) graphs, that allow to 
reduce the dimensionality of the microbiome data sets so that a summary of the data can be 





In this study, to characterize the gut microbiota, firstly the overall microbiota dissimilarities 
among all samples (beta-diversity), were accessed using the Bray-Curtis distance matrices 
and visualized by non-metric multiple dimensional scaling (nMDS) plots. The 
PerMANOVA test214, with the maximum number of permutations = 999, was performed 
using the [Adonis] function of the R package vegan 2.0-5215, 216 to test the significance of the 
overall microbiota differences between groups by PSC and IBD status. Secondly, the 
diversity of the microbial community within each sample (alpha-diversity), was measured 
using the Shannon Index as a metric to represent the species diversity217. Next, significant 
differential taxa features at the family and genus levels were selected using random forest 
algorithm, a supervised machine learning approach, using R package rfPermute and 
confirmed by Boruta feature selection (R package Boruta)218, 219. Only features that were 
consistent in both analyses were selected. The significance of the selected taxa was further 
tested by t-test. In addition, at the OTU level, we performed the log likelihood ratio test 
(QIIME command group_significance.py using g-test statistics) to further identify 
significant differential OTUs between PSC and the healthy controls using LC samples only. 
The resulted p-values were adjusted by the FDR (false-discovery rates) methods. We also 
compared the PSC vs. IBD-only at LC, RC and TI locations using the differential OTUs 
selected from LC samples. 
 
Blautia-specific long 16S rRNA sequencing  
Long 16S rRNA reads can further improve the taxa OTU inference220, 221. Therefore, we 
designed a 16-base-barcoded 404F/1263R primer pairs specifically for the Blautia genus 
based on 16S rRNA reference sequence of the Blautia genus (Supplementary Table 1). The 
~860 bp-sized PCR amplicons were pooled for sequencing on the PacBio RS II. Sequencing 
data from PacBio was processed using the manufacturer provided program smrtanalysis 
v.2.1.1 (https://github.com/PacificBiosciences/SMRT-Analysis/). Circular 
consensus sequencing (CCS) reads were then filtered by size (>800bp) and the quality score 
(>Q30) using CLC genomics workbench version 7. After split by barcode for each sample, 
all filtered reads were processed using QIIME pipeline 1.8.0222. The generated OTUs were 
filtered to only keep OTUs assigned to the Blautia genus and with more than 100 counts of 
reads.  We performed the G-test of independence222 to determine whether Blautia OTU 
presence/absence is associated with PSC status at LC samples only, in which we combined 





Representative sequences from significantly differential Blautia OTUs were further aligned 
with the Blautia reference sequences to construct the maximum likelihood phylogenetic tree 
using UPGMA (unweighted pair group method with arithmetic mean) method and 






Between November 2011 and November 2014, 46 patients were enrolled at both centres: 20 
with PSC (19 of which had concomitant IBD), 16 with IBD and 10 healthy controls. There 
were 27 males (61%) and the median age for the whole population was 47 years (IQR 33.5, 
58). The mean age of each group was as following: 43.8 years for healthy controls, 50.3 for 
the IBD group, and 45.3 for the PSC group. No patient was on antibiotics at the time of 
colonoscopy.  
 Samples from two subjects (one IBD patient and one healthy control) were eliminated from 
further analysis due to over-contamination (>90% relative abundance) with Escherichia 
coli). Therefore, 44 patients were included in the final analysis: 20 patients with PSC (19 
with PSC-IBD and one with PSC-only), 15 patients with IBD and 9 healthy controls (Table 
3). 
 
 PSC (n=20) IBD (n=15) 
Male (n, %) 16 (80%) 9 (60%) 
Age (y) 
Median, (IQR) 



























Extent of IBD 
UC/IBDU 
Extensive colitis – 100% 
UC 
Extensive colitis- 12 
(92%) 
Left colitis – 1 (8%) 
CD 




Colonic disease: 2(100%) 
PSC duration; median years 
(IQR) 
4 (2, 12.3) - 
IBD duration, median years, 
(IQR) 
9 (4.8, 18.9) 9 (4.75, 22) 
PSC Mayo score*, median, 
(IQR) 
0.03(-0.63, 0.42) - 































Table 3 - Clinical characteristics of PSC and IBD (the patient presenting PSC-only was included 
in the PSC group together with PSC-IBD). *The PSC Mayo score is a model that estimates patient 
survival in PSC including reproducible variables (age, bilirubin, albumin, aspartate aminotransferase, 
and history of variceal bleeding)223; it could not be calculated in two patients due to lack of 





by the subjective impression of the physician performing the colonoscopy into mild or moderate 
inflammation (the median CD-SES for the patients with CD in this study was 11.5, IQR 10-13). IQR: 
interquartile range; IBDU: inflammatory bowel disease unclassified; UC: ulcerative colitis; CD: 
Chron´s disease; SES-CD: simple endoscopic score for CD; 5-ASA: 5-aminosalycilates. 
 
 
Biopsies from different colonic locations (TI, RC and LC) were available in 18 subjects (11 
with PSC, 6 with IBD-only and 1 with PSC only), except for two cases, where the TI could 
not be intubated. The clinical characteristics of PSC and IBD patients are described in Table 
3. The patient with PSC-only was analysed in the PSC group. One of the PSC-IBD patients 
had a history of liver transplant and another had a history of choledochojejunostomy for a 
dominant stricture. There was no history of colon surgery among any of the participants.   
 
Samples 
16S rRNA amplicons from 81 samples (44 LC, 18 RC, 16 TI and 3 technical repeats) were 
sequenced and a total of 9.3 million reads were generated after filtering by size and quality, 
as described in the methods section. On average, each sample contained ~110,000 reads. The 
repeated measurements showed Pearson correlation to be 99% at the genus level. We used 
the mean of the repeated measurements for further analysis.  
 
The mucosa-associated microbiota is stable across different locations within each 
individual 
Considering the distinct phenotype of more inflammation and a higher prevalence of 
neoplasia in the right colon observed in PSC-IBD patients, we specifically assessed if there 
were any differences in the spatial distribution of the mucosa-associated microbiota between 
the RC, LC and TI. Therefore, we compared the microbiota composition at three biopsy 
locations in the 18 subjects, from whom multiple locations were available. Our results  
(Figure 13 A) showed that although a few samples from the same subjects showed 
substantial variations, in general, the overall microbiota was consistent across all three 
sampling locations. The distance across locations within the same subject was significantly 
smaller than the distance between samples from the same location but from different subjects 





differences in the species richness (measured by the Shannon index) were observed between 





Figure 13 – Microbiota profiles across multiple biopsy locations. (A) The overall microbiota 
dissimilarities between samples are compared. Dissimilarities were measured by distance metrics 
(Bray-Curtis) and visualized using non-parametric multidimensional scaling plot. The closer a dot is 
to the other, the closer, the less dissimilar those samples are in relation to the others. Each color 
corresponds to a single subject and the lines are linking the multiple sampling locations from the 
same subject. Insert at lower left corner shows the mean and variance of the distance between (beta-
diversity) and within (alpha-diversity) the samples from the same or different subjects. Triangles 
represent PSC patients; Circles represent non-PSC, IBD patients. It can be concluded that there are 












































































































































locations. (B) The boxplots show the alpha-diversity calculated using the Shannon index, in the three 
different locations between patients with and without PSC. As it can be seen there are no significant 
difference across multiple locations. 
 
PSC associated left colon mucosa microbiota features 
Observing that there were no overall differences in the microbiota diversity between TI, RC 
and LC, we next analyzed the microbiota composition only in the LC of all subjects. The 
overall microbiota dissimilarities among all 44 LC samples (20 PSC, 15 IBD patients and 9 
healthy controls) grouped by PSC and IBD status were accessed using the Bray-Curtis 
distance matrices (Figure 14 A). 
 
 
Figure 14 – Overall microbiota dissimilarities between samples grouped by PSC and IBD 
status, only in the samples from the left colon, representing all individuals in the study. 
Dissimilarities were measured by distance metrics (Bray-Curtis) and visualized using non-parametric 
multidimensional scaling plot. Although a separation in the different clusters can be seen, no 
significant differences were found between groups by the PerMANOVA test, using 999 









































































































































community (alpha-diversity) calculated using the Shannon Index, between different disease status. 
No significant differences were seen neither at the family or genus level. (C) Taxonomic groups 
selected by random forest algorithm to be differentially expressed among groups are represented and 
the log of their relative abundance is plotted at the family (top panel) and genus (bottom panel) level. 
In the top panel, the bacterial family Barnesiellaceae is significantly enriched in PSC as compared 
to healthy controls. In the bottom panel it can be seen that the genus Blautia and an unidentified 
genus from the Barnesiellaceae is also significantly enriched in PSC as compared to healthy controls. 
The asterisk indicates the p-value <0.05 between PSC and healthy controls. In green are represented 
the samples from non-PSC IBD patients; in blue the samples from PSC patients and in pink the 
samples from healthy controls. 
 
 
Although we noticed a separation between the healthy control and the IBD or PSC-IBD, the 
PerMANOVA test did not find a significant difference in the global LC microbiota profile 
by disease status.  We also did not observe a significant difference among controls, IBD and 
PSC samples in species richness using Shannon Index (Figure 14 B). At the taxa level, two 
families including Barnesiellaceae and Alcaligenaceae, as well as two genera including 
Blautia and an unidentified genus from Barnesiellaceae family were selected by random 
forest algorithm using R package rfPermute and confirmed by Boruta feature selection (R 
package Boruta) (Figure 14 C). Among those selections, we observed significant 
enrichment of Barnesiellaceae family and its further assigned unidentified genus (mean 
abundance=1.3% in PSC samples, 0.48% in IBD and 0.16% in healthy controls; p-
values=0.44, 0.025, respectively by t-test) and Blautia (mean= 4.5% in PSC samples, 2.9% 
in IBD and 2.1% in healthy controls; p-values=0.22 and 0.02, respectively by t-test) in PSC 
samples compared to healthy controls. To test whether or not the PSC-associated taxa 
features found in LC were consistent in the RC and TI, we further compared the abundance 
of Barnesiellaceae family and Blautia genus at three locations in the available samples from 
these locations. We found that not only did the enrichment of both taxa in PSC patients occur 
in all locations, but also that the abundance of those taxa was consistent across multiple 







Figure 15 - The relative abundance of the Barnesiellaceae family and the Blautia genus in PSC 
and non-PSC-IBD at multiple locations. The boxplots (left panel) show the mean and variance of 
the relative abundance in the left, right colon and terminal ileum between PSC and no-PSC IBD. In 
the right panel the dot plots show the relative abundance for each individual samples and the lines 
link the samples from the same subject. Green: non-PSC IBD; blue: PSC  
 
 
Further analysis excluding the patients with PSC with an history of OLT and an history of 





We then assessed whether there were any differences in microbiota composition according 
to PSC severity score. Based on the ranked PSC Mayo score, the PSC patients were assigned 
to low risk (Mayo score <0), intermediate risk (Mayo score from 0-2) and high-risk score 
(Mayo score>2). There were no patients with severe disease; however, among the low and 
intermediate risk, groups had a similar global microbiota composition (Figure 16 A) and 
taxa richness (Figure 16 B). At the taxa level, the level of Blautia was not different between 
the two different Mayo score risk groups.  The low risk group showed higher median level 
of Barnesiellaceae family compared to the intermediate risk group (Figure 16 C), but this 
did not reach statistical significance. 
  
 
Figure 16 - Microbiome profiles and PSC disease severity. (A) The overall microbiome 
dissimilarities (beta-diversity) between samples with low-risk severity and intermediate risk severity 
as assessed by the PSC Mayo score are compared. As it can be seen there are no significant 
differences in the overall microbiome composition in patients with low or intermediate risk for liver 
disease progression. (B) The boxplots show the mean and variance of the richness of the microbial 































































































disease severity. (C) The boxplots show the mean and variance of the relative abundance of Blautia 
and Barnesiellaceace in patients with low-risk and intermediate risk PSC. 
 
 
Differential OTUs by PSC status 
We performed de novo OTU picking using QIIME pipeline. Based on the 97% similarity of 
the 16S rRNA sequencing reads, all sequencing reads were clustered into individual OTUs. 
After removing rare OTUs (relative abundance < 0.1% in all samples), we compared 2439 
OTUs and selected 80 and 15 OTUs significantly (p<0.05 by parametric t-test, not adjusted) 
different between PSC, healthy control or IBD (Supplementary Figure 1 and 
Supplementary Table 2).  
We found that when compared with healthy controls, most of the PSC-associated shifts in 
the bacterial composition were observed in the Clostridiales and Bacteroidetes orders, with 
86% in the former order. In agreement with our above findings, several PSC-enriched OTUs 
belonged to the Blautia genus and the Barnesiellaceae family. When compared to IBD, 
many OTUs were from the Blautia genus. Similar enrichments and reductions at the PSC-
associated OTUs selected from LC samples (Supplementary Figure 2) were observed in 
RC and TI locations. 
 
Differential OTUs at Blautia genus between PSC and non-PSC by long-read 16S rRNA 
sequencing 
Our results showed that both Barnesiellaceae and Blautia genus were enriched in PSC 
patients. But unlike Barnesiellaceae, Blautia comprised >2% of the entire microbiota 
regardless of the disease status, so it is plausible to specifically enrich this genus and further 
use the long 16S rRNA reads to perform additional taxa OTU inference at Blautia genus in 
both patient and control samples.  After processing, 2967 OTUs were assigned to Blautia 
genus. Among those, 135 OTUs had reads of more than 100 counts. The G-test of 
independence further selected 7 out of 135 OTUs significantly different between PSC and 
non-PSC (unadjusted p-values<0.05). We aligned those Blautia OTUs with Blautia 
reference sequences and constructed the maximum likelihood phylogenetic tree using 
UPGMA method (Supplementary Figure 3).  
We also performed the pair-wise sequence alignment comparison and showed the number 





Figure 3 A). Our results showed that 4 OTUs (denovo17640, denovo28452, denovo13317, 
denovo6236) were enriched and 3 OTUs (denovo25871, denovo781, denovo18792) were 
reduced in PSC samples (Supplementary Figure 3 B). We also found that the OTUs 
denovo17640, denovo13317 and denovo28452 showed >99% percent identity to reference 
strains from species of Blautia wexlerae, Ruminococcus obeum and Blautia faecis, 





Herein we compared the mucosa-associated bacterial flora of patients with PSC to IBD alone 
and to normal subjects. Because fecal microbiota does not necessarily reflect the mucosa-
associated microbiota39, 224, we chose to examine the mucosa-associated microbiota, rather 
than stool, to gain more insight into the unique phenotype of PSC-IBD patients who tend to 
develop more right-sided inflammation, and more often proximal neoplasia as compared to 
IBD alone patients. We thought there might be some differences in the microbiota 
composition throughout different locations of the ileo-colon in this specific clinical context, 
given the phenotypic associations with disease location for PSC64. However, and in line with 
previous observations in healthy subjects225, no significant site-specific differences in the 
microbial composition were found throughout the colon. Although this analysis may have 
been limited by sample size, it is possible that other mechanisms may be operating and 
interacting differently with the microbiota in the right as opposed to the left colon226 in 
patients with PSC and IBD. Rossen et al227 in a prior study, also described similar 
hierarchical clustering between samples from the TI and RC from the same subject from 
between PSC, IBD and healthy controls. However, no comparisons with the mucosa-
associated from the left colon were available. The same authors described a lower diversity 
and abundance of uncultured Clostridiales II at the genus level compared to UC and healthy 
controls. However, this study, was limited by a smaller sample size and, by the use of a 
probe-based approach, the HITChip227, 228 that only allows to detect phylotypes present in 
the chip at the genus-like level. Our study, using a longer read 16S sequencing, allowed us 
to provide deeper taxonomic analysis that could inform on specific microbiome shifts 
associated with PSC. Another recently published study229, assessing differences in microbial 





diversity between PSC-IBD and UC, however different geographical provenience of 
samples was the main driver for microbial composition in this study. We observed a trend 
in the compositional dissimilarity of the overall microbiota between healthy controls, and 
PSC-IBD, but this did not reach statistical significance.  This could be due to the modest 
sample size, underrepresentation of healthy controls, and disease remission for most of the 
IBD patients, since shifts in the microbiota can vary according to disease activity230. Using 
bacterial 16S rRNA next-generation sequencing, we found, across all colonic locations, a 
consistent PSC-enrichment in Blautia and Barnesiellaceae genera and shifts under the 
Clostridiales, and less frequently under the Bacteroidales order in comparison with healthy 
controls. Deeper taxa analysis at the OTU level was consistent with these findings, also 
showing several enriched OTUs particularly from Blautia and Barnesiellaceae genera. 
Specifically, around 86% of the relative changes in the microbiota at the OTU level occurred 
within the Clostridiales order. This is interesting, as shifts in these taxa have been observed 
both in IBD and in cirrhosis206, 231. Bacteroidetes species play an important role in protein 
metabolism232 as well in bile acid deconjugation233. The Clostridiales order encompasses 
bacteria from Lachnospiraceae family, Ruminococcaceae family and Blautia genus, which 
can perform 7α-dehydroxylation208, an important step in converting primary to secondary 
bile acids in the intestine. Furthermore, it has been demonstrated that certain Clostridum spp. 
can affect number, function and differentiation of colonic Treg cells, therefore playing a 
crucial role in colonic homeostasis234. In advanced cirrhosis, a shift in the gut flora towards 
the enrichment of Enterobacteriaceae and the reduction of Clostridiales and Bacteroidetes 
in parallel with a reduced level of fecal secondary bile acids has been described206. 
Conversely, Islam and colleagues showed that feeding animal models with bile acids leads 
to an enrichment of colonic bile acids, which in turns results in the expansion of the 
Firmicutes phylum, specifically within the Clostridia class, with Blautia spp expanding 
significantly235. Being a cholestatic liver disease, characterized by scarring of the bile ducts, 
PSC is expected to lead to a reduction of the flow of bile acids from the liver to the intestine, 
at least in the more advanced stages of the disease. However, there also are data suggesting 
that during obstructive cholestasis, the apical sodium dependent bile acid transporter ASBT 
is down-regulated181, 236, as a feedback anti-cholestatic mechanism. This could 
hypothetically lead to a relative increase of BA in the proximal colon, which could in turn 
lead to an enrichment of bacterial species involved in bile acid handling208, 236. Since in our 





A limitation of our study is its relatively small sample size, so we were unable and 
unpowered to make any associations between disease severity and microbial composition, 
or to consider any impact of medication, diet, or disease course. Despite this limitation, and 
compared with previous studies, we were able to compare microbiota composition from 
multiple sites229, had representation of PSC-IBD patients, IBD and normal controls229, and a 
reasonable sample size227, that allowed to  perform deeper taxonomic analyses227. We 
observed that the mucosa-associated microbiota was consistent among all locations, and that 
the Blautia and Barnesiellaceae enrichment was consistently found not only in the left colon 
samples but also in other locations. Consistent with findings at the family and genus level, 
deeper OTU level analyses also found enrichment of Blautia and Barnesiellaceae OTUs in 
PSC.  Therefore, in that sense we validated our findings. The cross-sectional nature of the 
study does not allow us to conclusively determine a causal link between the abundance of 
these species and its role in PSC. It is possible that the shifts in the microbiota features we 
observed in PSC-IBD are a consequence, rather than the cause, of the interaction between 
cholestasis and colonic inflammation. Furthermore, in the absence of a non-PSC liver 
disease control group, it is difficult to appreciate if the microbiota shifts we observed are 
specific to PSC or belong to a broader dysbiosis observed in chronic liver diseases204, 206.  
Whether these changes contribute to the special phenotype observed in PSC-IBD patients 
can only be speculated upon at this stage, and merits further investigation. Future studies 
investigating the role of microbiota in PSC should aim in collecting larger samples sizes, 
that could allow adjustment for clinical and analytical variables that could influence 
microbial composition in PSC such disease duration and stage, medication intake, diet, 
geographical location of patients, impact of liver transplant and or biliary surgery, as well as 




































THE GUT MICROBIOTA, BILE ACIDS AND THEIR CORRELATION IN 
PRIMARY SCLEROSING CHOLANGITIS ASSOCIATED WITH 
















Bile acids (BA) are produced in the liver, from cholesterol, conjugated with glycine or 
taurine, and thereafter secreted into the small intestine following a meal204. Normally, most 
of the BA secreted by the liver are efficiently reabsorbed in the terminal ileum, through an 
active process carried out by the apical sodium-dependent BA transporter (ASBT), leaving 
only approximately 5% of the total BA to reach the colonic lumen. In the colon, mostly on 
the right side, primary BA are transformed into secondary BA by bacterially-mediated 
deconjugation and dehydroxylation161, 204. Therefore, BA mediate communication between 
the liver and intestine204. BA are important not only for the absorption of dietary fats and 
vitamins, but they also are ligands for the nuclear receptor Farnesoid X receptor (FXR) and 
the G-protein – coupled receptor TGR5. The TGR5 is a G-protein couple receptor specific 
for bile acids, whose activation results in changes in intestinal motility, and has role in 
immunity. Work has shown that TGR5 activation lowers the pro-inflammatory cytokines 
interleukin-1α (IL-1α), IL-1β, IL-6 and tumour necrosis factor-α (TNF-α)237.  
Bile salts have antimicrobial properties238 and have recently been shown, through FXR-
activation, to regulate the expression of host genes whose products promote innate defense 
against luminal bacteria165. Bacteria have different tolerances to the actions of bile salts, and 
bacterial pathogenic mechanisms can be modified through interaction with bile salts 239. 
Conversely, bile salt metabolism is a property of the gastrointestinal microflora; secondary 
BA, lithocholic (LCA) and deoxycholic (DCA) acid, are formed exclusively through 
microbial biotransformations in the large intestine240. It has also been shown that secondary 
BA have anti-inflammatory properties virtue of their activation of G protein-coupled specific 
membrane receptor TGR5199. However, some of the secondary bile salts generated by 
microorganisms can also be potentially toxic and/ or mutagenic or can lead to activation of 
other carcinogens in intestinal contents 239. Exposure of cells of the GI tract to repeated high 
levels of BA is an important risk factor for gastrointestinal cancer, with the secondary BA, 
LCA and DCA acid being the most significant BA with respect to human colorectal cancer 
(CRC)241. This phenomenon has been widely demonstrated both in animal and in human 
studies. Patients with colonic adenomas and CRC present higher than normal concentrations 
of secondary and total BA in serum and feces 242. BA can induce production of reactive 
oxygen and nitrogen species leading to DNA damage, mutation and genomic instability in 





strongly associated with CRC241, 244. Indeed, impaired absorption of BA in the small intestine 
has been related to colonic tumors. In one animal experiment, Kanamoto et al eliminated 
ASBT-mediated BA absorption by resecting the terminal ileum in rats. When these rats were 
then fed with DCA they had an increase in the influx of BA into the colon and a concomitant 
increase in the incidence of colonic tumors compared to controls 245. Cholestatic liver 
diseases such as PSC are characterized by defective hepatic excretion of BA and their 
accumulation in serum and tissues. This excessive build-up results in the activation of anti-
cholestatic responses in the kidneys, intestine and bile duct to provide alternative excretory 
routes and thus prevent hepatocellular accumulation of toxic components 246. For example, 
it has been demonstrated, in both animal and human experiments, that during cholestasis, 
the ileal expression of ASBT is downregulated 236, 247. These data suggest that intestinal BA 
absorption is reduced during obstructive cholestasis, which could lead to a relative increase 
of BA in the proximal colon, in turn producing heightened conversion of primary into 
secondary BA. Since concentrations of carcinogenic secondary BA are highest in the 




RATIONAL AND AIMS 
 
Rational:  The net result of cholestasis and of a BA pool altered by the diverse bacteria in 
the inflamed colon are unknown but we can hypothesize that a specific alteration of the 
microbiome in PSC-IBD patients could promote the specific phenotype observed including 
colorectal carcinogenesis either directly or indirectly through BA transformation. 
Alternatively, changes in BA compositions could select more anti-inflammatory and/or pro-
carcinogenic strains of bacteria in the gut. 
Approach: Paired stool and fasting serum samples from patients with PSC-IBD and IBD 
alone will be collected and compared between groups. To assess whether specific BA-









Contribution of the PhD candidate 
The PhD candidate developed the research idea and the protocol, under the supervision of 
Professor Marília Cravo and with the help of Professor Cecília Rodrigues. She applied and 
was granted with funding (GEDII investigation award 15.000 euros) that allowed her to 
complete the protocol. She contacted centers in Lisbon and developed a multicenter 
collaboration that allowed her to recruit the PSC-IBD patients. She collected samples and 
the clinical information. Samples were transferred to Mount Sinai Hospital in New York 
where she participated in the DNA extraction, library preparation and the bioinformatics 
analysis, supervised by Professor Hu. The extraction of serum and stool bile acids took place 
in Lisbon Pharmacy University under the supervision of Professor Cecília Rodrigues, and 
with the collaboration of PhD student Hugo Brito. The stool BA profile was examined in 
Paris in the lab of Professor Dominique Rainteau with the collaboration of Professor Jean-
Frédéric Colombel. This collaborative work resulted in the presentation of this work in 
several national and international conferences and in its publication in the United European 
Journal (Impact factor: 3.673):” The gut microbiota, bile acids and their correlation in 
primary sclerosing cholangitis associated with inflammatory bowel disease. J Torres, C 
Palmela, H Brito, X Bao, H Ruiqi, P Moura-Santos, J Pereira da Silva, A Oliveira, C Vieira, 
K Perez, SH Itzkowitz, JF Colombel, L Humbert, D Rainteau, M Cravo, CM Rodrigues, J 
Hu. United European Gastroenterology Journal, 6(1), 112-122, 
2018 https://doi.org/10.1177/2050640617708953”. 
In parallel with this project, and acknowledging the contribution of dietary patters to the gut 
microbiota, we conducted a separate study, assessing nutritional status and dietary intake 
between PSC-IBD patients and controls. This study was undertaken by Ana Paula Krieger, 
who under the supervision of Prof Marília Cravo and the PhD candidate used it for her 
Master thesis. Some of those results are presented here, and additionally the correlations 




Subjects and samples 
Between October 2014 and July 2015, 15 patients with PSC-IBD and 15 patients with IBD 
were prospectively recruited. The inclusion criteria were age greater than 18 years old, 





MRCP), a confirmed diagnosis of IBD by conventional endoscopic and histological criteria, 
and the presence of extensive colitis. Patients with a personal history of colectomy, a 
diagnosis of secondary sclerosing cholangitis or a history of OLT were excluded. All patients 
provided clinical and demographic information, and completed a semi-quantitative food 
frequency questionnaire (FFQ) validated for the Portuguese population249. Nutritional 
assessment was also conducted by a dedicated nutritionist, and included standard 
assessments (weight, height) as well as bioimpedance measurement. The conversion of food 
into nutrients was carried out by the Institute of Public Health of the University of Porto, 
based on the Food Processor Plus (ESHA Research, Salem, Oregon) software, with 
nutritional information from the Food Composition Tables of the Department of Agriculture 
of the United States of America, adapted to typical Portuguese foods. 
Clinical activity was scored according to the Mayo score for ulcerative colitis250, and the 
Harvey-Bradshaw index for Crohn´s disease251. Endoscopic activity was scored according 
to the Mayo endoscopic score for UC250 and the Simple Endoscopic 
Score for Crohn's Disease (SES-CD)252. All study participants collected a stool sample for 
BA analysis and microbiota analysis. All PSC patients on ursodeoxycholic acid (UDCA) 
therapy were required to stop it two weeks before specimen collection. A minimum interval 
of 3 months was required between antibiotic intake or bowel preparation (for colonoscopy) 
and sample collection. During colonoscopy disease severity was recorded, and biopsies for 
colorectal neoplasia screening were obtained, according to current guidelines.  
 
Serum bile acid profiles 
A fasting serum sample was obtained from each patient. Individual amidated bile acids in 
serum (1 mL) were determined by high-performance liquid chromatography (HPLC)253, 
after solid-phase extraction using Sep-Pak C18 cartridges (Waters Corp., Milford, 
Massachusetts, USA)254. Identification of BA was made based on gas chromatography 
retention index relative to a homologous series of n-alkanes, and the chromatograms 
compared with authentic standards. Quantitation was achieved by comparing the peak height 
response of the individual BA with the peak height response obtained from the internal 








Stool Bile acid profiles 
A morning stool sample was obtained and dried to obtain a lyophilized extract. To 
lyophilized fecal samples were weighing 1 g, 80% methanol was added. All samples were 
sonicated for 30 minutes, refluxed for two hours, and then cooled and filtered255. The residue 
was re-suspended in chloroform/methanol (1:1, v/v), refluxed for one hour, and filtered. The 
combined extracts were taken to dryness, and re-suspended in 10ml MeOH. An aliquot of 
1ml was added with 2µl of 1mg/ml nordeoxycholic acid, and was diluted in 10ml deionized 
water and deposed on a 300mg HLB Oasis column, washed with 10 volumes deionized, 1 
volume cyclohexane, and the BA were then eluted with 5ml MeOH which were taken to 
dryness and resuspended in 250µl MeOH. Four microliters were injected on the Liquid 
Chromatography Coupled with Tandem Mass Spectrometry (LC-MS/MS) as previously 
described256. Results are reported in nmol/g of dried stool for total BA and in proportion of 
the median after calibration of the method, with weighted mixtures and normalization 
relative to the internal standard256. The conjugate and non-conjugated species were 
quantified. 
 
Bile acid analysis 
BA were not normally distributed according to the Shapiro-Wilk test; therefore, their 
distributions were compared using non-parametric tests. The relative proportion of a given 
BA corresponds to its concentrations divided by the total of BA. BA results are presented as 
the median proportion. For example, the total primary stool BA is the sum of CA and CDCA 
and their respective glyco-, tauro-, and sulphoderivatives. Linear discriminant analysis 
(LDA) was conducted to illustrate the classification of disease groups (IBD only and PSC-
IBD) using stool BA. LDA is a dimension reduction statistical technique that looks for a 
combination of features (continuous variables) that maximize the separation between 
classes. LDA was performed using MASS package in R software. 
 
Stool DNA extraction 
Approximately 200mg of stool were transferred into bead tubes (MO-BIO, Carlsbad, CA) 
and homogenized using bead beating method. Homogenized stool samples were further 
processed using the Qiagen DNeasy Blood & Tissue Kit following the manufacturer’s 
protocol (Qiagen, Valencia, CA). Total DNA concentration was determined with Qubit 2.0 





16S ribosomal RNA (rRNA) sequencing 
The phylogenetically informative V3-V4 region of 16S ribosomal RNA (rRNA) gene was 
amplified using universal primer set 347F/803R210. The primers were synthesized by IDT 
(Integrated DNA Technology, Coralville, IA). We used a dual-barcoding approach to label 
the 16S rRNA amplicons from each sample as described previously257. The 16S rRNA 
amplicons were further pooled with equal molarity and submitted for MiSeq 2x300 pair-end 
sequencing at high depth. The paired sequence readings were merged and filtered by size 
(>400bp) and quality score (>Q30) using PANDAseq (PAired-eND Assembler for DNA 
sequences)258. The processed readings were further split by dual barcodes for each sample 
and assigned taxonomic classification using QIIME (Quantitative Insights Into Microbial 
Ecology) pipeline 1.9.0259. Repeated measurements of the same sample were made to assess 
sequencing reproducibility. After processing, QIIME provided detailed operational taxa unit 




First, we measured the diversity of the overall microbiota communities within or across each 
sample. The overall species richness within each patient group, so-called alpha-diversity, 
was measured using the Chao1 and Shannon Index on rarefied tables at 8000 sequences per 
sample260. Beta-diversity was measured using unweighted and weighted UniFrac distance 
matrices on the rarefied tables. The permutational analysis of variance (PERMANOVA) test 
(number of permutations = 999), was performed using QIIME command 
compare_categories.py to test the overall microbiota differences between groups by PSC and 
IBD status261. Secondly, at the taxa level, the LDA Effect Size (LefSe) analysis was used 
with default parameters to select taxa features that were associated to PSC status262. LEfSe 
combines robust tests for measuring statistical significance (Kruskal-Wallis test) with 
quantitative tests for biological consistency (Wilcoxon-rank sum test). The differentially 
abundant and biologically relevant features (clades, genes, pathways, functional categories) 
are ranked by effect size after undergoing LDA263. Only features with LDA score >2.0 were 
kept. A Kruskal-Wallis test on the LefSe selected differential taxa at the genus level was 
performed and corresponding p-values were adjusted for multiple comparisons. Finally, the 





differential abundance with respect to the PSC-IBD status. All singleton OTUs were 
removed prior to all analysis. 
 
Correlation networks 
We calculated the correlations between microbiota taxa and dietary components using the 
results obtained from the food-frequency questionnaires, stratified by study group. Pearson 
correlation was used to assess the relationship between nutrients and microbiota 
composition. P-values were adjusted for false discovery rate. 
We also calculated both Pearson’s and Spearman’s correlations between the most abundant 
(mean relative abundance >0.1%) 65 genera in the gut microbiota and the stool BA levels in 
PSC and non-PSC IBD. To reduce the bias in the correlation analysis due to non-normality, 
we removed the variables with more than 8 null value results, and removed the 
measurements beyond the 5% quantile of the distribution. We computed the raw 
probabilities. The p-values of the Pearson’s correlation were calculated using corr.test 
function in R software with FDR adjustment for multiple comparisons. Spearman’s 
correlations of the selected pairs with significant p-values in the Pearson correlations were 






Thirty patients with IBD, of whom 15 had concomitant PSC, were prospectively enrolled. 
All patients enrolled had pancolitis; 2 out of the 4 patients with CD also had ileal 
involvement. Two of the 15 PSC patients had concomitant liver cirrhosis (Child-Pugh A, 6 
points). No patient had a prior history of abdominal or liver surgery. There were no 
significant differences in the overall daily intake of macro or micronutrients as assessed by 
the food-frequency questionnaire (data not shown). Patients with PSC-IBD presented, as 
expected, significantly higher levels of cholestasis markers, and were more frequently 
medicated with ursodeoxycholic acid. No further significantly different clinical variables 
were found, except for body mass index (BMI) that was significantly lower in PSC-IBD 





days (9-62). The additional demographic and clinical characteristics of PSC and IBD patients 
are described in Table 4.  
 
 
 PSC-IBD (n=15) IBD (n=15) p value* 
































median years (IQR) 




median years, (IQR) 
11.4 (5.26) 11.1 (15.7) 
 
0.78 
PSC Mayo score 
median, (min, max) 
-0.57 (-1.6, 1.7) - - 
ALP (UI/L) (median, IQR) 
GGT (UI/L) (median, IQR) 





































Presence of colorectal dysplasia (n, %) 3/14(21%) 1/15 (6%) 0.2 





















Table 4 – Demographic and clinical characteristic of patients. *Variable distribution was 
compared using the t-Student´s test, the Mann-Whitney test or the "2 test, as appropriate. ALP: 
Alkaline phosphatase; GGT: Gammaglutamyl transpeptidase; CRP: C-Reactive Protein. IQR: 
interquartile range. BMI: body mass index. 5-ASA: 5-aminosalicilates. Anti-TNF: anti-Tumour 
necrosis factor. ‡: in the PSC-IBD group one patient refused colonoscopy.  
 
 
Nutritional assessment and nutrient intake 
As compared to IBD patients, PSC-IBD presented significantly lower weight and BMI. 
The remaining nutritional parameters were similar.  
 
Measurements  PSC-IBD IBD P value 
Weight (kg) 65,3 ±14,0  83,2 ±19,4  0,009 
Height (m) 1,65 ±0,10  1,66 ±0,10  0,595 
BMI (kg/m2) 23,9 ±4,5  30,1 ±6,4  0,005 
Fat mass (%) 27,9 ±10,2  30,4 ±9,5  0,436 
Lean mass (%) 72,1 ±10,2  69,6 ±9,5  0,436 
Total body water 56,0 ±10,0  51,7 ±6,8  0,116 
Table 5 -  Nutritional assessment parameters and bio-impedance results. 
 
 
No significant differences were found in the daily intake of macro and micronutrients among 







Nutrient PSC-IBD IBD P value 
Energy (kcal) 2330 ±626 2154 ±708 0,367 
Kcal/kg  37,6 ±13,2 26,8 ±9,0 0,019 
Proteins (g) 90,9 ±26,2 85,9 ±29,5 0,744 
Carbo-hydrates (g) 272,1 ±81,6 248,9 ±82,3 0,202 
Complex carbohydrates (g) 79,1 ±30,7 87,6 ±58,9 0,870 
Sugars (g) 116,0 ±46,0 101,9 ±29,8 0,367 
Total fiber (g) 23,5 ±10,6 23,5 ±8,9 0,870 
Total fat (g) 102,0 ±39,5 92,7 ±41,3 0,539 
Total saturated fat (g) 29,0 ±10,9 25,3 ±10,8 0,512 
Monounsaturated fat (g) 50,4 ±23,0 44,7 ±22,3 0,595 
Polyunsaturated fat (g) 14,9 ±6,5 15,4 ±8,2 0,870 
Cholesterol (mg) 301,9 ±110,3 319,5 ±139,8 0,595 
Fatty acids n-3 (g) 1,40 ±0,42 1,42 ±0,63 0,902 
Fatty acids n-6 (g) 11,97 ±5,82 12,37 ±7,06 0,902 
Ratio n-6 / n-3 8,37 ±2,52 8,69 ±3,39 0,838 
Table 6 – Daily ingestion of macronutrients between PSC-IBD and IBD alone. No significant 
differences were found between groups. 
 
 
Nutrient PSC-IBD IBD Valor de p 
Vitamin A (µg) 1887 ±1135 1778 ±846 0,806 
Vitamin D (µg) 3,10 ±0,70 3,54 ±2,04 0,683 
Vitamin E (mg) 12,29 ±5,01 11,59 ±5,49 0,567 
Vitamin K (µg) 8,85 ±7,67 12,58 ±10,41 0,285 
Vitamin B12 (µg) 7,98 ±2,80 8,34 ±3,28 0,567 
Vitamin C (mg) 120,1 ±79,4 120,5 ±83,8 0,902 
Folate (µg) 286,9 ±120,5 265,6 ±81,3 0,512 
Iron (mg) 14,91 ±4,60 14,05 ±4,96 0,436 





Potassium (g) 3226 ±1036 3109 ±961 0,870 
Iodine (µg) 49,8 ±40,9 35,4 ±28,6 0,305 
Phosphor 1288 ±396 1198 ±406 0,367 
Calcium (mg) 872,0 ±388,3 678,7 ±273,6 0,126 
Table 7. Daily ingestion of micronutrients between PSC-IBD and IBD alone. No significant 
differences were found between groups. 
 
 
Serum Bile acid 
The total serum bile acid (µmol/L) pool was significantly expanded in PSC-IBD (p-value = 
0.007, Mann-Whitney test) (Table 8). No significant differences were seen in the proportion 
of individual bile acids between groups. There was a positive correlation between PSC 
duration and total serum bile acids (#=0.66, p=0.009). 
 
 
Bile acids PSC-IBD IBD P value 
Total bile acids (µmol/L) 18.5(30.6) 8.2 (7.0) 0.007 
Total primary bile acids 80 (20) 70 (20) 0.20 
Total secondary bile acids 7.3 (5.6) 9.5 (5.2) 0.84 
Tauro/glyco-conjugates  4.7 (4.7) 3.8 (4.4) 0.53 
CA 18.5 (79.2) 40.4 (63.9) 0.683 
CDCA 42.0 (72.2) 38.4 (70.1) 0.325 
DCA 6.1 (5.8) 5.8 (11.5) 0.486 
LCA 1.5 (3.3) 2.5 (6.4) 0.174 
UDCA 9.4 (41.2) 19.1 (30.4) 0.074 
 
Table 8- Serum bile acids in PSC-IBD and IBD patients. Total Bile acids are expressed in 
(µmol/L). The other analytes are expressed as %median (interquartile range) of total BAs. 
Distributions were compared with non-parametric tests (Mann-Whitney).CA – cholic acid; CDCA – 









Stool bile acids profiles 
The median total stool BAs were significantly reduced in PSC-IBD (167.2 µmol/L in PSC-
IBD versus 282.4 µmol/L in IBD, p=0.021). Overall there were no significant differences in 
the proportions of each BA (Table 9) although the overall combination of stool allowed a 
good separation between PSC-IBD and IBD, as visualized in the linear discriminant analysis 




Figure 17 - Results of the linear discriminant analysis allowing to see the discrimination of 
PSC-IBD versus IBD alone, based on the combination of the main bile acids present in stool 
(CA, CDCA, LCA, DCA and UDCA). In the x axis each marker represents a sample from a patient. 
In the y axis is represented the probability of being correctly classified as PSC-IBD using the BA 
analytes. The green markers represent patients with PSC-IBD and in the pink markers patients with 
IBD. The circle represents patients that were correctly assigned to their disease group. 
The classification accuracy of the LDA was 73%, with a sensitivity and specificity of 86.7% and 
60% respectively. 
 
Using the main bile acids BA (CA, CDCA, LCA, DCA and UDCA), the classification 
accuracy of the LDA was 73%, with a sensitivity and specificity of 86.7% and 60% 
respectively (Figure 17). When we used all individual BA (taurine and glycine conjugates 
and sulphated BA), the accuracy of the LDA for classifying PSC-IBD versus IBD was 
100%(Supplementary Figure 4 A). Additional LDA analysis was conducted using the top 






PSC-IBD patients presented a higher proportion of conjugated BA, although this did not 
reach statistical significance. DCA, a secondary BA, was also elevated, albeit non-
significantly, in PSC-IBD. The proportion of UDCA in stool was not different in the PSC 
patients who had been medicated with UDCA versus those who were not (1.075 nmol/g 
versus 1.35 nmol/g, respectively, p-value=0.7, Mann–Whitney Test) but like stated in 
material and methods section, all patients were asked to stop UDCA therapy for 2 weeks 
prior to stool collection. Likewise, the results for all stool BA comparisons did not change 
after excluding the 2 CD patients with ileal involvement (data not shown). There was a 
negative correlation between the concentration of secondary BA and endoscopic disease 
activity (ρ=-539, p=0,003); this was also observed when the analysis was stratified by patient 
group (data not shown).  
 
Bile acids PSC-IBD IBD P value 
Primary BAs 9.5 (18) 4.2 (15.2) 0.29 
Secondary BAs 89.4 (24.6) 91.2 (15.1) 0.57 
CA 4.6 (6.45) 1.49 (4.77) 0.06 
CDCA 4.73 (10.4) 2.72 (11.0) 1.0 
DCA 52.5 (23.5) 43.6 (14.3) 0.55 
LCA 34.1 (33.8) 46.2 (1.9) 0.14 
UDCA 1.1 (1.9) 1.8 (3.9) 0.37 
Tauro/Glyco conjugates 0.47 (0.67) .34 (0.69) 0.98 
Sulfated BAs 2.1 (3.1) 2.4 (16.3) 0.41 
Conjugated BAs 4.5 (13.7) 2.7 (6.9) 0.23 
 
Table 9 - Stool bile acids (BA) in PSC-IBD and IBD patients. BA are expressed as %median 
(interquartile range) of total BAs. Distributions were compared with non-parametric tests (Mann-
Whitney). Due to a small amount of minor BA species in stool (muricholic acid, hycholic acid, 
hyodeoxycholic acid, or ursodeoxhycolic acid) which are considered by some authors as ‘tertiary 
BA’, the sum of primary and secondary bile acids is not 100%. CA – cholic acid; CDCA – 








Survey of gut microbiota 
Using 16S rRNA sequencing, we surveyed the microbiome composition of 30 stool samples. 
The duplicate measurements showed Pearson correlation over 99% at genus level, 
confirming the reproducibility of the experimental approach. The overall microbiota 
dissimilarities among all samples grouped by PSC and IBD status were assessed using the 
UniFrac distance matrices (Figure 18 A). The overall qualitative microbial composition of 
patients with PSC-IBD was different as observed in the multidimensional scaling (MDS) 
plot (Figure 18 A: unweighted UniFrac, PERMANOVA: pseudo-F statistic: 2.99, p 
value=0.008). PSC-IBD presented lower alpha-diversity, albeit not significantly different 
(Chao1 899.3 for IBD vs 832.0 for PSC-IBD, p-value=0.36; Shannon index 5.7 for IBD vs 
5.3 for PSC-IBD, p=0.23) (Figure 18 B). Patients with PSC and concomitant cirrhosis (n=2) 
presented significantly lower bacterial alpha-diversity (p=0.005) as compared to those with 
PSC without cirrhosis (data not shown). At the individual taxa level (Figure 18 C:), we 
found 5 genera differentially expressed in PSC-IBD vs IBD (logarithmic LDA score>2 by 
LEfSe analysis): Ruminococcus, and Fusobacterium were more abundant in PSC-IBD, while 
Dorea, Veillonella, Lachnospira, Blautia, and Roseburia were less abundant.  
 
All of those genera were found to be significant (p<0.05) when their relative abundance was 
compared using a Kruskal-Wallis test (p values adjusted for multiple comparisons).  No 
significant differences in the microbial overall composition (ß-diversity) were observed by 
PSC disease severity (as measured by the PSC Mayo score), BMI, UDCA use, IBD type, or 









Figure 18 - Overall microbiota dissimilarities between samples grouped by PSC and IBD 
status. (A) Dissimilarities were measured using UniFrac unweighted distances and visualized using 
a multidimensional plot (MDS) plot. The blue circle represents patients with PSC-IBD, while the red 
circle is circling the samples from IBD patients. The PerMANOVA test (permutations= 999= showed 
that the distances between samples from both groups were significantly different (p= 0.008). (B) The 
boxplots show the mean and variance of the richness of the microbial community between different 
disease status (Chao1 in the left and and PD_whole tree index on the right); no significant differences 
are seen (p value: 0.36 and 0.23 respectively). (C) Top discriminative bacteria in PSC-IBD and IBD 
patients as determined by LEfSe analysis (LDA, linear discriminant analysis). In the right are 
represented the taxa increased in PSC-IBD, while in the left the taxa decreased in PSC-IBD, as 
compared to IBD. 
 
 
Differential OTUs by PSC status 
Based on 97% similarity of the 16S sequencing reads, the open-reference OTU picking using 
QIIME pipeline assigned all sequencing reads into individual OTUs. After removing 
singletons, we compared 3839 OTUs and selected 143 OTUs which were significantly 
(p<0.05 by Kruskal–Wallis test, not adjusted) differential and presented a >2 fold changes 






















































































































































































































































                                        Decreased in PSC-IBD                  Enriched in PSC-IBD 
 
 
Figure 19 - Differential OTUs by PSC status. The dot plot shows the 225 OTUs with p-value <0.05 
by Kruskal–Wallis test selected from 26 genera and coloured by their assigned phyla. The fold 
changes are calculated using the mean relative abundance of OTUs in IBD divided by the mean 
relative abundance of OTUs in PSC.  The area of each dot was scaled to the mean relative abundance 
of represented OTU in IBD.   
 
Compared to IBD only, the relative abundance of 32 OTUs were increased and 111 OTUs 
were decreased in PSC-IBD. At the phylum level, we found that most of the shifts associated 
with PSC occurred within the Firmicutes (73%) and Bacteroidetes phyla (17%). Consistent 



















































most significant differential genera by PSC status, we found that all 16 OTUs of Blautia 
genus were reduced while 4 of 5 OTUs of Ruminococcus genus and Ruminococcaceae 
family were enriched in PSC samples.  
 
Correlation between microbiota genera and nutrients  
Despite no significant differences were found in the daily intake of macro and micronutrients 
among groups, correlations between certain taxa and dietary components were disease 
specific. In IBD, Dialister (p=0.00028, r:0.93), and unknow genus from Corioabacteriaceae 
correlated with complex carbohydrate intake (p=0.00062, r=0.92), and Veillonella correlated 
with saturated fatty acids [(eicosanoic acid, p=0.044, r=0.84); (docosanoic acid, p=0.043, 
r=0.84). In PSC-IBD, SMB53 genus was correlated with alcohol intake (p=0.012, r=0.87), 
Bifidobacterium with omega-6 (p=0.044, r=0.84), f_Enterobactericae with Boron 
(p=0.0025, r=0.90), and Parabacteroides with manganese (p=0.0071, r=0.88), and Selenium 
intake (p=0.0067, r=0.88). These results further support the already known modulating effect 
of diet on microbiota. 
 
Correlation between microbiota genera and stool bile acids  
Correlations between microbiota genus and the stool BA were calculated as described in our 
method section to test the interactions between gut microbiota and stool BA. Without 
stratifying by PSC status, we found four genera, including Blautia and Veillonella to be 
correlated to specific types of bile acids. In PSC-IBD, bacteria with significant correlations 
with BA metabolites mostly belonged to the Firmicutes phylum, specifically within the 
Clostridia and Bacilli classes. Different correlations were observed in IBD (Table 10).  
 
 
Genus BAs Correlation1 Correlation2 p1 p2 
All samples      
Blautia TLCA 0.71 0.46 2.07E-02 1.78E-02 
Collinsella GDCA 0.69 0.45 4.66E-02 1.96E-02 









0.81 0.4 3.00E-04 4.52E-02 
IBD samples      
SMB53 GCDCA 0.88 0.56 3.00E-02 4.56E-02 
Megasphaera GLCA-3S 0.96 0.56 6.39E-05 4.72E-02 
PSC samples      
Coriobacteriace
ae.g 
TCDCA 0.88 0.9 4.06E-02 3.32E-05 




0.96 0.8 5.05E-05 1.14E-03 
Alistipes GDCA 0.95 0.77 3.42E-04 1.87E-03 
Veillonella CDCA-3S 0.94 0.76 5.87E-04 2.62E-03 
Roseburia GDCA 0.89 0.73 2.85E-02 4.37E-03 
Lactococcus TUDCA 0.97 0.68 1.46E-05 1.03E-02 
Bifidobacterium TUDCA 0.9 0.63 1.27E-02 2.13E-02 
Clostridiaceae.g TLCA 0.99 0.63 6.60E-08 2.13E-02 









-0.91 -0.62 9.06E-03 2.26E-02 














Coprococcus GDCA 0.94 0.58 1.09E-03 3.88E-02 
Coprococcus GCA 0.9 0.57 1.25E-02 4.73E-02 
Streptococcus CDCA 0.97 0.56 1.08E-05 4.86E-02 
 
Table 10– The genus-BA pairs with both significant Pearson’s correlation (adjusted p<0.05) 





Compared to IBD, seven genera appeared and two genera disappeared in PSC-IBD. The total 
relative abundance of genera correlated to BA was 12% in PSC-IBD, compared to 0.4% in 
IBD. Two Firmicutes, Lachnospira and Veillonella, which were significantly reduced in 





Herein, for the first time we have analyzed the stool BA profiles and their correlation with 
the fecal microbiota composition in patients with PSC-IBD as compared to IBD alone. The 
serum BA pool was increased and the stool BA pool was significantly reduced in PSC-IBD 
as compared to IBD alone. No significant differences in the individual stool bile acid 
components were found, but their overall composition differed from IBD (Figure 17). A 
significantly different microbiota composition based on the unweighted UniFrac distances 
was found between IBD and PSC-IBD, indicating differences in taxon composition for rare 
taxa (Figure 18 A). Specifically, PSC-IBD patients presented an enrichment in bacteria 
belonging to the genera Ruminococcus and Fusobacterium as compared to IBD alone 
(Figure 18 A). Finally, specific microbiota-stool BA correlations were observed in PSC-
IBD (Table 10). 
In the past, some authors have hypothesized that the increased risk of right-sided colorectal 
neoplasia in PSC-IBD could be linked to an increase in secondary BA, although this had 
never been demonstrated155, 264. Normally, most of the bile acids (BA) secreted by the liver 
are efficiently reabsorbed in the terminal ileum, through the sodium-dependent BA 





lumen. In the right colon, primary BA are transformed in secondary BA mostly by bacterial 
mediated deconjugation, oxidation/reduction, epimerization and de-hydroxylation 265. 
Therefore, fecal BA are mainly deconjugated, secondary BA.  A small fraction of secondary 
BA is passively absorbed through the colonic mucosa, whilst the rest will be extruded with 
faeces240. During obstructive cholestasis, the expression of the apical BA transporter, which 
permits intracellular absorption of BA, is down-regulated, as a compensatory mechanism236. 
This could hypothetically lead to a relative increase in the proportion of BA entering the 
proximal colon in PSC-IBD patients, where they would be converted from primary into 
secondary BA. Interestingly, secondary BA have been shown to have anti-inflammatory 
properties but at the same have been shown to bear carcinogenic properties256, 266-269. Herein, 
we observed a significant reduction in the total stool BA in PSC-IBD as compared to IBD, 
which was expected taking into consideration the obstructive cholestatic nature of PSC. 
However, we did not find an increase in the relative proportion of the stool secondary BA in 
PSC-IBD patients, as previously hypothesized264, 270. No significant differences in individual 
proportion of serum or stool BA were found, which could perhaps be due to the small sample 
size. The proportion of DCA, a secondary BA was increased in PSC-IBD, although this did 
not reach statistical significance. Furthermore, the proportion of conjugate BA was also non-
significantly increased in PSC-IBD as compared to IBD, which could indirectly indicate a 
decrease in the deconjugation activity of the microbiota, as previously observed in liver 
cirrhosis206. The decrease in Bacteroides, Clostridium, Bifidobacterium, and Lactobacillus 
genus, observed at the OTU level, bacteria known to be involved in bile acid deconjugation, 
could hypothetically be involved in this finding271. In this cohort, patients with PSC-IBD 
demonstrated an enrichment in bacteria from the Ruminococcus and Fusobacterium taxa, 
and a decrease in bacteria from the genus Dorea, Veillonella, Lachnospira, Blautia, and 
Roseburia. At the OTU level most shifts were observed within the Firmicutes (73%) and 
Bacteroidetes phyla (17%). Some of our findings are in consonance with recently published 
results on PSC microbiota also showing an increase of Fusobacterium272 (a bacterial taxon 
that has been linked with adenomas and colorectal cancer) and in Ruminococcus in stool 
from patients with PSC-IBD or a decrease in Roseburia genus. However, as opposed to our 
findings, Kummen et al. reported PSC patients to have a significant increase in Veillonella 
genus in comparison to healthy controls and patients with IBD. In this cohort, Veillonella 
genus was positively correlated with disease severity and was more abundant in patients that 





conditions such as liver or lung fibrosis or cystic fibrosis273-276 In cirrhosis, Veillonella has 
also been associated with complications such as hepatic encephalopathy277. In another large 
cohort of patients with PSC-IBD, Veillonella was only significantly elevated in patients with 
PSC that presented concomitant liver cirrhosis.(7) Of note, in our PSC population, only 2 
patients presented early liver cirrhosis, no patient presented severe PSC as measured by the 
PSC Mayo score or had undergone liver transplant. In our prior work we observed that 
Blautia was increased in the mucosa from PSC-IBD patients as compared to healthy 
controls270. This could be due to small sample size, and different populations with different 
geographic background and likely different diet habits. Furthermore, we cannot exclude the 
impact of different medications, disease severity etc in these contrasting findings, since the 
small sample sizes does not allow us to control for all these factors. Also worthy of note is 
the well described disconnect between mucosa and stool microbiota, as in prior work in liver 
cirrhosis, the stool and mucosa microbiome from the same individuals was also found to be 
distinct.278  
The most important message from our work however, is that patients with PSC-IBD present 
distinct fecal microbiome-fecal BA correlation and interactions. No study had yet looked at 
the correlations between stool bile acid and the stool microbiota in PSC-IBD. However, BA 
pool size and composition have been shown to be important factors in regulating the gut 
microbiota279-281. Herein, despite our relatively small sample size, and after correcting for 
multiple comparisons, we were able to observe unique correlations between stool microbiota 
and stool bile acids in PSC-IBD. Within IBD alone, this broad BA-microbiota correlation 
disappeared. In particular, in PSC-IBD, the taxa that significantly correlated to the stool BA 
corresponded to ~12% of the total microbiota, while in IBD, this was less than 1%. Without 
any functional data, we may only speculate that these results suggest that under PSC 
condition, the BA changes may have dominant effects on defining the gut microbiota shifts, 
potentially towards a more pro-carcinogenic profile. Interestingly, bacteria from both 
Fusobacterium and Ruminococcus genus, are known to be involved in oxidation, 
epimerization and desulfatation of bile acids271. 
The major limitation of this study is our small sample size, which prevented us from 
adjusting for potential confounders in the microbiota and BA analysis. To overcome this, we 
tried to make our cohort as uniform as possible. All patients had pancolitis, and no patient 
had prior abdominal surgery or history of liver transplantation; all patients had mild to 





groups as assessed by the food frequency questionnaire. Furthermore, all patients stopped 
UDCA intake for 2 weeks and had no antibiotics or bowel preparation within at least 3 
months of sample collection, all external factors that could potentially impact microbiota 
composition. While it may be argued that a 2-week interval to stop UDCA may not be 
enough to remove its effects, we did not observe any differences in the fecal bile acid 
composition or in the microbiota composition between those who were medicated with 
UDCA as compared to those who were not, consistent with what has been previously 
reported(7). 
In summary, in this exploratory study, patients with PSC-IBD had a distinct stool bile acid 
and stool microbiota composition, as well as specific microbiota-stool bile acid correlations 
when compared to IBD. Whether these changes are associated with or may predispose to the 
specific PSC-IBD phenotype including the increased risk of colorectal neoplasia needs to be 






























HIGH RISK OF ADVANCED COLORECTAL NEOPLASIA AND 
ACCELERATED DYSPLASIA-CARCINOMA SEQUENCE IN PATIENTS WITH 
PRIMARY SCLEROSING CHOLANGITIS ASSOCIATED WITH 














Data on the risk of colorectal dysplasia and cancer (collectively termed as colorectal 
neoplasia - CRN) in patients with PSC were conflicting for some years. Studies with small 
sample sizes, different end points, and different comparison groups, as well problems in 
determining time of onset of IBD in patients with PSC, gave rise to disparate results.  Broomé 
et al. in 1992 were the first to suggest that patients with IBD and PSC could have an increased 
risk for developing CRN 282. Three years later, the same group showed that the absolute 
cumulative risk of developing CRN in PSC-UC patients after 10, 20, and 25 years of disease 
duration was 9%, 31%, and 50%, respectively, compared to 2%, 5% and 10% in those with 
UC alone (p<0.001)283. In this landmark study, 40 PSC patients with extensive UC who had 
been enrolled in a surveillance programme were matched to two control patients of the same 
age, also with extensive colitis and a comparable duration of disease but without PSC. 
Among the 40 PSC patients with UC, 16 developed CRN, versus only 10 out of 80 in the 
control group (p< 0.001).  
These observations have since been reproduced in other studies284-286. By now, many 
publications have confirmed the increased risk of CRN in PSC-IBD patients, even when 
controlling for location and extent of disease114, 119, 122, 284, 286-290, although in some series this 
increase in risk appeared to be low or even absent64, 291-295.  A large recently published meta-
analysis evaluating 13,379 patients with IBD, 1,022 (7.63%) of whom had concomitant PSC, 
showed that there was a three-fold increased risk of CRN and cancer among patients with 
PSC-IBD compared to the IBD-only population (odds ratio (OR) 3.24 [95% CI 2.14-
4.90])123. Most importantly, Navaneethan et al. suggested a higher risk in the first two years 
after diagnosis of PSC-UC, but did not find any increased risk in the subsequent years, which 
decreases the likelihood that a longer disease course would increase the CRN risk296. There 
seems to be common features of CRN in PSC-IBD patients: extensive colon involvement297, 
more frequent CRN in the right colon (proximal to the splenic flexure)64, 117, 118, 122, 248, 298, 
299; and more frequent bile duct dominant stenosis (i.e. extrahepatic bile duct high-grade 
stenosis with obstruction)300. 
Given that the risks of CRN have been widely described in the PSC-IBD population, the 
different gastroenterology societies have commented on recommendations for surveillance 





in PSC-IBD patients from the time of PSC diagnosis, without taking into account the 
duration of IBD since it is often not known301, 302.  
However, we must acknowledge that prior studies had been performed in relatively small 
series of patients (due to the rarity of disease) and all studies report to an era when 
endoscopic enhanced surveillance (white light high definition scopes and/or 
chromoendoscopy) were still not used. Recent studies have shown that the risk of colorectal 
cancer and dysplasia in IBD seems to be decreasing. A large Danish population-based study 
including data from the National Patient Registry (NPR) and the Danish Cancer Registry 
during a 30-year follow-up period (1977- 2008) revealed no overall increase in risk of CRC 
in patients with IBD, except for some sub-groups. This trend, has been attributed to better 
control of inflammation, better implementation of colonoscopic surveillance and better 
endoscopic surveillance techniques, increased implementation of colectomy in some 
countries, and possibly chemopreventive effect the medications used for the treatment of 
IBD. Historically, random biopsies would be performed in the 4-quadrant and with 10 cm 
interval. The rationale for this was that most dysplasia was not visible. However, the advent 
of high definition endoscopes and chromoendoscopy techniques has changed this paradigm, 
and nowadays, targeted biopsies are being increasingly used, as it is believed that dysplasia 
is now in most cases visible. However, how and if these data apply the sub-group of patients 
with PSC-IBD is unknown.  
 
The development of neoplasia in IBD colitis follows a multistep sequence from chronic 
inflammation and no dysplasia or indefinite dysplasia (IND) to low grade-dysplasia (LGD) 
and high-grade dysplasia (HGD) prior to final malignant transformation to adenocarcinoma. 
As such, the presence and grade of dysplasia remain the best current indicators of cancer risk 
in IBD. Despite providing estimate rates on advanced colorectal neoplasia (aCRN) in 
patients with PSC-IBD, prior studies had failed to study the natural history of lower grades 
of dysplasia (such as indefinite or low-grade dysplasia) to more advanced neoplasia (high-
grade dysplasia or colorectal cancer). Patients with HGD have a high risk of developing 
cancer, and therefore colectomy is recommended in those cases that cannot be managed 
endoscopically. The management of IND and LGD dysplasia is however more controversial, 
because of the heterogeneous reported rates of progression to cancer varying between 16-
54%, and while some centers may choose to follow a tighter surveillance protocol, others 





patients with LGD on intensive surveillance instead of recommending proctocolectomy. 1819 
However, while some studies have described the rate of progression of indefinite and LGD 
in IBD-only patients, the rate of progression of colorectal neoplasia in patients with PSC-
IBD has not been thoroughly studied, and the fate of IND and LGD and the rate of 
progression of IND and LGD to more advanced neoplasia in PSC-IBD patients are not well 
characterized. One would hypothesize that the rate of progression of IND/LGD to HGD or 
CRC is faster than in patients with UC alone, but this has never been confirmed. A small 
study on 10 patients with PC-IBD and LGD reported a rate of progression of LGD to 
HGD/CRC in 30% of patients over a follow-up period of 13±11months303. In an earlier study 
including IBD patients with LGD, PSC was the only risk factor for increased risk of 
progression from LGD to HGD/CRN304. 
 
 
RATIONAL AND AIMS FOR THIS STUDY 
 
Rational: Despite the well accepted risk of colorectal neoplasia in PSC-IBD, data comes 
predominantly from older studies. Whether the same decrease in the rates of aCRN are still 
seen in these patients remains to be described in a modern cohort. Additionally, no specific 
recommendations exist on the management and follow-up of indefinite or LGD exist for this 
high-risk population that may be more prone to be referred for colectomy, given the elevated 
risk of CRC. One would hypothesize that once indefinite or low-grade dysplasia (LGD) is 
diagnosed in PSC-IBD, the rate of progression to high-grade dysplasia or CRC would be 
faster than in IBD patients. Hence, further studies are needed to better determine the 
outcomes regarding low-grade and indefinite dysplasia in PSC-IBD patients.  
Aim:  Our aim was to verify whether in this era of improved medical treatment and improved 
surveillance, patients with PSC-IBD will still have higher proportion of advanced colorectal 
neoplasia overall, and to assess the rates of aCRN development following the diagnosis of 
Indefinite dysplasia or low-grade dysplasia. 
Approach: A large multicenter international retrospective cohort, with longitudinal data, 
comprising patients with a confirmed diagnosis of PSC and established colonic IBD 
undergoing colonoscopic surveillance for neoplasia between 2000-2015 from 2 secondary 
and 6 tertiary centers from the Netherlands and one tertiary center from Mount Sinai Hospital 





endoscopic, and histological information was retrieved at every colonoscopy during follow-
up and documented according to a predefined protocol using the same database. The 
incidence rates of aCRN overall and of aCRN following a diagnosis of IND and LGD will 
be compared.  
 
Contribution of the PhD candidate 
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which was used to identify patients within the Mount Sinai Health System Data warehouse. 
The candidate contributed to data abstraction and data capture alongside with junior 
colleagues who showed interest in participating in this research. Later on, after a meeting 
with Dutch investigators where preliminary results were presented, the decision was made 
to combine both databases. The candidate participated in this process and contributed to the 
framework of the statistical analysis in collaboration with Dr. Joren tenHove in the 
Netherlands. The candidate was involved in the planning and writing of the paper in 
collaboration with Dr. Sha and Dr. tenHove. This fruitful collaboration resulted in the 
successful presentation of the work below in several international conferences, and finally 
in the publication of this work in Clinical Gastroenterology and Hepatology (Impact factor: 
7.39): “High Risk of Advanced Colorectal Neoplasia in Patients with Primary Sclerosing 
Cholangitis Associated with Inflammatory Bowel Disease. Shah SC, Ten Hove JR, 
Castaneda D, Palmela C, Mooiweer E, Colombel JF, Harpaz N, Ullman TA, van 
Bodegraven AA, Jansen JM, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, van 
der Woude CJ, Oldenburg B, Itzkowitz SH, Torres J. Clin Gastroenterol Hepatol. 2018 Mar 








MATERIAL AND METHODS  
 
Study population and case identification 
Patients with established IBD colitis undergoing colonoscopic surveillance between 2000-
2015 were retrospectively identified from two databases: A Dutch database inclusive of 2 
secondary and 6 tertiary centers and the Mount Sinai Hospital database in New York City 
inclusive of one tertiary IBD referral center. Cases were identified by query of the electronic 
health record (EHR)-linked database utilizing both ICD-9 and -10 codes and free text 
searches for cases of IBD and free text searches for PSC. 
 
Patient selection (inclusion and exclusion criteria) 
After initial identification through the EHR query, individual charts were reviewed.  For 
PSC-IBD patients, a clinical diagnosis of PSC had to be confirmed by distinctive features 
on cholangiography or liver biopsy (for those with small-duct PSC).  Additional inclusion 
criteria were: 1) diagnosis of IBD [UC, CD, IBD unclassified (IBD-U)] with colonic 
involvement confirmed endoscopically and histologically; 2) confirmed colonic disease 
duration of at least 8 years for non-PSC IBD or any colonic disease duration for PSC-IBD 
patients; 3) enrollment in a surveillance program and 4) at least left-sided colitis (UC or IBD-
U) or involvement of >30% of the colonic surface (CD or IBD-U). Patients with a history of 
colectomy prior to enrollment or history of aCRN prior to or at the index colonoscopy during 
the defined study period were excluded. Surveillance procedures were defined as 
colonoscopies in which either segmental random biopsies or chromoendoscopy were 
employed. Colonoscopies with other indications, e.g. medically refractory disease, were 
excluded. The index colonoscopy was defined as the first surveillance colonoscopy 
performed within the study period (2000-2015). 
 
Data collection 
Database coding was identical for all study populations. The date of study entry was set at 
the first surveillance colonoscopy in the database. The time of onset of PSC or IBD was 






The following baseline demographic and clinical data were abstracted: date of birth, sex, 
date of PSC diagnosis (if applicable), date of IBD diagnosis, IBD type, maximum disease 
extent, and date of prior diagnosis of IND and/or LGD (if applicable). Maximum disease 
extent was defined as the maximum documented extent of endoscopic disease on any 
colonoscopy and was coded as follows: extensive/pancolitis (>50%) or intermediate/left-
sided (30-50%). Medication exposure (at least one prescription) was recorded for 5-
aminosalicylates (5-ASA), thiopurines, and biologics.  
Data from each surveillance colonoscopy was recorded, including date of exam, quality of 
bowel preparation (adequate or inadequate), most proximal extent examined, use of 
chromoendoscopy, presence and severity of endoscopic inflammation, presence of post-
inflammatory polyps (“pseudopolyps”), stricture(s) and visible lesions. Endoscopically 
detected neoplastic lesions were categorized based on morphology (polypoid/non-polypoid). 
Endoscopically invisible neoplasia was defined as neoplasia detected in a random biopsy 
with no corresponding morphologic lesion seen on endoscopy. Right-sided lesions were 
defined as those proximal to the splenic flexure.  For each surveillance colonoscopy, severity 
of active endoscopic inflammation was scored on a 4-point scale for each colonic segment 
visualized: 0 (no inflammation/remission), 1 (mild inflammation), 2 (moderate 
inflammation) or 3 (severe inflammation). A mean inflammatory severity score per patient 
and per colonoscopy was calculated by dividing the sum of inflammatory severity scores by 
the total number of colonic segments visualized per colonoscopy and then by the total 
number of surveillance colonoscopies.  
 
Histology 
Dysplasia was recorded as indefinite (IND), low-grade (LGD), or high-grade (HGD). All 
histologic diagnoses were as reported in the original pathology report; no specimens were 
re-reviewed or altered for this study. Of note, it is routine clinical practice at each 
participating institution that all pathology concerning for colorectal neoplasia is reviewed at 
the time of diagnosis and agreed upon by at least two pathologists.  
 
Primary and secondary outcomes 
The primary outcome was a diagnosis of aCRN, defined as HGD or CRC, during follow-up. 





development of aCRN following a diagnosis of IND and/or LGD. Factors associated with a 
diagnosis of aCRN in both PSC-IBD and non-PSC IBD patients with or without a prior 
diagnosis of IND and/or LGD were explored.   
 
Statistical analysis 
Basic descriptive statistics were generated for patients meeting inclusion criteria. Chi-square 
and Fisher’s exact tests were used to compare categorical variables and dichotomous 
outcomes, while the Student’s t-test and Mann-Whitney U-test were used for analyzing 
continuous data. Incidence rates were calculated as the number of cases per 100 patient-
years (pty) of follow-up. Univariate and multivariate Cox-regression modeling was used to 
identify factors associated with aCRN. The proportional hazards assumption of time-static 
covariates was assessed using log-log plots and Schoenfeld residuals. Because inflammatory 
scores were not stable over time, these were inputted as time-changing covariates into the 
models. Mean inflammation scores were re-calculated at every time-point for each patient 
to correct for the also variable number of colonoscopies. A p-value of ≤0.10 was used as the 
cutoff for selecting variables for the multivariate analysis. Kaplan-Meier survival curves 
were generated to compare cumulative incidence rates. Follow-up data were censored at the 
last point of colonoscopic follow-up, aCRN diagnosis, or colectomy. All data analyses were 





Baseline demographic and clinical characteristics  
Of 1,911 patients with colonic IBD in the combined database meeting inclusion criteria, 293 
patients were confirmed to have PSC-IBD; the remaining 1,618 patients with non-PSC IBD 







Figure 20 - Description of patient selection and main outcomes in each database. Overall, 293 
PSC-IBD patients were compared with 1618 IBD alone patients. The man follow-up period for the 
whole cohort was 4.8 years. 
 
 







Male (%) 205 (70.0%) 796 (49.2%) <0.001 
Age at study inclusion, mean (SD) 39 (14) 45 (13) <0.001 
IBD type 
- Ulcerative colitis 














































- Indeterminate colitis 14 (4.8%) 45 (2.8%) 
Disease extent 
- Not specified 














Age at IBD diagnosis, mean (SD) 27 (13) 28 (12) 0.11 
IBD duration, mean (SD) 12 (10) 17 (9) <0.001 

















Duration of follow-up after index 
colonoscopy  












Number of surveillance colonoscopies 
(mean) 
3.8 3.3 <0.001 
 
Table 11 - Baseline characteristics of the study population. PSC: Primary sclerosing cholangitis; 
IBD: inflammatory bowel disease. 
 
 
Compared with the non-PSC IBD group, PSC-IBD patients were more often male and 
younger at study entry, although the age of IBD diagnosis was similar between groups 
(p=0.11), and thus reflecting earlier surveillance start in the PSC-IBD group. Likewise, the 
IBD disease duration was shorter in the PSC group. As expected, UC was the predominant 
IBD type in the PSC-IBD group. PSC-IBD patients were less frequently exposed to IBD 





In 151 patients (51.5%), the PSC diagnosis was established after the IBD diagnosis, while 
in 36 (12.3%) PSC was established before the IBD diagnosis. For the remainder, PSC and 
IBD were diagnosed within the same year or the sequence of diagnoses was not recorded. 
The mean follow-up for the total cohort was 4.8 (±3.0) years, with a total of 9,265 patient-
years of follow-up; there was no difference in follow-up time between PSC-IBD and non-
PSC IBD patients. The number of surveillance colonoscopies performed within the study 
period was higher in PSC-IBD patients (3.8 vs. 3.3, p<0.01). 
 
Inflammatory activity 
The endoscopic severity of inflammation on surveillance exams was similar between PSC-
IBD and non-PSC IBD patients (Table 12). As expected, the proportion of procedures in 
which extensive active disease was observed in PSC-IBD vs. non-PSC IBD patients was 
27% vs. 12% (p<0.01), 23% vs. 10% (p<0.01), and 27% vs. 10% (p<0.01) for the first, 
second and third surveillance colonoscopy, respectively. The proportion of patients in 
endoscopic remission on each of their surveillance colonoscopies during the entire study 
period was higher in non-PSC IBD compared to PSC-IBD patients (p=0.02). 
 
  PSC-IBD Non-PSC IBD p-value 
Severity of active inflammation, mean [0-3]* 0.55 0.56 0.89 
Extent of active inflammation, mean [0-3]* 1.36 1.17 0.003 
Activity ratio for all surveillance 
colonoscopies (active/inactive) 
45% 41% 0.19 
No inflammation on ALL surveillance 
colonoscopies 
76 (27.1%) 546 (34.1%) 0.02 
Inflammation extent (1st colonoscopy) 















Inflammation extent (2nd colonoscopy) 












Table 12 -  Inflammatory parameters during surveillance. *=corrected for total number of 














Inflammation extent (3rd colonoscopy) 

















Endoscopic inflammation severity (1st 
colonoscopy) 



















Endoscopic inflammation severity (2nd 
colonoscopy) 
- No activity  
- Mild  
- Moderate   


















Endoscopic inflammation severity (3rd 
colonoscopy) 
- No activity  
- Mild 
- Moderate   




















Occurrence of aCRN and associated risk factors 
Among PSC-IBD patients, aCRN was diagnosed in 17 patients (5.8%), with CRC in 7 
(2.4%) and HGD in 10 patients (3.4%) (Table 13).  
 
 
Table 13 - Description of the outcomes during the study period. CRC=colorectal cancer, 




The frequency of aCRN during follow-up was significantly lower in non-PSC IBD patients 
(2.9%), with CRC and HGD diagnosed in 1.4% and 1.5% patients respectively (p=0.01). 
The incidence rate of aCRN in PSC-IBD compared to non-PSC IBD patients was 




















(patients with ≥1 LGD lesion) 
60 (20.5%) 295 (18.2%) 0.37 
IND 
(patients with IND as highest grade 
lesion) 
27 (9.2%) 74 (4.6%) 0.001 
Time from IBD diagnosis to aCRN 
diagnosis, mean (years) 
19.4 24.3 0.15 
Time from database entry to aCRN 
diagnosis, mean (years) 
4.2 3.4 0.31 
Time from LGD to aCRN diagnosis, 
mean (years) 
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Figure 21 - Kaplan-Meier time-to-event (aCRN) analysis, all patients since study entry. The 
Incidence rates were calculated as the number of cases per 100 patient-years (pty) of follow-up. The 
incidence rate of aCRN in PSC-IBD compared to non-PSC IBD was 1.3 vs. 0.6 per 100 patients 
years (Log rank, p<0.01). 
 
While aCRN was more often right-sided in PSC-IBD compared to non-PSC IBD patients, 
this was not statistically significant (53% vs. 31%, p=0.12). Among 40 PSC-IBD patients 
(14%) where the diagnosis of PSC was newly established within the study period, three cases 
of aCRN occurred, with a mean duration of 4.0 years (±2.5) between the PSC diagnosis and 
aCRN occurrence.  
Since we were including patients from different geographic region and different medical 
settings (tertiary and secondary centers), we compared the main patient´s characteristics, as 
well the primary outcomes stratified by study site. Results can be found detailed in Table 
14. As it can be seen, there were some differences between study sites, namely higher 
proportion of exams with high-grade and low-grade dysplasia in the US vas compared to the 
Netherlands, probably reflecting the tertiary center setting. No major differences in the 
patient population were found, namely in what regards proportion of extensive 











Male (%) 674 (53.1%) 327 (50.9%) 0.37 
Age at study inclusion, mean (SD) 45 (12) 41 (15) <0.001 
Age at IBD diagnosis, mean (SD) 29 (12) 26 (14) <0.001 
Primary sclerosing cholangitis (PSC) 171 (13.5%) 122 (19.0%) 0.002 
Age at PSC diagnosis, mean (SD) 33 (12) 32 (16) 0.37 
IBD type 
- Ulcerative colitis 
- Crohn’s colitis 



























Number of surveillance colonoscopies 
(mean) 
3.4 3.3 0.25 
Interval between surveillance 
colonoscopies, years (mean) 
1.6 1.2 <0.001 
Neoplasia Outcomes:    
Colorectal cancer (CRC) 17 (1.3%) 12 (1.9%) 0.37 
High-grade dysplasia (HGD) 15 (1.2%) 20 (3.1%) 0.003 
Low-grade dysplasia (LGD) 264 (20.8%) 88 (13.7%) <0.001 
 







We then sought to determine which were the independent risk factors for advanced colorectal 
neoplasia development. On multivariate Cox-regression analysis, PSC (adjusted HR (aHR) 
2.01, 95%CI: 1.09-3.71), increasing age (aHR 1.03, 95% CI: 1.01-1.05), and active 
inflammation (aHR 2.39, 95%CI: 1.63-3.49) remained independent predictors of aCRN 
diagnosis during follow-up after adjusting for severity of inflammation over time, as time 
changing co-variate (Table 15). 
  
 Univariate Multivariate 
Variable HR 95% CI P-value aHR 95% CI P-value 
Age (years) 1.02 1.01-1.04 0.03 1.03 1.01-1.05 0.007 
Age at IBD diagnosis  1.00 0.98-1.02 0.78    
Sex (male) 1.83 1.08-3.08 0.02 1.62 1.94-2.79 0.08 
PSC 2.13 1.22-3.70 0.01 2.01 1.09-3.71 0.03 
Inflammation severity, 
mean [0-3]* 
2.14 1.48-3.09 <0.001 2.39 1.63-3.49 <0.001 
IBD type (reference: UC) 0.99 0.60-1.61 0.95 
ns 
Maximum disease extent 
(reference: pancolitis) 
1.43 0.85-2.41 0.18 
Thiopurine exposure 0.84 0.51-1.40 0.85 
Biological exposure 0.72 0.36-1.46 0.36 
5-ASA exposure 1.14 0.58-2.25 0.70 
Number of surveillance 
procedures 
0.96 0.84-1.09 0.53 
 
Table 15: Uni- and multivariate Cox-regression analysis for the overall risk of aCRN (all 
patients). Listed are the Hazard ratios (HR) and corresponding p values. Non-significant values are 
not listed. *entered as time-changing covariate; 0 (no inflammation/remission), 1 (mild), 2 









Correcting for geography (US vs. Netherlands) did not affect these findings (Table 16). 
 Univariate Multivariate 
Variable HR 95% CI p-value aHR 95% CI p-value 
PSC 2.13 1.22-3.70 0.008 1.85 1.00-3.43 0.049 
Inflammation  
(severity [0-3])* 
2.14 1.48-3.09 <0.001 2.08 1.42-3.07 <0.001 
Sex (reference: male) 1.83 1.08-3.08 0.02 1.68 0.97-2.89 0.06 
IBD type (reference: UC) 0.99 0.60-1.61 0.95    
Maximum disease extent 
(reference: pancolitis) 
1.43 0.85-2.41 0.18    
Age at IBD diagnosis  1.00 0.98-1.02 0.78    
Age (years) 1.02 1.01-1.04 0.03 1.03 1.01-1.05 0.004 
Thiopurine exposure 0.84 0.51-1.40 0.85    
Biological exposure 0.72 0.36-1.46 0.36    
5-aminosalicylate 
exposure 
1.14 0.58-2.25 0.70    
Number of surveillance 
procedures 
0.96 0.84-1.09 0.53    
Population (reference: US) 2.82 1.72-4.62 <0.001 2.20 1.30-3.74 0.003 
 
Table 16 -  Uni- and multivariate Cox-regression analysis for the overall risk of aCRN (all 
patients), corrected for study site. *entered as time-changing covariate; 0 (no 
inflammation/remission), 1 (mild), 2 (moderate), 3 (severe). 
 
 
Risk of aCRN following a diagnosis of IND and/or LGD 
The number of patients in the total cohort with at least one diagnosis of IND was 147 (7.7%). 
In 101 patients (5.3%) no additional dysplasia was detected. Among patients with a diagnosis 
of IND, the rate of developing aCRN following detection of IND was higher in PSC-IBD 
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Figure 22 - Kaplan-Meier time-to-event (aCRN) analysis for patients with IND; time from first 
IND within study interval to event. (p=0.02, log-rank test). IND: indefinite dysplasia 
 
 
However, when patients with a synchronous or metachronous diagnosis of LGD (n=46) were 
excluded from this analysis (i.e. no grade of dysplasia higher than IND), this difference was 
no longer significant. 
 
The occurrence of at least one LGD-containing lesion during the study period was similar 
for both PSC-IBD and non-PSC IBD patients (21% vs. 18%, p=0.37). Despite a similar 
proportion of patients with LGD, the rate of developing aCRN following detection of LGD 
was almost 3-fold higher in PSC-IBD compared to non-PSC IBD patients (8.4 vs. 
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Figure 23 - Kaplan-Meier time-to-event (aCRN) analysis, patients with LGD only. The 
incidence rate of aCRN patients following a diagnosis of LGD was The incidence rate of aCRN in 
PSC-IBD compared to non-PSC IBD was 8.4 versus 3.0 per 100 patient years (Log rank, p<0.001)- 
 
 
For the subgroup of patients with LGD, the number of patients in whom endoscopically 
invisible LGD was detected over the course of surveillance was higher in PSC-IBD patients 
(38% vs. 22%, p=0.01). The proportion of invisible LGD cases among the total number of 
LGD cases (per-colonoscopy analysis) was also higher. In a sub-analysis of the Netherlands 
population, we corrected for the total number of random biopsies taken (107,745 biopsies in 
total); the number of random biopsies needed to detect invisible dysplasia was 826 in PSC-
IBD patients compared to 1,703 in non-PSC IBD patients. 
On univariate Cox regression analysis, only PSC and multifocal dysplasia were associated 
with higher risk of aCRN diagnosis following LGD detection, while polypoid morphology 
of the lesion (vs. nonpolypoid or invisible) was associated with a lower risk. On multivariate 





risk of aCRN (aHR 0.31, 95%CI: 0.14-0.65) following LGD detection compared to 
nonpolypoid or endoscopically invisible lesions (Table 17).  
 
 Univariate Multivariate 
Variable HR 95% CI p-value aHR 95% CI p-value 
PSC 2.52 1.19-5.31 0.02 1.79 0.83-3.88 0.14 
Sex (reference: male) 1.23 0.60-2.49 0.57    
Thiopurine exposure 1.20 0.60-2.40 0.60    
Biological exposure 0.74 0.23-2.44 0.74    
5-Aminosalicylate 
exposure 
1.07 0.44-2.59 0.88    
Dysplasia characteristics       
Distal location 1.69 0.77-4.32 0.17    
Multifocality 2.46 1.22-4.95 0.01 1.90 0.93-3.87 0.08 
Polypoid morphology 0.27 0.13-0.57 0.001 0.31 0.14-0.65 0.002 
Invisible dysplasia 1.64 0.76-3.53 0.21    
Nonpolypoid 
morphology 
1.82 0.70-4.74 0.22    
 
Table 17- Uni- and multivariate Cox-regression analysis for the risk of aCRN* following 
detection of low-grade dysplasia (LGD). *advanced colorectal neoplasia, aCRN: defined as 





In the work herein presented through a collaboration developed with a Dutch group that also 
performs research on the field of dysplasia and IBD, we were able to assemble a large 
multicenter international retrospective cohort with longitudinal data. This cohort comprised 
patients with a confirmed diagnosis of PSC and established colonic IBD undergoing 
colonoscopic surveillance for neoplasia between 2000-2015 from 2 secondary and 6 tertiary 





City. Patients were carefully characterized and clinical, endoscopic, and histological 
information was retrieved at every colonoscopy during follow-up and documented according 
to a predefined protocol using the same database. Through this collaboration, we could 
include 1911 patients (293 PSC-IBD, 1618 non-PSC IBD) for a total of 9,265 patient-years 
of follow-up, making our study probably the largest cohort of PSC-IBD patients undergoing 
surveillance. Having access to such a large database with longitudinal information, we were 
not only able to corroborate previous literature reporting a higher risk of aCRN in patients 
with concomitant PSC as compared to those without PSC, but also add to the literature by 
confirming this in the current era of improved endoscopic technology and more effective 
medical therapy for inflammation. In our well-characterized surveillance cohort, which, to 
our knowledge, is the largest published cohort of PSC-IBD patients undergoing surveillance, 
we found that PSC-IBD is associated with a 2-fold higher risk of aCRN. This risk is slightly 
lower as compared to prior studies as a recent meta-analysis of 16 studies reported a 3.4-fold 
higher odds for colorectal neoplasia in PSC-IBD patients305. Importantly, the increased risk 
in our study remained after correcting for active endoscopic inflammation over time (which 
was employed as a time-changing covariate rather than a mean overall score). Endoscopic 
activity assessed during subsequent colonoscopies was strongly associated with the risk of 
future aCRN, congruent with studies in the non-PSC IBD population306. Whether the 
outcomes of endoscopic inflammation compared to histologic inflammation are distinct 
remains a question for future investigation. 
  
We further expand knowledge in the field by reporting an even higher risk of aCRN 
following detection of LGD (but not IND alone). An important observation from our study 
that distinguishes PSC-IBD from non-PSC IBD patients, is that dysplasia was more often 
detected in random biopsies. While previous retrospective studies have shown a low overall 
yield for dysplasia with random biopsies as opposed to only targeted biopsies of visible 
lesions, there was higher yield for dysplasia on random biopsy in those with concurrent PSC. 
Our data further add to this body of evidence, and therefore it can be questioned whether the 
current recommendation based on the results of prospective studies to move away from 
random biopsies as part of CRC surveillance should be applied to PSC-IBD patients307, 308 
That LGD was more often endoscopically invisible in PSC-IBD compared to non-PSC IBD 
validates the more intensive management considerations for this population. During 





sided cancers seem to be more common in PSC-IBD compared to non-PSC IBD colitis155. 
While the proportion of right-sided aCRN was higher in the PSC- subgroup, this difference 
was not statistically significant in the present study and may be due to insufficient power; it 
may also reflect selection bias since one of our inclusion criteria for the non-PSC IBD 
subgroup was at least left-sided disease extent or more than 30% involvement, and thus may 
not represent the overall IBD population. Our study confirms that the date of PSC diagnosis 
is particularly relevant when risk-stratifying patients, since it seems that the risk of neoplastic 
progression is highest within the first few years of the PSC diagnosis.36 In a sub-analysis of 
newly diagnosed PSC-IBD patients within our study time frame, all cases of aCRN occurred 
within 8 years of PSC diagnosis. Thus, while CRC surveillance is recommended after disease 
duration of 8 years in patients with colonic IBD and no PSC, CRC surveillance at the time 
of diagnosis in the setting of PSC is recommended and further corroborated by our findings. 
 
Our study has several strengths. In addition to being perhaps the largest IBD surveillance 
cohort in the modern era, our cohort is particularly robust since each patient was confirmed 
to have colonic IBD and to be actively enrolled in a colonoscopic CRC surveillance program. 
Comprehensive data on disease history and endoscopic findings during surveillance allowed 
for more accurate neoplastic risk assessment, particularly with respect to measurement of 
inflammatory burden over time. Importantly, detailed information on inflammatory activity 
at each colonoscopy was incorporated into the analysis for more accurate assessment of 
aCRN development in PSC-IBD. Our study also has some limitations, most notably the 
retrospective design. Although we combined surveillance cohorts from two different 
countries, we predefined the inclusion/exclusion criteria, variables to be assessed, and 
definitions of outcomes. Combining these two cohorts enhanced not only our power to detect 
meaningful differences, but also the generalizability of our findings given that our study 
population included patients from affiliated sites as well as tertiary IBD referral centers. 
Even so, while we did not detect striking differences in patient demographics or follow-up 
patterns between the two countries, there may be unmeasured differences in care pathways 
between the included sites. That said, our results remained significant even after adjusting 
for geography. Unfortunately, the lack of standardized guidelines for the use of 
chromoendoscopy for CRC surveillance in IBD colitis precluded a meaningful analysis of 
its impact on dysplasia detection and diagnosis since ≤10% of exams in our combined cohort 





between the two groups are also unclear, but some possible explanations include a milder 
clinical course prompting less therapeutic intervention, possible liver test abnormalities in 
the PSC-IBD population raising clinicians’ threshold for thiopurine and biologic use, and 
possible hesitancy of additional immunosuppression if PSC-IBD patients are post-liver 
transplant, particularly in the absence of clinical colitis symptoms. Lastly, we could not 
reliably assess the impact of PSC phenotype (e.g. small-duct PSC), ursodeoxycholic acid, 
liver tests abnormalities, or liver transplant/post-transplant immunosuppression on aCRN 
risk in the PSC-IBD population since this information was not universally available in the 
whole cohort. 
 
The increased risk of CRC in patients with PSC and concomitant colonic IBD has firmly 
been established, although the underlying mechanism remains unclear36.The nearly 3-fold 
higher rate of aCRN diagnosis following LGD detection, as well as the difference in location, 
morphology, and endoscopic conspicuousness of dysplasia in PSC-IBD compared to non-
PSC IBD suggests nuances in the pathogenesis of neoplasia between these groups. Because 
the mechanisms underlying PSC as an independent risk factor for CRC in the setting of IBD 
colitis are unclear, the best strategy for CRC prevention in PSC-IBD remains frequent, 
attentive surveillance colonoscopy. Therefore, our findings suggest that while continued 
meticulous CRC surveillance with annual colonoscopy is indicated in the absence of 
dysplasia for PSC-IBD patients, and that the detection of LGD or higher-grade pathology 
should lead to a careful weighting of the pros and cons of more aggressive therapeutic 













































IBD are diseases with an increasing incidence worldwide, affecting young patients and with 
great impact in quality of life. In the past years, significant progress has been made in the 
management of IBD due to better knowledge about disease pathophysiology leading to the 
definition of new therapeutic targets and discovery of novel therapies. The association of 
IBD with PSC, despite being a rare event, carries a bad prognosis, due to higher likelihood 
of developing hepatobiliary cancer, colorectal cancer and/or greater risk of progressing to 
OLT or death56. PSC-IBD remains a disease where the few advances in the knowledge about 
pathophysiology have not yet translated into better treatment for patients and improved 
prognosis. In this thesis, we have tried to gain insight into some specific aspects of PSC-IBD 
natural history and pathophysiology: 
 
1.! Patients with PSC-IBD have a high risk of advanced colorectal neoplasia (aCRN) and 
higher rate of progression from low-grade to aCRN 
Due to their high risk of developing colorectal dysplasia and cancer76, patients with PSC-
IBD need special colonic surveillance protocols. Therefore, all IBD societies recommend 
annual colonoscopy starting at the time of the PSC diagnosis, independently of the duration 
of the IBD. However, one important unanswered question in clinical practice remained the 
management of low-grade dysplasia (LGD) in these patients. This question is relevant, as in 
IBD alone, LGD progresses very rarely into more advanced forms of dysplasia (high-grade 
dysplasia or colorectal cancer), and many clinicians are reluctant to recommend a 
proctocolectomy in this situation, and rather continue an intensive surveillance protocol309-
311. This approach has been gaining even more popularity due to better surveillance 
techniques (with the advent of high-definition scopes and chromoendoscopy) and better 
endoscopic management and ability to resect dysplastic mass lesions. However, not enough 
data was available in PSC-IBD.  
The PhD candidate therefore, proposed to start a project looking into the natural history of 
LGD lesions in PSC-IBD. The project started at Mount Sinai Hospital, a tertiary center with 
a high-volume of PSC patients; during an investigator meeting the opportunity to collaborate 
with Dutch investigators who perform research in the area of dysplasia in IBD appeared, and 
a fruitful collaboration was started. We gathered a cohort of almost 300 PSC-IBD and 1600 





surveillance colonoscopies and histopathology reports available. We confirmed the high risk 
for PSC-IBD patients to develop aCRN as compared to IBD alone, and we showed, 
unequivocally, that once patients with PSC-IBD have a diagnosis of LGD in their colon, 
there is a faster progression to aCRN (incidence rate of 1.3 per 100 patient-years as compared 
to 0.6 per 100 patient-years in IBD alone). Like in other cohorts, we also observed that 
colorectal neoplasia was more frequent in the right colon, albeit non-significantly. 
Importantly, and with an impact on the surveillance protocols we also showed that patients 
with PSC-IBD present more often invisible dysplasia, suggesting that in this subset of 
patients, the practice of performing random as opposed to targeted biopsies should probably 
not be abandoned. We thus believe our cohort has made a substantial contribution to the 
literature, with a direct impact on the care of patients. 
 
2.! Patients with PSC-IBD present lower expression of the primary bile acid receptor in their 
colon, as compared to IBD alone.  
The reasons to why patients with PSC-IBD present with a unique phenotype characterized 
by extensive but mild colitis, and high risk for colorectal neoplasia (CRN) remains unknown. 
Since these patients have usually mild forms of colitis, other mechanisms besides 
inflammation must be at play to explain the increased risk of cancer.  
BA homeostasis is tightly regulated by the activation of Farnesoid X Receptor (FXR), a 
nuclear bile acid receptor, expressed at high levels in liver and intestine152, which plays an 
important role in entero-hepatic circulation of bile acids. It has been previously shown that 
intestinal inflammation decreases FXR cellular expression and that FXR knockout mice have 
an increased risk of colorectal cancer. We were able to show that FXR expression was 
diminished in dysplasia and cancer, with an inverse correlation within the neoplastic 
sequence (more severe degrees of dysplasia presented lower FXR expression), and was also 
globally down-regulated in PSC-IBD patients, independently of inflammation and more so 
in the right colon. This finding was unexpected,  but led us to hypothesize that a lower 
expression of FXR in the right colon could expose colonocytes to higher levels of secondary 
bile acids or other toxic products, increasing carcinogenesis risk312. It is thus tempting to 
hypothesize that agonists of FXR could be an interesting approach for patients with PSC-
IBD. As a matter of fact  an FXR agonist, obeticolic acid,  has been developed and approved 





Recently, positive results of the use of this agonist in PSC have been released by the 
Pharmaceutical company developing the drug314. 
 
3.! PSC-IBD patients display a different mucosa-associated microbiome as compared to 
IBD patients alone 
In the past years there has been increasing indirect evidence that luminal gut bacteria play a 
role in the pathogenesis of IBD36, liver diseases315, and colorectal cancer316.  
The first project that we developed at Mount Sinai, involved the collection of colonic 
biopsies from PSC-IBD patients, IBD alone patients and healthy volunteers.  Considering 
the higher prevalence of neoplasia in the right colon in PSC-IBD patients, we specifically 
wanted to assess if there were any differences in the spatial distribution of the mucosa-
associated microbiota between 3 different locations: terminal ileum, right and left colon. No 
significant site-specific differences in the microbial composition were found throughout the 
colon, suggesting that other mechanisms may be operating and interacting differently with 
the microbiota in the right as opposed to the left colon in patients with PSC-IBD. In this 
study, using bacterial 16S rRNA next-generation sequencing, we found, across all colonic 
locations, a consistent PSC-enrichment in Blautia and Barnesiellaceae genera and shifts in 
the Clostridiales, and less frequently under the Bacteroidales order. More specifically, 
around 86% of the relative changes in the microbiota occurred within the Clostridiales order, 
which is interesting as shifts in these taxa have also been observed in IBD and cirrhosis206, 
231. It has been shown in the literature that the Clostridiales order, encompassing bacteria 
from Lachnospiraceae family, Ruminococcaceae family and Blautia genus, are able to 
perform 7α-dehydroxylation208, an important step in converting primary to secondary bile 
acids in the intestine. Furthermore, in advanced cirrhosis, and in parallel, with a reduced 
level of fecalsecondary bile acids, a shift in the gut flora towards the enrichment of 
Enterobacteriaceae and the reduction of Clostridiales and Bacteroidetes has also been 
described206. Altogether, our findings point to a shift in the mucosa-associated microbiome 
in PSC-IBD, driven by changes in the BA pool; however, since we were not able to collect 
serum or stool bile acids we could only infer this conclusion from our ecological description 







4.! PSC-IBD patients have a different fecal bile acid pool and microbiome and distinct 
microbiome-bile acid correlations 
There is a close relationship between gut flora and bile acids (BA)155, as BA have 
antimicrobial properties317, and conversely, bile salt metabolism is a property of the 
gastrointestinal microflora. We collected paired serum and stool bile acids from patients with 
PSC-IBD and IBD alone and studied its correlations with the gut flora. All samples were 
collected from Portuguese patients, and then shipped to Mount Sinai for fecal microbiome 
study and analysis. Serum BA were studied at Prof. Cecilia Rodrigues´s lab, and the stool 
bile acid profiles in in Prof. Dominique Rainteau´s lab (Paris, France). We observed that 
patients with PSC-IBD displayed different fecal microbiota composition and stool BA 
profiles, as well as different correlations with the gut microbiota. Their stool bile acid pool 
was significantly reduced as compared to IBD alone. Although the individual stool bile acid 
components were not significantly different (possibly due to small sample size) between 
PSC-IBD and IBD, there was a non-significant increase in deoxycholic acid, a secondary 
bile acid with carcinogenic properties in vitro in PSC-IBD, and overall the fecal BA 
composition differed between the two groups. PSC-IBD patients presented an enrichment in 
bacteria belonging to the genera Ruminococcus and Fusobacterium as compared to IBD 
alone. At the OTU level, we observed a decrease in Bacteroides, Clostridium, 
Bifidobacterium, and Lactobacillus genus, taxa known to be involved in bile acid 
deconjugation271. Some of our findings are in consonance with recently published results on 
PSC microbiota also showing an increase of Fusobacterium272, a bacterial taxon that has 
been linked with adenomas and colorectal cancer. We did observe an increase in the genus 
Blautia in IBD, which was in contrast with our findings in the mucosa-associated 
microbiome in our previous study. This may be explained by the reported differences 
between mucosa and stool microbiota278, and by the fact that different patient populations 
with different geographical background were studied. Without any functional data, we may 
only speculate that under PSC condition, the BA changes may have dominant effects on 
defining the gut microbiota shifts, potentially towards a more pro-carcinogenic profile. 
Bacteria from both Fusobacterium and Ruminococcus genus, are known to be involved in 
oxidation, epimerization and desulfatation of bile acids271. Future studies should consider 
the functional properties of the gut microbiome, going beyond the mere genetic 
characterization allowed by 16S sequencing. Along this line, we have started a collaboration 





patients. In summary, despite all the advances provided by many investigators, including 
ourselves, in the characterization of the gut microbiome in the setting of PSC-IBD, it remains 
to be shown whether these changes are cause or consequence of altered bile acid pool, 
inflammatory milieu, or other. Most importantly, whether microbiome-based biomarkers 
could be used to screen for disease complications, or whether microbiome-based therapies 
could be used in PSC-IBD (as suggested by preliminary results) should also be explored.  
It is clear that the gut-liver axis contributes to PSC pathogenesis and that further work 
unravelling this complex relationship could contribute to improve disease knowledge, 



















































Supplementary Table 1 
   






























The sequences of 16S PCR primers targeted on 860bp amplicons for PacBio 
sequencing. The reversed primer sequences include 16 bp barcodes (lower case) at the 
5'end  
Forward Primer  
Blautia-404F ATTGCACAATGGGGGAAACC 














Supplementary Table 1- 16S sequencing PCR primer sequences. The sequences of dual-
barcoding 16S PCR primers targeted on 460bp amplicons for Miseq sequencing. The primer 
sequences include 2 bp linker (italicized) and 6 bp barcodes (bold) at the 5’ end. 
 




PSC/Control Status Taxonomy P value 
606927 43.18 Enr. 




189960 35.34 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; [Barnesiellaceae]; ; 0.0197 
4433417 33.83 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Dorea; 0.0480 









188348 21.65 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0170 
334340 21.09 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0069 
4451907 18.37 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Dorea; 0.0455 
190653 18.29 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0451 
574038 14.50 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0190 
178977 13.44 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0162 
180721 12.99 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0149 
4372382 12.90 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0372 
199501 11.63 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Blautia; 0.0412 
360660 11.39 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Blautia; 0.0269 





335816 10.93 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0467 
184174 10.67 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; 0.0102 
190058 9.95 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0405 
2223978 9.75 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0303 
186981 8.76 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; [Barnesiellaceae]; ; 0.0247 
189996 8.65 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0309 
2177184 7.53 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0459 
174672 7.14 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0267 
182036 7.12 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0202 
2119695 6.98 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0459 
4423882 6.97 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; [Ruminococcus]; gnavus 0.0499 
808794 6.93 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0331 





563572 6.84 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0283 
184114 6.66 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0225 
187924 6.63 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0268 
192461 6.53 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0410 
4451899 6.08 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0275 
4344861 6.04 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; [Ruminococcus]; gnavus 0.0284 
180878 6.00 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0145 
2996838 5.99 Enr. Firmicutes; Clostridia; Clostridiales; ; ; 0.0405 
194758 5.79 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Coprococcus; 0.0077 
3424669 5.61 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0451 
174332 5.25 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Blautia; 0.0395 
190815 5.17 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; 0.0106 
4418787 5.13 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Roseburia; 0.0014 
195508 4.87 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; caccae 0.0303 
2724175 4.85 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0241 
3090048 4.69 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Coprococcus; 0.0344 
332210 4.67 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0474 
4472158 4.63 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; [Ruminococcus]; gnavus 0.0294 
191361 4.41 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0343 
182287 4.25 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0219 
186772 4.21 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0368 
177463 4.16 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Coprococcus; 0.0038 
191913 4.12 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0291 
198426 4.05 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0286 





199354 3.85 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; [Barnesiellaceae]; ; 0.0205 
194670 3.70 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; 0.0338 
4354582 3.65 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Dorea; 0.0418 
3702906 3.64 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; [Ruminococcus]; gnavus 0.0497 
191487 3.64 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; 0.0480 
199490 3.62 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0249 
3715618 3.59 Enr. Firmicutes; Clostridia; Clostridiales; ; ; 0.0369 
189760 3.51 Enr. Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; ; 0.0393 
194008 3.48 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Coprococcus; 0.0259 
183340 3.32 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Blautia; 0.0288 
3004856 3.30 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0365 
194415 3.30 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0469 
199694 3.29 Enr. Firmicutes; Clostridia; Clostridiales; Clostridiaceae; Clostridium; 0.0459 
185281 3.21 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Dorea; 0.0281 
176197 3.15 Enr. Firmicutes; Clostridia; Clostridiales; ; ; 0.0434 
198751 3.15 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Blautia; 0.0454 
187572 3.09 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0282 
174862 3.06 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0420 
2762219 2.88 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0325 
183662 2.75 Enr. Bacteroidetes; Bacteroidia; Bacteroidales; Bacteroidaceae; Bacteroides; 0.0483 
191081 2.74 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Coprococcus; 0.0194 
1860112 2.63 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0363 
1602805 2.62 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; ; 0.0103 
187569 2.58 Enr. Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Coprococcus; 0.0360 
192462 0.21 Red Firmicutes; Clostridia; Clostridiales; ; ; 0.0398 





4358921 0.10 Red Firmicutes; Clostridia; Clostridiales; ; ; 0.0490 
 
Supplementary Table 2 - The fold changes and relative abundance of selected differential 
OTUs in PSC vs. healthy controls in the left colon biopsies. Table columns represent mean of the 
selected OTUs in each study group: controls, IBD and PSC. The ratio between mean OTUs in PSC 










Supplementary Figure 1 
After OTU picking, the fold changes and the relative abundance of selected differential 
OTUs in PSC vs. IBDs in the LC, RC and TI biopsies were compared. The bar plots show 
the fold changes of the relative abundance of each selected OTUs in PSC vs. non-PSC IBDs. 
The pink color indicates the enrichment in PSC. The green color indicates the reduction in 
PSC. The mean abundance in PSC, non-PSC IBD and healthy controls is shown on the right. 
red: healthy control; green: non-PSC IBD; blue: PSC. When compared with healthy controls, 
most of the PSC-associated shifts in the bacterial composition were observed in the 
Clostridiales and Bacteroidetes orders, with 86% in the former order. In agreement with our 
above findings, several PSC-enriched OTUs belonged to the Blautia genus and the 
Barnesiellaceae family. When compared to IBD, many OTUs were from the Blautia genus. 
 
Supplementary Figure 2 
After OTU picking, the fold changes and the relative abundance of selected differential 
OTUs in PSC vs. IBDs in the LC, RC and TI biopsies were compared. The bar plots show 
the fold changes of the relative abundance of each selected OTUs in PSC vs. non-PSC IBDs 
at each different location (terminal ileum, right and left colon). Similar enrichments and 
reductions at the PSC-associated OTUs selected from LC samples were observed in RC and 
TI locations. 
 
Supplementary Figure 3 
The maximum likelihood phylogenetic tree within Blautia genus using UPGMA method was 
constructed. We combined 7 significantly PSC-associated OTUs and 15 reference sequences 
to construct the tree.  The colored bar plots present the relative abundance of selected OTUs 
in PSC and non-PSC (combined healthy control and non-PSC IBDs) subjects. The table 
shows the number of differences (upper) and the percent identity (lower) calculated from 
pair-wise sequence alignment comparison. The color gradient from blue to red indicates the 








Supplementary Figure 4 
Results of the linear discriminant analysis. (A) all analytes (glycine and taurine BA 
conjugates, BA sulfates) were used. In the top panel, the y axis represents the linear 
discriminant coefficient. In the lower figure, in the y axis is represented the probability of 
being correctly classified as PSC-IBD using all stool BA. In both panels, the x axis each 
marker represents a patient. The green markers represent patients with PSC-IBD and in the 
pink markers patients with IBD. The circle represents patients that were correctly assigned 
to their disease group. The classification accuracy of the LDA using all bile acids was 100%. 
(B) The probability of being correctly assigned to the PSC-IBD group using only the top 4 
most discriminative bile acids (GLCA, TLCA, TUDCA, and TLCA3S) is illustrated; the 
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FARNESOID X RECEPTOR EXPRESSION IS DECREASED IN COLONIC MUCOSA 








Farnesoid X Receptor Expression Is Decreased in Colonic
Mucosa of Patients with Primary Sclerosing Cholangitis and
Colitis-associated Neoplasia
Joana Torres, MD,*,† Xiuliang Bao, MS,* Alina C. Iuga, MD,‡ Anli Chen, MS,* Noam Harpaz, MD, PhD,‡
Thomas Ullman, MD,* Benjamin L. Cohen, MD,* Guillaume Pineton de Chambrun, MD,§,k
Stefania Asciutti, MD, PhD,¶ Joseph A. Odin, MD,** David B. Sachar, MD,* H. Rex Gaskins, PhD,††
Kenneth Setchell, PhD,‡‡ Jean-Frédéric Colombel, MD, PhD,*,§§ and Steven H. Itzkowitz, MD*
Background: The expression and distribution of farnesoid X receptor (FXR) in colitis and colitis-associated neoplasia (CAN) is unknown. We
investigated FXR expression in neoplastic and nonneoplastic tissue from ulcerative colitis (UC) patients, with or without primary sclerosing cholangitis
(PSC), as well as the role of DNA methylation in FXR expression in colorectal cancer (CRC) cell lines.
Methods: Samples from the right (RC) and left (LC) colon of patients with UC, with and without PSC, and with or without CAN, were stained by
immunohistochemistry and scored semiquantitatively for nuclear FXR expression. FXR expression was analyzed by western blot and polymerase chain
reaction (PCR) in nine different CRC cell lines before and after demethylation with 5-azacytidine.
Results: In nondysplastic samples, FXR expression demonstrated a diminishing expression from proximal to distal colon (strong FXR expression: 39%
RC samples vs. 14% LC samples; P ¼ 0.007). With moderate-to-severe inflammation, FXR expression was almost always absent or weak in both UC
and PSC-UC, regardless of location. With quiescent/mild inflammation, 56% of UC samples in the RC retained strong FXR expression versus 24% of
PSC-UC samples (P¼ 0.017). FXR was absent in 72% of the neoplastic samples, with an inverse association with the grade of dysplasia. FXR expression
was absent in all CRC cell lines, in some cases due to DNA methylation.
Conclusions: FXR expression is inversely correlated with neoplastic progression and severity of inflammation in UC. Patients with PSC-UC
have diminished FXR expression in the proximal colon compared to UC patients. This finding could contribute to the higher risk of proximal neoplasia in
PSC patients.
(Inflamm Bowel Dis 2013;19:275–282)
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P atients with inflammatory bowel disease (IBD) are atincreased risk for developing colitis-associated neoplasia
(CRN).1 Risk factors for developing CRN in the setting of
IBD include longer disease duration, more extensive inflamma-
tion of the colonic mucosa, family history of sporadic colon
cancer, endoscopically or histologically active inflammation,
and associated primary sclerosing cholangitis (PSC).2 Of all
these risk factors, PSC confers the highest risk of developing
colorectal neoplasia, z5-fold in some studies.3 Chronic inflam-
mation is considered a very strong promoter of colon car-
cinogenesis.2,4 Intriguingly, despite their very high colorectal
cancer (CRC) risk, patients with PSC-IBD typically have
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colitis that is very mild, with little or no symptoms and mini-
mal changes on colonoscopy. This high risk of CRC in PSC-
IBD patients in the setting of little inflammation poses an
intriguing paradox regarding inflammation-associated colonic
carcinogenesis.
Cancer risk may vary depending on the location in the
colon in patients with IBD. We recently demonstrated that
dysplasia and cancer occur more often in the left colon
(LC) of patients with extensive UC.5 Moreover, progression
from low-grade dysplasia (LGD) to high-grade dysplasia
(HGD) or CRC in UC patients is more common in the LC
compared to the right colon (RC).6 In contrast, patients
with PSC in the setting of UC have been reported to have
higher neoplasia risk in the proximal colon, for reasons that
are yet to be explained.7 One theory is that altered bile acid
composition and/or concentration in PSC patients, which may
be procarcinogenic, affect the proximal colon more so than the
distal colon.8
Bile acids have been implicated as causative factors in
colorectal carcinogenesis.9 Patients with UC and dysplasia or car-
cinoma have been shown to have higher concentrations of bile
acids in feces as compared to UC patients without neoplasia.10
Additionally, exposure of colonocytes to a higher load of second-
ary bile acids has been proposed as an explanation for the
increased risk of proximal CRN observed in the subset of patients
with PSC.8
Farnesoid X receptor (FXR) is a member of the nuclear
receptor superfamily, highly expressed in the liver and terminal
ileum, where it functions as the primary sensor for bile acids and
regulates cholesterol, fatty acid, and glucose metabolism.11
Recently, FXR has also been shown to have a role in maintaining
the integrity of the epithelial barrier and in innate immunity.12,13
In the colon, FXR expression has been inversely correlated with
both inflammation and carcinogenesis. FXR- knockout mice are
more susceptible to chronic intestinal inflammation and, con-
versely, FXR activation protects against intestinal inflammation
in mice, possibly by repressing nuclear factor kappa-B and by
counterregulating inflammatory cytokine expression in immune
cells.14,15 FXR mRNA expression seems to be decreased in colon
biopsies from macroscopically inflamed mucosa of patients with
Crohn’s disease (CD) but maintained in those with a normal
appearance at colonoscopy.13
With respect to neoplasia, FXR seems to function as a
tumor suppressor. For example, FXR mRNA expression is
decreased in sporadic adenomatous polyps, an effect that is even
more pronounced in colonic adenocarcinoma.16 Furthermore,
APC2/+ mice developed more intestinal neoplasms when they
were crossed with FXR2/2 mice.17
In the present study we evaluated FXR expression by
immunohistochemistry in colonic mucosa of patients with UC,
with or without PSC, and correlated this with location in the
colon, degree of inflammation, and presence or absence of CRN.
We also measured FXR mRNA expression in CRC cell lines and




Patients were identified using the Mount Sinai GI
Pathology and UC-Surveillance databases described in previous
studies.18 Besides demographic information, clinical information
such as extraintestinal manifestations and pathologic findings
from colonoscopies and operations, including anatomic extent
of disease at diagnosis, presence and grade of any dysplasia, and
presence and severity of inflammation at each biopsied segment
of colon were recorded. Additionally, for the measurement
of FXR expression in colitis-associated neoplasms, we ana-
lyzed samples in two tissue microarrays (TMAs) containing
samples of CRN from IBD patients (CRC, low- and high-grade
dysplasia).
Patients with extensive UC at diagnosis, with or with-
out PSC, were identified and their pathology blocks retrieved.
The presence or absence of PSC was based on the results
of serum biochemical tests and cholangiography and/or
hepatic biopsy. Patients with CD and indeterminate IBD were
excluded. From each patient, whenever available, samples
from the RC and LC were recovered. An attempt was made
to have samples representative of different degrees of histolog-
ical inflammation.
In all, 112 patients (84 males, median age 51 years)
were included in this study. All patients had extensive UC at
diagnosis (defined by greatest microscopic extent proximal
to the splenic flexure). Median disease duration for the patients
in whom that information was available was 20 6 13 years
(range 1–60 years). Twenty-one patients had no neoplasia in
the colon, whereas the others had neoplasia somewhere in the
colon. There were 24 patients with concomitant PSC. From all
these patients, 231 colonic samples (biopsy specimens, surgical
samples, and tissue microarrays) were obtained: 155 from
UC patients (62 from the RC) and 76 from PSC-UC (39 from
the RC).
Histologic Grading of Inflammation
and Neoplasia
For each nondysplastic sample, the severity of histol-
ogic inflammation was taken from the pathology report. These
specimens had been scored according to the histologic
activity index (HAI) that we previously validated and
described.18 Briefly, the degree of inflammation for each biopsy
site was scored as: absent or quiescent (0); mildly active (1);
moderately active (2); or severely active (3). Dysplasia was
diagnosed initially by one of the authors (N.H.) using the
criteria of the IBD Dysplasia Morphology Study Group19
and confirmed as a part of this study by a second GI patholo-
gist (A.C.I.).
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Immunohistochemistry
Immunohistochemistry for FXR was performed man-
ually on samples and tissue microarrays, using a mouse
antihuman FXR monoclonal antibody (Perseus Proteomics,
Tokyo, Japan). This antibody specifically recognizes human
FXR and crossreacts with mouse and rat FXR. From the
formalin-fixed, paraffin-embedded tissue blocks of biopsies
and colectomy specimens, sequential sections were cut at
4-mm thickness and mounted on adhesive slides. Slides
were deparaffinized in xylene and subsequently washed in
graded ethanol (100%, followed by 95%) and rehydrated
in distilled water. For antigen retrieval, sections were incubated
in a microwave for 30 minutes using a 0.1% sodium citrate
buffer and subsequently washed in phosphate-buffered saline
(PBS) at room temperature. Endogenous peroxidase activity
was blocked by incubating the slides with 3% H2O2 for
10 minutes and then rinsed three times with PBS. Sections
were incubated for 60 minutes at room temperature in 2%
bovine serum albumin (BSA) to avoid nonspecific signal,
and then overnight at 48C with the primary anti-FXR antibody.
Subsequently, slides were rinsed three times in PBS and
treated for 30 minutes at room temperature with a polyclonal
antimouse secondary antibody (EnVision+ System-HRP
Labeled Polymer Anti-mouse; Dako, Glostrup, Denmark),
and again washed three times with PBS. Slides were then incu-
bated with diaminobenzidine (DAB) using the peroxidase
substrate DAB kit (Vector Laboratories, Burlingame, CA).
After cleansing with water, slides were counterstained with
Harris modified hematoxylin solution for 50 seconds, dipped
in ethanol and in ammonia water, and rinsed in tap water
in between. Finally, sections were dehydrated in 95% and
100% alcohol consecutively, washed with xylene, and mounted
with VectaMount (Vector Laboratories). At least one section
with normal small intestinal mucosa was included for each
run as a positive control.
Evaluation of Immunohistochemistry
FXR nuclear expression was scored by two indepen-
dent, experienced observers (S.I. and A.C.I.) who were blinded
to the clinicopathological information. FXR nuclear staining
intensity was scored as absent (0), weak (+), and strong (++).
There was z95% concordance between the two observers.
Differences were resolved by consensus evaluation of the
slides.
FXR Gene Demethylation Experiments
Cell Culture
Human liver cell line HepG-2 cells were cultured in
RPMI-1640 medium (Invitrogen, La Jolla, CA) with 10%
fetal bovine serum (FBS) cell at 378C in 5% CO2 atmosphere.
Human colorectal cancer cell lines (Caco-2, HCT-116, HT-2,
and SW-480 cells) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen) with 10% FBS Cell
at 378C in 5% CO2 atmosphere. HepG-2, Caco-2, HCT-116,
HT-2, and SW-480 cells were seeded at a concentration 1 ·
104 cells/mL in 6-well cell culture plate, 2 mL/well, and the
following day, were treated with 0, 1, and 10 mM 5-aza-20-
deooxycytidine (5-aza) (Sigma-Aldrich, St. Louis, MO) in fresh
culture medium. 5-aza was removed by replacing the medium 24
hours later. The cells were harvested 4 days after removal of 5-
aza for RNA extraction.
Quantitative Real-time PCR Analysis of FXR
mRNA Expression
Total RNA was extracted using RNeasy Mini Kit (Qiagen,
Chatsworth, CA). One mg total RNA was used for cDNA synthesis
in RNA to DNA EcoDry Premix (Double Primed) (ClonTech, Palo
Alto, CA). FXR mRNA levels were evaluated by SYBE Green assay
using advantage qPCR premix (ClonTech) and primers: 50-
GCCTGTCTCCTGGGTCGCCT-30 (forward) and 50-TCCCCAT-
CACTGCACGTCCCA-30 located in exon 11. The mRNA level of
the target genes was normalized to GAPDH mRNA. Primers of
GAPDH: 50-ACCACAGTCCATGCCATCAC-30 and 50-TCCAC-
CACCCTGTTGCTGTA-30. All samples were analyzed in triplicate.
Statistical Analysis
Data analysis was performed using the computer software
Statistical Package for Social Sciences (SPSS for Mac, v. 19.0,
Chicago, IL). When appropriate, Fisher’s exact test, Student’s
t-test, and x2 tests were used for comparison between groups.
Statistical significance was set at P , 0.05.
Ethical Considerations
This study was approved by the Mount Sinai School of
Medicine Institutional Review Board.
RESULTS
FXR Expression in Nonneoplastic Mucosa
There were 152 samples without dysplasia from 62 patients:
66 from 22 PSC-UC patients, and 86 from 40 UC patients. Among
the nondysplastic samples, 70 came from 21 patients without
neoplasia, while 82 came from patients with neoplasia elsewhere
in the colon. Seventy-two samples were from the RC (mostly
ascending colon and proximal transverse) and 80 from the LC
(mostly sigmoid colon).
We observed that FXR expression was higher in the
RC than the LC. Overall, 32% of the samples from the RC
demonstrated strong expression, compared to only 14% in
the LC (P ¼ 0.011). When stratified by disease type, this dif-
ference remained statistically significant only for UC samples:
39.5% of the samples from the RC versus 16.7% had strong
FXR expression (P ¼ 0.017). In PSC-UC samples, while there
was also a trend toward stronger FXR expression in the prox-
imal colon (strong FXR expression in 23.5% of samples
from RC vs. 9.4% from LC), this did not reach significance
(P ¼ 0.11). Thus, FXR expression seems to be weaker in the
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LC of patients with UC and PSC-UC. FXR expression did
not differ according to location or disease type in samples from
patients without neoplasia compared to those with neoplasia
somewhere in the colon (data not shown).
When we compared FXR expression to the degree of
inflammation, as expected, samples with the highest degrees of
inflammation (moderate or severe inflammation) demonstrated
FXR expression that was almost always absent or weak in both
UC and PSC-UC, regardless of colonic location (Table 1).
Very few of the highly inflamed samples demonstrated strong
FXR expression. With quiescent or mild inflammation, FXR
expression was almost always absent or weak in the LC (87%
in UC, 90% in PSC-UC), reflecting the normal distal decrease
in FXR expression (Fig. 1E,F). In samples from the RC of UC
patients, FXR expression decreased with higher degrees of
inflammation: 56% of specimens with quiescent/mild inflam-
mation had strong FXR expression, compared to 7.7% (1/13)
with moderate/severe inflammation (P ¼ 0.005). Unexpect-
edly, the same pattern of FXR expression was not observed
in the RC of PSC-UC patients: 24% of the RC samples dis-
playing quiescent/mild inflammation had strong FXR expres-
sion compared to 20% of samples with moderate/severe
inflammation (Fig. 1B,C). Indeed, the main difference between
PSC-UC and UC was the finding that in the RC with quiescent
or mild inflammation 56% of UC samples retained strong FXR
expression, compared to only 24% of PSC-UC samples (P¼
0.017) (Table 1; Fig. 1).
Similar to previous observations in normal colon,20 we
observed that FXR immunoreactivity presented a gradient of
expression throughout the crypts, which was especially evident
in the RC. Thus, FXR expression was stronger at the crypt surface
and gradually decreased toward the base of the crypts, where it
was often absent (see Fig. 1B).
FXR Expression in Neoplastic Mucosa
From 9 PSC-UC and 62 UC patients, 79 samples of CRN
(19 colonoscopic biopsies and 60 samples from the TMAs) were
analyzed. There were 52 CRC (15 well differentiated; 14
moderately differentiated; 23 poorly differentiated), six high-
grade dysplasia (HGD) and 21 low-grade dysplasia (LGD).
Overall, FXR expression was absent in most (57/79;
72.2%) of the dysplastic and CRC samples. Among the samples
maintaining any FXR expression, there was an inverse correlation
with the degree of neoplasia (Fig. 2). FXR was expressed in LGD
(13/21; 61.9%), HGD (3/6; 50%), and CRC (6/52; 11.5%),
although the difference was significant only between dysplastic
samples versus cancer (Table 2).
No significant differences were observed according to
colonic location of the neoplasm, or between UC and PSC-UC
patients (data not shown). In the CRC samples that retained some
weak expression, no differences were found according to cancer
differentiation.
In Vitro Studies with Colon Carcinoma
Cell Lines
Compared to the HepG2 cell line, FXR expression at the
mRNA level was very low, and was undetectable by western blot
in all nine CRC cell lines. In HCT-116 and SW480 cells, 5-aza
treatment resulted in dose-dependent increases in FXR mRNA
expression. There were no significant changes in FXR mRNA
expression in Caco-2, SW480, and HepG2 cells after treatment
with 5-aza (Fig. 3).
DISCUSSION
The involvement of the FXR nuclear bile acid receptor in
both intestinal inflammation and carcinogenesis makes it an
interesting target to study in colitis and in colitis-associated
neoplasia. Furthermore, being the major regulator of the enter-
ohepatic circulation of bile acids, we specifically wanted to analyze
the influence of concomitant PSC in FXR’s colonic expression.
A recent study showed that there was no difference in ileal
and ascending colon FXR mRNA expression between controls,
CD, and UC patients in remission.21 However, the distribution of
FXR throughout the colon of patients with UC, or the regional
distribution and relation to inflammation in PSC-UC patients, has
not previously been reported. In UC patients, we observed a distal
TABLE 1. Relationship Between Degree of FXR Expression and the Degree of Inflammation According to Colonic
Location and Disease Type
Inflammation Location Disease type (n)
Absent or Weak
FXR Expression n (%)
Strong FXR
Expression n (%) P value
Quiescent-mild RC PSC-UC (29) 22 (75.9) 7 (24.1) 0.017
UC (25) 11 (44) 14 (56)
LC PSC-UC (29) 26 (89.7) 3 (10.3) 0.52
UC (30) 26 (86.7) 4 (13.3)
Moderate-severe RC PSC-UC (5) 4 (80) 1 (20) 0.49
UC (13) 12 (92.3) 1 (7.7)
LC PSC-UC (3) 3 (100) 0 (0) 0.51
UC (18) 14 (77.8) 4 (22.2)
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decrease in FXR expression, with a stronger expression in the RC
samples as compared to the LC samples. This pattern of distribu-
tion has been described in normal subjects, and proposed to occur
in parallel with the proximal-distal gradient of bile acid flow along
the colon.20 However, when we stratified by disease type we
observed decreased FXR expression in samples from the RC of
PSC-UC patients.
Since FXR has been shown to be downregulated in the
presence of intestinal inflammation, we also analyzed the
results according to the degree of histologically active inflammation.
Perhaps not unexpectedly, we observed that with more severe
inflammation, FXR expression was usually absent or weak,
independent of location or disease type. With quiescent/mild
inflammation, FXR expression was also typically weak/absent in
both UC and PSC-UC patients if the tissue sample was from the LC,
reflecting the normal distal decrease in FXR expression. Interest-
ingly, with little or no inflammation, the RC of UC patients retained
the normal pattern of rather high expression of FXR, but the RC of
PSC-UC patients did not. Thus, PSC-UC patients appear to
lose FXR expression in the RC even without much inflammation.
There are data implicating FXR as a tumor suppressor
gene.22 FXR is decreased in human sporadic CRC with an inverse
FIGURE 1. FXR immunohistochemical staining of nonneoplastic mucosa. (A) Normal terminal ileum from patient with UC: there is strong nuclear
staining in villi with gradual decrease towards the crypts (10·). (B) RC biopsy of a patient with UC and quiescent inflammation; a strong nuclear
positivity at the surface and upper part of the colonic glands with a gradual loss of expression in the crypts is seen (20·). (C) RC biopsy of patient
with PSC and quiescent inflammation displaying diminished FXR nuclear expression (20·). (D) RC of a patient with UC and moderate inflammation:
decreased FXR nuclear expression compared to uninflamed mucosa in (B) (20·). (E) Uninflamed LC in a patient with UC lacks strong FXR staining
(20·). (F) Uninflamed LC of patient with PSC-UC displays only minimal or no FXR nuclear staining (20·).
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correlation between the degree of expression and tumor stage.16,20
Furthermore, FXR2/2 mice have been shown to have increased
intestinal carcinogenesis, increased cell proliferation via promo-
tion of Wnt signaling, and upregulation in the expression of genes
involved in cell cycle progression and inflammation, such as cy-
clin D1 and interleukin-6.17 The expression of FXR in the differ-
ent stages of colitis-associated neoplasia had not yet been
described. We herein observed that there was an inverse
correlation within the neoplastic sequence in colitis-associated car-
cinogenesis, with complete loss of FXR expression in 38%, 50%,
and 88.5% of LGD, HGD, and colitis-associated cancers, respec-
tively. FXR expression in the nonneoplastic adjacent mucosa did
not present a similar pattern of expression (data not shown), and
therefore it is likely that FXR downregulation occurs during neo-
plastic transformation from LGD, to HGD, and finally adenocarci-
noma, rather than representing a field defect.
FIGURE 2. Examples of colitis-associated neoplasia. (A) LGD showing retained FXR nuclear expression (20·). (B) High-power image of a focus of
LGD highlights nuclear FXR positivity (40·). (C) HGD: loss of FXR expression (20·). (D) Invasive adenocarcinoma: loss of FXR expression (20·).
TABLE 2. Relationship Between FXR Expression and Degree of Colitis-associated Neoplasia
CRN Absent FXR expression n (%) Low FXR expression n (%) Strong FXR expression n (%)
P value
LGD HGD
LGD (n¼21) 8 (38.1%) 13 (61.9%) 0 ns
HGD (n¼6) 3 (50%) 2 (33.3%) 1 (16.7%)
CRC (n¼52) 46 (88.5%) 6 (11.5%) 0 , 0.001 0.003
ns, not significant.
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We additionally sought to explore the potential role of DNA
methylation as a molecular mechanism of downregulation of FXR
mRNA expression in colorectal cancer cell lines. DNA methylation
is a common mechanism occurring in the development and
progression of sporadic CRC, which may also have a role in
colitis-associated neoplasia.23 Putative CpG islands within the pro-
moter and the fourth exon of the human FXR gene have previously
been described.24 We observed that while in Caco-2, HT-29, and
HepG2 cell lines there where no changes in FXRmRNA expression
after 5-aza treatment, in HCT-116 and SW480 cells, 5-aza treatment
resulted in dose-dependent increases in FXR mRNA expression.
This suggests that loss of expression of FXR in colonic cells may
be regulated, at least in part, by DNA methylation.
Bearing in mind the role of FXR in colorectal carcinogenesis, it
is tempting to suggest that FXR downregulation observed in PSC-UC
samples could explain, in part, the high risk of right-sided CRN in
these patients, even in the presence of quiescent to mild inflammation.
There are data suggesting that during cholestatic liver disease, such as
PSC, intestinal bile acid absorption is reduced which could lead to
a relative increase of bile acid in the proximal colon, in turn producing
heightened conversion of primary bile acids into secondary, more
carcinogenic, bile acids.25,26 Downregulation of FXR could therefore
expose colonocytes to high levels of secondary bile acids or other
toxic products, increasing carcinogenesis risk.
Our study has some limitations. Although a large number of
samples were studied overall, the difference of FXR expression in
the RC of PSC-UC patients was based on a somewhat small
sample size. These findings should be confirmed in other studies.
In addition, as a descriptive, retrospective immunohistochemical
study on archival tissue, our study does not allow us to draw any
mechanistic conclusions, such as whether low FXR expression
results from FXR downregulation or from posttranscriptional
events modulating FXR expression. Further research is required
to elucidate the underlying mechanisms for FXR downregulation
in PSC-UC patients.
We can hypothesize that the reduced uptake of bile acids in
the terminal ileum occurring during cholestasis or the reduced bile
acid secretion occurring in PSC could lead to a secondary feedback
downregulation of colonic FXR; this would make more sense in
advanced disease but unfortunately no data about PSC stage or
serum bilirubin levels among the PSC-UC group was available.
Recent animal experiments have shown that activation of
FXR in the intestine protects the liver from cholestasis by reducing
the hepatic pool of bile acids.27 Failure to activate FXR or consti-
tutive downregulation of FXR could therefore exacerbate PSC and
hepatic cholestasis by increasing bile acids levels within hepato-
cytes. In a recent study, 2355 IBD patients (1193 with UC) and 853
controls were genotyped with seven tagging SNPs and two func-
tional SNPs for FXR. None of the SNPs was associated with the
presence of IBD; however, no information or subanalysis for pa-
tients with PSC-UC was provided.21 Ongoing28 and future genome-
wide association studies in PSC will probably shed some light on
the role of FXR and other nuclear receptors and their role for PSC
development and progression. It is apparent that the crosstalk
between the liver and the colon in PSC-UC patients has yet to be
explored and FXR may be just another piece of the puzzle.
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Little is known about the role of the microbiome in primary sclerosing
cholangitis.
Aim
To explore the mucosa-associated microbiota in primary sclerosing cholan-
gitis (PSC) patients across different locations in the gut, and to compare it
with inflammatory bowel disease (IBD)-only patients and healthy controls.
Methods
Biopsies from the terminal ileum, right colon, and left colon were collected
from patients and healthy controls undergoing colonoscopy. Microbiota pro-
filing using bacterial 16S rRNA sequencing was performed on all biopsies.
Results
Forty-four patients were recruited: 20 with PSC (19 with PSC-IBD and one
with PSC-only), 15 with IBD-only and nine healthy controls. The overall
microbiome profile was similar throughout different locations in the gut.
No differences in the global microbiome profile were found. However, we
observed significant PSC-associated enrichment in Barnesiellaceae at the
family level, and in Blautia and an unidentified Barnesiellaceae at the genus
level. At the operational taxa unit level, most shifts in PSC were observed
in Clostridiales and Bacteroidales orders, with approximately 86% of shifts
occurring within the former order.
Conclusions
The overall microbiota profile was similar across multiple locations in the
gut from the same individual regardless of disease status. In this study, the
mucosa associated-microbiota of patients with primary sclerosing cholangi-
tis was characterised by enrichment of Blautia and Barnesiellaceae and by
major shifts in operational taxa units within Clostridiales order.
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INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic idio-
pathic cholestatic liver disease, characterised by progres-
sive inflammation and fibrosis of bile ducts, strongly
associated with inflammatory bowel disease (IBD), espe-
cially with ulcerative colitis (UC).1–3 PSC-IBD patients
have a distinctive phenotype as compared to IBD alone.
They typically present asymptomatic or mildly symp-
tomatic extensive colitis, a quiescent clinical course, more
right-sided inflammation, rectal sparing, backwash ileitis,
increased risk of pouchitis, and an increased risk for
developing colorectal neoplasia.4–10 Neither the cause of
PSC,11 nor the mechanisms by which IBD patients
develop this unique phenotype when they have concomi-
tant PSC are known.
Some data from basic and clinical studies support the
hypothesis that the intestinal microbiota may have a role
in disease pathogenesis.12, 13 For example, animal models
of surgically induced small intestinal bacterial over-
growth develop abnormalities in the intra- and extra-
hepatic bile ducts that resemble PSC by cholangiography
and histology.12 The improvement of liver enzymes fol-
lowing a trial of antibiotic therapy, and a recent case
reporting laboratorial and histological abnormalities
reversal following vancomycin treatment in a liver trans-
plant PSC recurrence, also suggest a role for the gut flora
in disease pathogenesis.14–16
With the advent of culture-independent techniques, a
better understanding of how the gut microbiome can affect
and modulate the development of liver diseases has
emerged. Indeed microbiota alterations in cirrhosis are now
well-documented.17 A prior study has observed a lower
abundance of uncultured Clostridiales in PSC patients as
compared to IBD and healthy controls, not providing how-
ever more in-depth analysis.18 Being a cholestatic liver
disease with profound alterations in bile acid pool,19 and
acknowledging the reciprocal relationship between gut flora
and bile acid metabolism,20–23 it is very likely that
patients with PSC-IBD exhibit alterations in the gut
microbiota. The main objective of this study was to further
explore the mucosa-associated microbiota in PSC patients,
and to compare it with IBD-only and healthy controls.
MATERIAL AND METHODS
Ethical considerations
This study was approved by the Institutional Review
Boards of Icahn School of Medicine at Mount Sinai and
the University of Chicago. All patients and healthy
controls signed an informed consent form.
Subjects and sampling
Between November 2011 and November 2014, patients
with PSC, patients with IBD and healthy controls under-
going colonoscopy at the Mount Sinai Medical Center
and at the University of Chicago, were prospectively
recruited, within a collaborative multicentre programme
for integrated studies in IBD [Sinai-Helmsley Alliance
for Research Excellence (SHARE) Network]. Sample col-
lection protocol was standardised across two institutions
to avoid possible bias during sample collection and pro-
cessing. The inclusion criteria were age greater than
18 years, confirmed diagnosis of PSC based on histology
and/or abnormal cholangiogram (ERCP or MRCP), and
confirmed diagnosis of IBD by conventional endoscopic
and histological criteria.24 Patients with a personal his-
tory of colectomy, a diagnosis of secondary sclerosing
cholangitis, or concomitant infectious colitis at the time
of colonoscopy were excluded. Patients with newly diag-
nosed PSC, who were scheduled for their initial colono-
scopy to screen for IBD, and healthy controls
undergoing screening colonoscopy, were also recruited.
Demographical and clinical information were recorded
for every patient. During colonoscopy, disease severity
was recorded, and biopsies for colorectal neoplasia
screening were obtained, according to current guidelines.
On all subjects, biopsies were collected from the left
colon (LC) for microbiota analysis, and in a subset of
patients, biopsies were also collected from the terminal
ileum (TI) and right colon (RC) for comparison of the
microbiota features across different colonic locations.
Biopsies were either snap frozen or stored in RNAlater
(Qiagen, Valencia, CA, USA) for subsequent analysis. All
samples were analysed at Icahn School of Medicine at
Mount Sinai, New York.
Tissue DNA extraction and 16S ribosomal RNA
amplification
Tissue samples were transferred into bead tubes (MO-
BIO, Carlsbad, CA, USA) and homogenised using bead
beating method. Homogenised tissue samples were fur-
ther processed using the Qiagen DNeasy Blood & Tissue
Kit following the manufacturer’s protocol (Qiagen). Total
DNA concentration was determined with Qubit 2.0 Fluo-
rometer (Life Technologies, Norwalk, CT, USA). The
phylogenetically informative V3–V4 region of 16S ribo-
somal RNA (rRNA) gene was amplified using universal
primer set 347F/803R.25 The primers were synthesised
by IDT (Integrated DNA Technology, Coralville, IA,
USA). We used a dual-barcoding approach to label the
16S rRNA amplicons from each sample as described
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previously. Briefly, the 6-mer barcodes were attached on
the 50 ends of both forward and reverse PCR primers so
that 16S rRNA PCR amplicons from each sample con-
tained a unique dual barcode combination. The 16S
rRNA amplicons were further pooled with equal molar-
ity and submitted for MiSeq 2 9 300 pair-end sequenc-
ing at high depth. The paired sequence readings were
merged and filtered by size (>400 bp) and quality score
(>Q30) using CLC genomics workbench version 7. The
processed readings were further split by dual barcode for
each sample and assigned taxonomic classification using
QIIME pipeline 1.8.0.26 Repeated measurements of the
same sample were made to assess sequencing repro-
ducibility. After processing, QIIME provided detailed
operational taxa unit (OTU) tables containing the micro-
biota composition and abundance for each individual
sample.
Metagenomic 16S rRNA data analysis. To characterise
the gut microbiota, firstly the overall microbiota dissimi-
larities among all samples, also known as beta-diversity,
were accessed using the Bray–Curtis distance matrices
and visualised by nonmetric multiple dimensional scaling
plots. The PerMANOVA test,27 with the maximum num-
ber of permutations = 999, was performed using the
[Adonis] function of the R package vegan 2.0-528, 29 to
test the significance of the overall microbiota differences
between groups by PSC and IBD status. Secondly, the
diversity of the microbial community within each sam-
ple, so-called alpha-diversity, was measured using the
Shannon Index as a metric to represent the species diver-
sity.30 Next, significant differential taxa features at the
family and genus levels were selected using random for-
est algorithm, a supervised machine learning approach,
using R package rfPermute and confirmed by Boruta fea-
ture selection (R package Boruta).31, 32 Only features that
were consistent in both analyses were selected. The sig-
nificance of the selected taxa was further tested by t-test.
In addition, at the OTU level, we performed the log like-
lihood ratio test (QIIME command group_significance.py
using G-test statistics) to further identify significant dif-
ferential OTUs between PSC and the healthy controls
using LC samples only. The resulted P-values were
adjusted by the FDR methods. We also compared the
PSC vs. IBD-only at LC, RC and TI locations using the
differential OTUs selected from LC samples.
Blautia-specific long 16S rRNA sequencing
Long 16S rRNA reads can further improve the
taxa OTU inference.33, 34 Therefore, we designed
16-base-barcoded 404F/1263R primer pairs (Table S1)
specifically for the Blautia genus based on 16S rRNA ref-
erence sequence of the Blautia genus. The ~860 bp-sized
PCR amplicons were pooled for sequencing on the Pac-
Bio RS II. Sequencing data from PacBio was processed
using the manufacturer provided programme smrtanaly-
sis v.2.1.1 (https://github.com/PacificBiosciences/SMRT-
Analysis/). Circular consensus sequencing reads were
then filtered by size (>800 bp) and the quality score
(>Q30) using CLC genomics workbench version 7. After
split by barcode for each sample, all filtered reads were
processed using QIIME pipeline 1.8.0.35 The generated
OTUs were filtered to only keep OTUs assigned to the
Blautia genus and with more than 100 counts of reads.
We performed the G-test of independence35 to determine
whether Blautia OTU presence/absence is associated
with PSC status at LC samples only, in which we com-
bined healthy control and non-PSC IBD together as
non-PSC group to compare with PSC. Representative
sequences from significantly differential Blautia OTUs
were further aligned with the Blautia reference sequences
to construct the maximum likelihood phylogenetic tree




Between November 2011 and November 2014, 46
patients were enrolled at both centres: 20 with PSC (19
of which had concomitant IBD), 16 with IBD and 10
healthy controls. There were 27 males (61%) and the
median age for the whole population was 47 years (IQR
33.5–58). The mean age of each group was as following:
43.8 years for healthy controls, 50.3 for the IBD group
and 45.3 for the PSC group. No patient was on antibi-
otics at the time of colonoscopy.
Samples from two subjects (one IBD patient and one
healthy control) were eliminated from further analysis
due to over-contamination (>90% relative abundance
with Escherichia coli). Therefore, 44 patients were
included in the final analysis: 20 patients with PSC (19
with PSC-IBD and one with PSC-only), 15 patients with
IBD and nine healthy controls (Table 1). Biopsies from
different colonic locations (TI, RC and LC) were avail-
able in 18 subjects (11 with PSC, six with IBD-only and
one with PSC only), except for two cases, where the TI
could not be intubated. The clinical characteristics of
PSC and IBD patients are described in Table 1. The
patient with PSC-only was analysed in the PSC group.
792 Aliment Pharmacol Ther 2016; 43: 790–801
ª 2016 John Wiley & Sons Ltd
J. Torres et al.
One of the PSC-IBD patients had a history of liver trans-
plant and another had a history of choledochojejunos-
tomy for a dominant stricture. There was no history of
colon surgery among any of the participants.
Samples
16S rRNA amplicons from 81 samples (44 LC, 18 RC,
16 TI and three technical repeats) were sequenced and a
total of 9.3 million reads were generated after filtering by
size and quality, as described in the methods section. On
average, each sample contained ~110 000 reads. The
repeated measurements showed Pearson correlation with
be 99% at the genus level. We used the mean of the
repeated measurements for further analysis.
The mucosa-associated microbiota is stable across
different locations within each individual
Taking into account, the distinct phenotype of more
inflammation and a higher prevalence of neoplasia in
the RC observed in PSC-IBD patients, we specifically
assessed if there were any differences in the spatial dis-
tribution of the mucosa-associated microbiota between
the RC, LC and TI. Therefore, we compared the micro-
biota composition at three biopsy locations in the 18
Table 1 | Clinical characteristics of PSC and IBD (the patient presenting PSC-only was included in the PSC group
together with PSC-IBD)
PSC (n = 20) IBD (n = 15)
Male (n, %) 16 (80) 9 (60)
Age (years)
Median (IQR) 47 (33.5–59.3) 48 (34.5–59.5)
Smoking status (%)
Never 13 (65) 10 (67)
Ever 6 (30) 5 (33)
Unknown 1 (5)
Type of IBD
UC/IBDU 13 (65) 13 (87)
CD 6 (30) 2 (13)
No IBD 1 (5)
Extent of IBD UC/IBDU
Extensive colitis – 100%
UC
Extensive colitis – 12 (92%)
Left colitis – 1 (8%)
CD
Colonic disease: 3 (50%)
Ileocolonic disease:3(50%)
CD
Colonic disease: 2 (100%)
PSC duration; median years (IQR) 4 (2–12.3) –
IBD duration, median years (IQR) 9 (4.8–18.9) 9 (4.75–22)
PSC Mayo score*, median (IQR) 0.03 (!0.63 to 0.42) –




Medications at the time of colonoscopy




Ursodeoxycholic acid 10 –
Tacrolimus 1 –
Cholestyramine 1 –
IQR, interquartile range; IBDU, IBD unclassified.
* The PSC Mayo score could not be calculated in two patients due to lack of information.
† For purposes of simplicity the endoscopic score CD-SES was replaced in this table by the subjective impression of the endo-
scopist performing the colonoscopy into normal, mild or moderate inflammation (the median CD-SES for the patients with CD in
this study was 11.5, IQR 10–13).
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subjects, from whom multiple locations were available.
Our results (Figure 1a) showed that although a few
samples from the same subjects showed substantial
variations, in general, the overall microbiota was consis-
tent across all three sampling locations. The distance
across locations within the same subject was signifi-
cantly smaller than the distance between samples from
the same location but from different subjects
(mean = 0.18 and 0.45, s.d. = 0.13 and 0.17, respec-
tively, P < 0.05). No significant differences in the
species richness (measured by the Shannon index) were
observed between PSC and IBD-only patients in all
three locations (Figure 1b).
PSC associated LC mucosa microbiota features
Observing that there were no overall differences in the
microbiota diversity between TI, RC and LC, we next
analysed the microbiota composition only in the LC of
all subjects. The overall microbiota dissimilarities among
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Figure 1 | Microbiota profiles across multiple biopsy locations. (a) Overall microbiota dissimilarities between samples.
Dissimilarities were measured by distance and visualised using nonparametric multidimensional scaling plot. Lines link
the multiple sampling locations from the same subject. Insert at lower left corner shows the mean and variance of the
distance between the samples from the same or different subjects. Triangles represent PSC patients; Circles represent
non-PSC, IBD patients. (b) The boxplots show the mean and variance of the richness of the microbial community
within each sample, showing no significant difference across multiple locations.
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healthy controls) grouped by PSC and IBD status were
accessed using the Bray–Curtis distance matrices
(Figure 2a). Although we noticed a separation between
the healthy control and the IBD or PSC-IBD, the Per-
MANOVA test did not find a significant difference in
the global LC microbiota profile by disease status. We
also did not observe a significant difference among con-
trols, IBD and PSC samples in species richness using
Shannon Index (Figure 2b). At the taxa level, two fami-
lies including Barnesiellaceae and Alcaligenaceae, as well
as two genera including Blautia and an unidentified
genus from Barnesiellaceae family were selected by ran-
dom forest algorithm using R package rfPermute and
confirmed by Boruta feature selection (R package
Boruta) (Figure 2c). Among those selections, we
observed significant enrichment of Barnesiellaceae family
and its further assigned unidentified genus (mean abun-
dance = 1.3% in PSC samples, 0.48% in IBD and 0.16%
in healthy controls; P = 0.44, 0.025, respectively by
t-test) and Blautia (mean = 4.5% in PSC samples, 2.9%
in IBD and 2.1% in healthy controls; P = 0.22 and 0.02,
respectively by t-test) in PSC samples compared to
healthy controls. To test whether or not the PSC-asso-
ciated taxa features found in LC were consistent in the
RC and TI, we further compared the abundance of Bar-
nesiellaceae family and Blautia genus at three locations
in the available samples from these locations. We found


























































Figure 2 | Microbiota dissimilarities by PSC and IBD status in left colon samples. (a) Overall microbiota dissimilarities
between samples grouped by PSC and IBD status. Dissimilarities were measured by distance and visualised using
nonparametric multidimensional scaling plot. (b) The boxplots show the mean and variance of the richness of the
microbial community between different disease status. (c) The log-scaled boxplots show the differential taxa features
selected at family and genus level by health status. The asterisk indicates the P values < 0.05 between PSC and
healthy controls.
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patients occur in all locations but also that the abun-
dance of those taxa was consistent across multiple loca-
tions within the same individual (Figure 3). Further
analysis excluding the patients with PSC with an history
of OLT, and an history of choledochojejunostomy did
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Figure 3 | The relative abundance of Barnesiellaceae and Blautia in PSC and non-PSC-IBD at multiple locations.
Boxplots (left panel) show the mean and variance of the relative abundance; Dot plots (right panel) show the relative
abundance for each individual samples and the lines link the samples from the same subject. Green: non-PSC IBD;
blue: PSC.
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We then assessed whether there were any differences
in microbiota composition according to PSC severity
score. Based on the ranked PSC Mayo score, the PSC
patients were assigned to low risk (Mayo score <0),
intermediate risk (Mayo score from 0 to 2) and high-risk
score (Mayo score >2). There were no patients with sev-
ere disease; however, among the low and intermediate
risk, groups had a similar global microbiota composition
(Figure S1a) and taxa richness (Figure S1b). At the taxa
level, the level of Blautia was not different between two
risk groups. The low risk group showed higher median
level of Barnesiellaceae family compared to the interme-
diate risk group (Figure S1c), but this did not reach
statistical significance.
Differential OTUs by PSC status
We performed de novo OTU picking using QIIME pipe-
line. Based on the 97% similarity of the 16S rRNA
sequencing reads, all sequencing reads were clustered
into individual OTUs. After removing rare OTUs (rela-
tive abundance <0.1% in all samples), we compared
2439 OTUs and selected 80 and 15 OTUs significantly
(P < 0.05 by parametric t-test, not adjusted) different
between PSC, healthy control (Table S2) or IBD (Fig-
ure S2). We found that when compared with healthy
controls, most of the PSC-associated shifts in the bacte-
rial composition were observed in the Clostridiales and
Bacteroidetes orders, with 86% in the former order. In
agreement with our above findings, several PSC-enriched
OTUs belonged to the Blautia genus and the Barnesiel-
laceae family. When compared to IBD, many OTUs
were from the Blautia genus. Similar enrichments
and reductions at the PSC-associated OTUs selected
from LC samples (Figure S2) were observed in RC and
TI locations.
Differential OTUs at Blautia genus between PSC and
non-PSC by long-read 16S rRNA sequencing
Our results showed that both Barnesiellaceae and Blau-
tia genus were enriched in PSC patients. But unlike
Barnesiellaceae, Blautia comprised >2% of the entire
microbiota regardless of the disease status, so it is
plausible to specifically enrich this genus and further
use the long 16S rRNA reads to perform additional
taxa OTU inference at Blautia genus in both patient
and control samples. After processing, 2967 OTUs
were assigned to Blautia genus. Among those, 135
OTUs had reads of more than 100 counts. The G-test
of independence further selected seven of 135 OTUs
significantly different between PSC and non-PSC
(unadjusted P < 0.05). We aligned those Blautia OTUs
with Blautia reference sequences and constructed the
maximum likelihood phylogenetic tree using UPGMA
method (Figure S3a). We also performed the pair-wise
sequence alignment comparison and showed the num-
ber of difference (upper) and the per cent identity
(lower) between pairs (Figure S3c). Our results showed
that four OTUs (denovo17640, denovo28452, den-
ovo13317, denovo6236) were enriched and three OTUs
(denovo25871, denovo781, denovo18792) were reduced
in PSC samples (Figure S3b). We also found that the
OTUs denovo17640, denovo13317 and denovo28452
showed >99% identity to reference strains from species
of Blautia wexlerae, Ruminococcus obeum and Blautia
faecis, respectively (Figure S3c).
DISCUSSION
Herein, we compared the mucosa-associated bacterial
flora of patients with PSC to IBD alone and to normal
subjects. As faecal microbiota does not necessarily
reflect the mucosa-associated microbiota,36, 37 we chose
to examine the mucosa-associated microbiota, rather
than stool, to gain more insight into the unique pheno-
type of PSC-IBD patients who tend to develop more
right-sided inflammation, and proximal neoplasia. We
thought there might be some differences in the micro-
biota composition throughout different locations of the
ileo-colon in this specific clinical context, given the
phenotypic associations with disease location for PSC.5
However, and in line with previous observations in
healthy subjects,38 no significant site-specific differences
in the microbial composition were found throughout
the colon. Although this analysis may have been limited
by sample size, it is possible that other mechanisms
may be operating and interacting differently with the
microbiota in the right as opposed to the LC39 in
patients with PSC and IBD. Rossen et al.18 in a prior
study, also described similar hierarchical clustering
between samples from the TI and RC from the same
subject from between PSC, IBD and healthy controls.
However, no comparisons with the mucosa-associated
from the LC were available. The same authors
described a lower diversity and abundance of uncul-
tured Clostridiales II at the genus level compared to
UC and healthy controls. However, this study, was lim-
ited by a smaller sample size and, by the use of a
probe-based approach, the HITChip18, 40 that only
allows detection of phylotypes present in the chip at
the genus-like level. Our study, using a longer read 16S
sequencing, allowed us to provide deeper taxonomic
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analysis that could inform on specific microbiome shifts
associated with PSC. Another recently published
study,41 assessing differences in microbial composition
PSC-UC and UC patients, did not report differences in
overall microbial diversity between PSC-IBD and UC,
however different geographical provenience of partici-
pating individuals, was the main driver for microbial
composition in this study. We observed a trend in the
compositional dissimilarity of the overall microbiota
between healthy controls, and PSC-IBD, but this did
not reach statistical significance. This could be due to
the modest sample size, underrepresentation of healthy
controls, and disease remission for most of the IBD
patients, since shifts in the microbiota can vary accord-
ing to disease activity.42 Using bacterial 16S rRNA
next-generation sequencing, we found, across all colonic
locations, a consistent PSC-enrichment in Blautia and
Barnesiellaceae genera and shifts under the Clostridiales,
and less frequently under the Bacteroidales order. Dee-
per taxa analysis at the OTU level was consistent with
these findings, also showing several enriched OTUs par-
ticularly from Blautia and Barnesiellaceae genera.
Specifically, around 86% of the relative changes in the
microbiota occurred within the Clostridiales order, with
reduction in three and enrichment in 66 OTUs. This is
interesting, as shifts in these taxa have been observed
both in IBD and also in cirrhosis.20, 43 Bacteroidetes
species play an important role in protein metabolism44
as well as in bile acid deconjugation.45 The Clostridiales
order encompasses bacteria from Lachnospiraceae fam-
ily, Ruminococcaceae family and Blautia genus, which
are able to perform 7a-dehydroxylation,23 an important
step in converting primary to secondary bile acids in
the intestine. Furthermore, it has been demonstrated
that certain Clostridum spp. can affect number, function
and differentiation of colonic Treg cells, therefore play-
ing a crucial role in colonic homeostasis.46 In advanced
cirrhosis, a shift in the gut flora towards the enrich-
ment of Enterobacteriaceae and the reduction in
Clostridiales and Bacteroidetes in parallel with a reduced
level of faecal secondary bile acids has been described.20
Conversely, Islam and colleagues showed that feeding
animal models with bile acids leads to an enrichment
of colonic bile acids, which in turn results in the
expansion of the Firmicutes phylum, specifically within
the Clostridia class, with Blautia spp expanding signifi-
cantly.47 Being a cholestatic liver disease, characterised
by scarring of the bile ducts, PSC is expected to lead to
a reduction in the flow of bile acids from the liver to
the intestine, at least in the more advanced stages of
the disease. However, there also are data suggesting that
during obstructive cholestasis, the apical sodium depen-
dent bile acid transporter ASBT is down-regulated,48, 49
as a feedback anti-cholestatic mechanism. This could
hypothetically lead to a relative increase in BA in the
proximal colon, which could in turn lead to an enrich-
ment of bacterial species involved in bile acid han-
dling.23, 48 Since in our study, we did not have
patient0s bile acid profiles we could not test for this
hypothesis.
A limitation of our study is its relatively small sam-
ple size, so we were unable and unpowered to make
any associations between disease severity and microbial
composition, or to take into account any impact of
medication, diet or disease course. Despite this limita-
tion, and compared with previous studies, we were able
to compare microbiota composition from multiple
sites,41 had representation of PSC-IBD patients, IBD
and normal controls,41 and a reasonable sample size,18
that allowed to perform deeper taxonomic analyses.18
We observed that the mucosa-associated microbiota
was consistent among all locations, and that the Blau-
tia and Barnesiellaceae enrichment was consistently
found not only in the LC samples but also in other
locations. Consistent with findings at the family and
genus level, deeper OTU level analyses also found
enrichment of Blautia and Barnesiellaceae OTUs in
PSC. Therefore, in that sense we validated our findings.
The cross-sectional nature of the study does not allow
us to conclusively determine a causal link between the
abundance of these species and its role in PSC. It is
possible that the shifts in the microbiota features we
observed in PSC-IBD are a consequence, rather than
the cause, of the interaction between cholestasis and
colonic inflammation. Furthermore, in the absence of a
non-PSC liver disease control group, it is difficult to
appreciate if the microbiota shifts we observed are
specific to PSC or belong to a broader dysbiosis
observed in chronic liver diseases.17, 20 Whether these
changes contribute to the special phenotype observed
in PSC-IBD patients can only be speculated upon at
this stage, and merits further investigation. Future stud-
ies investigating the role of microbiota in PSC should
aim at collecting larger samples sizes, that could allow
adjustment for clinical and analytical variables that
could influence microbial composition in PSC such dis-
ease duration and stage, medication intake, diet, geo-
graphical location of patients, impact of liver transplant
and or biliary surgery, as well as serum and faecal bile
acid pool.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Microbiome profiles and PSC disease
severity. (a) Overall microbiome dissimilarities between
samples with low-risk severity and intermediate risk
severity as assessed by the PSC Mayo score. (b) The
boxplots show the mean and variance of the richness
of the microbial community within each sample, show-
ing no significant difference according to disease
severity. (c) The boxplots show the mean and variance
of the relative abundance of Blautia and Barnesiel-
laceace in patients with low-risk and intermediate risk
PSC.
Figure S2. The fold changes and relative abundance
of selected differential OTUs in PSC vs. non-PSC IBDs
in the LC, RC and TI biopsies. Bar plots show the
fold changes of the relative abundance of each select
OTUs in PSC vs. non-PSC IBDs. Red color indicates
the enrichment in PSC. Green color indicates the
reduction in PSC. The mean abundance in PSC, non-
PSC IBD and healthy controls is shown on the right.
red: healthy control; green: non-PSC IBD; blue: PSC.
Figure S3. The maximum likelihood phylogenetic
tree within Blautia genus using UPGMA method. We
combined seven significantly PSC-associated OTUs and
15 reference sequences to construct the tree. The col-
ored bar plots present the relative abundance of
selected OTUs in PSC and non-PSC (combined
healthy control and non-PSC IBDs) subjects. The table
showed the number of differences (upper) and the per
cent identity (lower) calculated from pair-wise
sequence alignment comparison. The color gradient
from blue to red indicates the low to high sequence
similarity.
Table S1. 16S sequencing PCR primer sequences.
The sequences of dual-barcoding 16S PCR primers tar-
geted on 460 bp amplicons for Miseq sequencing. The
primer sequences include 2 bp linker (italicised) and
6 bp barcodes (bold) at the 50 end.
Table S2. The fold changes and relative abundance
of selected differential OTUs in PSC vs. healthy con-
trols in the left colon biopsies. Table columns repre-
sent mean of the selected OTUs in each study
group: controls, IBD and PSC. The ratio between
mean_OTUs in OSC and controls is represented with
its corresponding taxonomy and P value.
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The gut microbiota, bile acids and their
correlation in primary sclerosing cholangitis
associated with inflammatory bowel disease
J Torres1,2, C Palmela1, H Brito3, X Bao4, H Ruiqi5, P Moura-Santos6,
J Pereira da Silva7, A Oliveira8, C Vieira9, K Perez10, SH Itzkowitz2,
JF Colombel2, L Humbert10, D Rainteau10, M Cravo1, CM Rodrigues3 and J Hu4
Abstract
Background: Patients with primary sclerosing cholangitis associated with inflammatory bowel disease (PSC-IBD) have a very
high risk of developing colorectal neoplasia. Alterations in the gut microbiota and/or gut bile acids could account for the
increase in this risk. However, no studies have yet investigated the net result of cholestasis and a potentially altered bile acid
pool interacting with a dysbiotic gut flora in the inflamed colon of PSC-IBD.
Aim: The aim of this study was to compare the gut microbiota and stool bile acid profiles, as well as and their correlation in
patients with PSC-IBD and inflammatory bowel disease alone.
Methods: Thirty patients with extensive colitis (15 with concomitant primary sclerosing cholangitis) were prospectively
recruited and fresh stool samples were collected. The microbiota composition in stool was profiled using bacterial 16S rRNA
sequencing. Stool bile acids were assessed by high-performance liquid chromatography tandem mass spectrometry.
Results: The total stool bile acid pool was significantly reduced in PSC-IBD. Although no major differences were observed in
the individual bile acid species in stool, their overall combination allowed a good separation between PSC-IBD and
inflammatory bowel disease. Compared with inflammatory bowel disease alone, PSC-IBD patients demonstrated a different
gut microbiota composition with enrichment in Ruminococcus and Fusobacterium genus compared with inflammatory bowel
disease. At the operational taxonomic unit level major shifts were observed within the Firmicutes (73%) and Bacteroidetes
phyla (17%). Specific microbiota-bile acid correlations were observed in PSC-IBD, where 12% of the operational taxonomic
units strongly correlated with stool bile acids, compared with only 0.4% in non-PSC-IBD.
Conclusions: Patients with PSC-IBD had distinct microbiota and microbiota-stool bile acid correlations as compared with
inflammatory bowel disease. Whether these changes are associated with, or may predispose to, an increased risk of
colorectal neoplasia needs to be further clarified.
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Summary of the established knowledge on this subject
1. Primary sclerosing cholangitis is a chronic cholestatic disease of unknown etiology and frequently asso-
ciated with inflammatory bowel disease.
2. Emerging evidence suggests that alterations in the microbiome may be associated with this special
phenotype.
3. No studies have yet investigated the net result of cholestasis and a potentially altered BA pool interacting
with a dysbiotic gut flora in the inflamed colon of PSC-IBD.
What are the significant and/or new findings of this study?
1. Patients with PSC-IBD presented demonstrated a different gut microbiota composition, and specific
microbiota-fecal BA correlations.
2. Despite no significant differences in the specific BA in stool, the overall combination of stool BA was
discriminant between PSC-IBD and IBD.
Introduction
Primary sclerosing cholangitis (PSC) is a rare chronic
cholestatic liver disorder of unclear aetiology.1 It is
characterized by chronic inflammation of the biliary
epithelium, that eventually leads to fibrosis, resulting
in multifocal strictures of the intrahepatic and extrahe-
patic bile ducts. It can lead to cirrhosis, and end-stage
liver disease requiring orthotopic liver transplantation
(OLT).1 Furthermore, PSC is also associated with an
increased risk of cholangiocarcinoma, gallbladder
cancer and colorectal cancer.2,3 The strongest risk
factor for having PSC is a history of inflammatory
bowel disease (IBD). Around 60–80% of PSC patients
will also have IBD, most commonly ulcerative colitis
(UC). Ironically, despite having mild or quiescent
extensive colitis, patients with PSC-IBD have the high-
est risk of developing colitis-associated neoplasia,
which, in comparison with IBD, tends to be located
preferentially in the right side of the colon.2,4 The fac-
tors that contribute to the increased risk of colorectal
neoplasia in PSC remain unknown.5,6 A potential role
for altered luminal concentration and/or composition
of secondary bile acids (BAs) has been suggested, but
never confirmed.7 Data from basic and clinical studies
have long supported the hypothesis that the intestinal
microbiota may have a role in PSC pathogenesis.8–10
Recently, studies using next-generation sequencing
have reported a distinct fecal or mucosal microbiota
composition in PSC-IBD patients.11–18 There is a
close interplay between gut flora and BA metabolism.
Besides their role in nutrient absorption and lipid diges-
tion, BAs are important signaling molecules, acting in
inflammation and metabolism, through activation of
BA receptors such as the G-protein-coupled BA
transmembrane receptor TGR5, and the nuclear BA
receptor Farnesoid X receptor (FXR).19 BAs have anti-
microbial properties, and through FXR-activation they
regulate the expression of host genes whose products
promote innate defence against luminal bacteria.20,21
On the other hand, BA metabolism is a property of
the gastrointestinal microflora; BAs are transformed
from primary BA (cholic acid (CA) and chenodeoxy-
cholic acid (CDCA)) to secondary BA (litocholic acid
(LCA) and deoxycholic acid (DCA)) by deconjugation,
7-alpha de-hydroxylation and epimerization (CDCA!
ursodeoxycholic acid (UDCA)) by the gut microbiota;
therefore the degree of activation of the BA receptors is
also largely influenced by the gut microbiota.22–24
Nothing is known about the net result of cholestasis
associated with PSC, and a potentially altered BA
pool interacting with a dysbiotic gut flora in the
inflamed colon of PSC-IBD patients. In this article,
we have explored the BA profiles, the gut microbiota,




This study was approved by the Portuguese National
Committee for Data Protection and the local ethics
committee. All patients signed an informed consent
form.
Subjects and samples
Between October 2014–July 2015, 15 patients with
PSC-IBD and 15 patients with IBD were prospectively
recruited. The inclusion criteria were age greater than
18 years old, confirmed diagnosis of PSC based on hist-
ology and/or abnormal cholangiogram (Endoscopic
Retrograde Cholangio-Pancreatography or Magnetic
resonance cholangiopancreatography), a confirmed
diagnosis of IBD by conventional endoscopic and
histological criteria, and the presence of extensive col-
itis. Patients with a personal history of colectomy, a
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diagnosis of secondary sclerosing cholangitis or a his-
tory of OLT were excluded. All patients provided clin-
ical and demographic information, and completed a
semi-quantitative food frequency questionnaire (FFQ)
validated for the Portuguese population.25 Clinical
activity was scored according to the Mayo score for
ulcerative colitis,26 and the Harvey-Bradshaw index
for Crohn’s disease.27 Endoscopic activity was scored
according to the Mayo endoscopic score for UC26 and
the Simple Endoscopic Score for Crohn’s Disease (SES-
CD) for CD.28 All study participants collected serum
sample, and a stool sample for BA analysis and micro-
biota analysis. All PSC patients on UDCA therapy
were required to stop it two weeks before specimen
collection. A minimum interval of three months was
required between antibiotic intake or bowel prepar-
ation (for colonoscopy) and sample collection. During
colonoscopy disease severity was recorded, and biopsies
for colorectal neoplasia screening were obtained,
according to current guidelines.
Serum BA profiles
A fasting serum sample was obtained from each
patient. Individual amidated BAs in serum (1ml) were
determined by high-performance liquid chromatog-
raphy (HPLC),29 after solid-phase extraction using
Sep-Pak C18 cartridges (Waters Corp., Milford,
Massachusetts, USA).30 Only the conjugate fraction
of BAs was measured in serum.
Stool BA profiles
A morning stool sample was obtained and dried to
obtain a lyophilized extract. To lyophilized faecal sam-
ples weighing 1 g, 80% methanol was added. All sam-
ples were sonicated for 30min, refluxed for two hours,
and then cooled and filtered.31 The residue was re-sus-
pended in chloroform/methanol (1:1, v/v), refluxed for
one hour, and filtered. The combined extracts were
taken to dryness, and re-suspended in 10ml methanol
(MeOH). An aliquot of 1ml was added with 2 ml of
1mg/ml nordeoxycholic acid, and was diluted in 10ml
deionized water and deposed on a 300mg HLB Oasis
column, washed with 10 volumes deionized, 1 volume
cyclohexane, and the BAs were then eluted with 5ml
MeOH and were taken to dryness and resuspended in
250 ml MeOH. Four microliters were injected on liquid
chromatography coupled with tandem mass spectrom-
etry (LC-MS/MS) as previously described.32 Results
are reported in nmol/g of dried stool for total BAs
and in proportion of the median after calibration of
the method, with weighted mixtures and normalization
relative to the internal standard.32 The conjugate and
non-conjugated species were quantified.
BA analysis
BAs were not normally distributed according to the
Shapiro-Wilk test; therefore, their distributions were
compared using non-parametric tests. The relative
proportion of a given BA corresponds to its concen-
trations divided by the total of BAs. BA results are
presented as the median proportion. For example, the
total primary stool BA is the sum of CA and CDCA
and their respective glyco-, tauro-, and sulphoderiva-
tives. Linear discriminant analysis (LDA) was con-
ducted to illustrate the classification of disease
groups (IBD only and PSC-IBD) using stool BAs.
LDA is a dimension reduction statistical technique
that looks for a combination of features (continuous
variables) that maximize the separation between
classes. LDA was performed using the MASS pack-
age in R software.
Stool DNA extraction
Approximately 200mg of stool were transferred into
bead tubes (MO-BIO, Carlsbad, California, USA)
and homogenized using the bead-beating method.
Homogenized stool samples were further processed
using the Qiagen DNeasy Blood and Tissue Kit follow-
ing the manufacturer’s protocol (Qiagen, Valencia,
California, USA). Total DNA concentration was deter-
mined with Qubit 2.0 Fluorometer (Life Technologies,
Norwalk, Connecticut, USA).
16S ribosomal RNA (rRNA) sequencing
The phylogenetically informative V3–V4 region of
16S ribosomal RNA (rRNA) gene was amplified
using universal primer set 347F/803R.33 The primers
were synthesized by IDT (Integrated DNA
Technology, Coralville, Iowa, USA). We used a
dual-barcoding approach to label the 16S rRNA
amplicons from each sample as described previ-
ously.34 The 16S rRNA amplicons were further
pooled with equal molarity and submitted for
MiSeq 2! 300 pair-end sequencing at high depth.
The paired sequence readings were merged and fil-
tered by size (>400 bp) and quality score (>Q30)
using paired-end assembler for DNA sequences
(PANDAseq).35 The processed readings were further
split by dual barcodes for each sample and assigned
taxonomic classification using the Quantitative
Insights Into Microbial Ecology (QIIME) pipeline
1.9.0.36 Repeated measurements of the same sample
were made to assess sequencing reproducibility. After
processing, QIIME provided detailed OTU tables
containing the microbiota composition and abun-
dance for each individual sample.
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Data analysis
First, we measured the diversity of the overall micro-
biota communities within or across each sample. The
overall species richness within each patient group, so-
called alpha-diversity, was measured using the Chao1
and Shannon Index on rarefied tables at 8000 sequences
per sample.37 Beta-diversity was measured using
unweighted and weighted UniFrac distance matrices
on the rarefied tables. The permutational analysis of
variance (PERMANOVA) test (number of permuta-
tions¼ 999), was performed using QIIME command
compare_categories.py to test the overall microbiota
differences between groups by PSC and IBD status.38
Secondly, at the taxa level, the LDA effect size (LefSe)
analysis was used with default parameters to select taxa
features from phylum to genus level that were asso-
ciated to PSC status.39 Only features with LDA score
>2.0 were kept. A Kruskal-Wallis test on the LefSe
selected differential taxa at the genus level was per-
formed, and corresponding p-values were adjusted for
multiple comparisons. Finally, the Kruskal-Wallis test
was also performed at individual OTUs to select OTUs
with significant differential abundance with respect to
the PSC-IBD status. All singleton OTUs were removed
prior to all analysis.
Correlation networks
We calculated both Pearson’s and Spearman’s correl-
ations between the most abundant (mean relative
abundance >0.1%) 65 genera in the gut microbiota
and the stool BA levels in PSC and non-PSC IBD.
To reduce the bias in the correlation analysis due to
non-normality, we removed the variables with more
than eight null value results, and removed the meas-
urements beyond the 5% quantile of the distribution.
We computed the raw probabilities. The p-values of
the Pearson’s correlation were calculated using the
corr.test function in R software with false discovery
rate (FDR) adjustment for multiple comparisons.
Spearman’s correlations of the selected pairs with sig-
nificant p-values in the Pearson correlations were also
computed to check the consistency of the correl-
ations. We listed the genus-BA pairs with both sig-
nificant Pearson’s correlation (adjusted p< 0.05) and
strong Spearman’s correlations (p< 0.05) in the
Supplementary Material, Table 2.
Results
Study population
Thirty patients with IBD, of whom 15 had concomitant
PSC, were prospectively enrolled. All patients enrolled
had pancolitis; two out of the four patients with CD
also had ileal involvement. Two of the 15 PSC patients
had concomitant liver cirrhosis (Child-Pugh A, six
points). No patient had a prior history of abdominal
or liver surgery. There were no significant differences in
the overall daily intake of macro or micronutrients as
assessed by the food-frequency questionnaire (data not
shown). Patients with PSC-IBD presented, as expected,
significantly higher levels of cholestasis markers, and
were more frequently medicated with ursodeoxycholic
acid. No further significantly different clinical variables
were found, except for body mass index (BMI) that was
significantly lower in PSC-IBD patients (Table 1). The
median interval between stool collection and colonos-
copy was 17.5 days (9–62). The additional demographic
and clinical characteristics of PSC and IBD patients are
described in Table 1.
Serum BA
The total BA (mmol/l) pool was significantly expanded
in PSC-IBD (p-value¼ 0.007, Mann–Whitney)
(Supplementary Material, Table 1). No significant dif-
ferences were seen in the proportion of individual BAs
between groups. There was a positive correlation
between PSC duration and total serum BAs (r¼ 0.66,
p¼ 0.009).
Stool BA profiles
The median total stool BAs were significantly reduced
in PSC-IBD (167.2 mmol/l in PSC-IBD versus
282.4 mmol/l in IBD, p¼ 0.021). Overall there were no
significant differences in the proportions of each BA
(Table 2), although the overall combination of stool
BA allowed a good separation between PSC-IBD and
IBD, as visualized in the linear discriminant analysis
(Figure 1). Using the main BAs (CA, CDCA, LCA,
DCA and UDCA), the classification accuracy of the
LDA was 73%, with a sensitivity and specificity of
86.7% and 60% respectively (Figure 1). When we
used all individual BAs (taurine and glycine conjugates
and sulphated BA), the accuracy of the LDA for clas-
sifying PSC-IBD versus IBD was 100%
(Supplementary Material, Figure 1). Additional LDA
analysis was conducted using the top four most dis-
criminatory stool BA (Supplementary Material,
Figure 1). PSC-IBD patients presented a higher propor-
tion of conjugated BA, although this did not reach stat-
istical significance. DCA, a secondary BA, was also
elevated, albeit non-significantly, in PSC-IBD. The pro-
portion of UDCA in stool was not different in the PSC
patients who were medicated with UDCA versus those
who were not (1.075 nmol/g versus 1.35 nmol/g,
respectively, p-value¼0.7, Mann–Whitney U Test).
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Likewise, the results for all stool BA comparisons did
not change after excluding the two CD patients with
ileal involvement (data not shown). There was a nega-
tive correlation between the concentration of secondary
BAs and endoscopic disease activity (r¼ –539,
p¼ 0.003); this was also observed when the analysis
was stratified by patient group (data not shown).
Survey of gut microbiota
Using 16S rRNA sequencing, we surveyed the micro-
biome composition of 30 stool samples. The duplicate
measurements showed Pearson correlation over 99% at
genus level, confirming the reproducibility of the experi-
mental approach. PSC-IBD presented lower alpha-diver-
sity, albeit not significantly different (Chao1 899.3 for
IBD vs 832.0 for PSC-IBD, p-value¼ 0.36; Shannon
index 5.7 for IBD vs 5.3 for PSC-IBD, p¼ 0.23)
(Figure 2(b)). Patients with PSC and concomitant cir-
rhosis (n¼ 2) presented significantly lower bacterial
alpha-diversity (p¼ 0.005) as compared with those with
PSC without cirrhosis (data not shown). The overall
microbiota dissimilarities among all samples grouped
by PSC and IBD status were accessed using the
Table 1. Demographic and clinical characteristic of patients.
PSC-IBD (n¼ 15) IBD (n¼ 15) p valuea
Male (n, %) 5 (33%) 10 (67%) 0.07
Age (years)
Median, IQR 42(24) 45 (13) 0.6
Smoking status (n, %)
Never 12 (80%) 12 (80%) 1.0
Ever 3 (20%) 3 (20%)
Type of IBD (n, %)
UC 11 (73%) 12 (80%) 0.6
CD 4 (27%) 3 (20%)
PSC duration
Median years (IQR) 7.8 (11.7) – –
IBD duration
Median years, (IQR) 11.4 (5.26) 11.1 (15.7) 0.8
PSC Mayo score
Median, (min, max) –0.57 (–1.6, 1.7) – –
ALP (UI/l) (median, IQR) 200 (166) 54 (28) <0.001
GGT (UI/l) (median, IQR) 332 (414) 28 (20) <0.001
CRP (mg/dl) (median, IQR) 0.2 (0.7) 1.1 (1.3) 0.061
Disease clinical activity (n, %)
Remission-mild 13 (87%) 15 (100%) 0.5
Moderate-severe 2 (13%) 0
Disease endoscopic activity (n, %)b
Remission-mild 9 (64%) 13 (87%) 0.2
Moderate-severe 5 (36%) 2 (13%)
Mean BMI (Kg/m2) 24" 4.5 30.1" 6.4 0.005
Presence of colorectal dysplasia (n, %) 3/14 (21%) 1/15 (6%) 0.2
Medications (n, %)
5-ASA 12 (80%) 11 (73%) 1.0
Thiopurines 5 (33%) 8 (53%) 0.3
Anti-TNF 3 (20%) 3 (20%) 1.0
UDCA 10 (67%) – <0.001
5-ASA: 5-aminosalicilate; ALP: alkaline phosphatase; anti-TNF: anti-tumor necrosis factor; BMI: body mass index; CRP: C-reactive protein; GGT: gamma-
glutamyl transpeptidase; IQR: interquartile range; PSC: primary sclerosing cholangitis; PSC-IBD: primary sclerosing cholangitis associated with inflam-
matory bowel disease; UC: ulcerative colitis; UDCA: ursodeoxycholic acid.
aVariable distribution was compared using the Student’s t test, the Mann–Whitney test or the !2 test, as appropriate; bin the PSC-IBD group one patient
refused colonoscopy.
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UniFrac distance matrices (Figure 2(a)). The overall
qualitative microbial composition of patients with
PSC-IBD was different as observed in the multidimen-
sional scaling (MDS) plot (Figure 2(a): unweighted
UniFrac, PERMANOVA: pseudo-F statistic: 2.99, p
value¼0.008). At the individual taxa level (Figure 2(c)),
we found seven genera differentially expressed in PSC-
IBD vs IBD (logarithmic LDA score>2 by LEfSe ana-
lysis): Ruminococcus and Fusobacterium were more
abundant in PSC-IBD, while Dorea, Veillonella,
Lachnospira, Blautia, and Roseburia were less abundant.
All of those genera were found to be significant
(p< 0.05) when their relative abundance was compared
using a Kruskal-Wallis test (p values adjusted for mul-
tiple comparisons). No significant differences in the
microbial overall composition (ß-diversity) were
observed by PSC disease severity (as measured by the
PSC Mayo score), BMI, UDCA use, IBD type, or IBD
disease activity (data not shown).
Differential OTUs by PSC status
Based on 97% similarity of the 16S sequencing reads,
the open-reference OTU picking using QIIME pipeline
assigned all sequencing reads into individual OTUs.
After removing singletons, we compared 3839 OTUs
and selected 143 OTUs which were significantly
(p< 0.05 by Kruskal–Wallis test, not adjusted) differ-
ential and presented a >2 fold changes in the mean
abundance between IBD and PSC-IBD
(Supplementary Material, Figure 2). Compared with
IBD only, the relative abundance of 32 OTUs were
increased and 111 OTUs were decreased in PSC-IBD.
At the phylum level, we found that most of the shifts
associated with PSC occurred within the Firmicutes
(73%) and Bacteroidetes phyla (17%). Consistent with
the LEfSe analysis at the genus level, that found Blautia

















Figure 1. Results of the linear discriminant analysis allowing to see the discrimination of primary sclerosing cholangitis associated with
inflammatory bowel disease (PSC-IBD) versus inflammatory bowel disease (IBD) alone, based on the combination of the main bile acids
(BAs) present in stool (cholic acid (CA), chenodeoxycholic acid (CDCA), litocholic acid (LCA), deoxycholic acid (DCA) and ursodeoxycholic
acid (UDCA)). On the x axis each marker represents a patient. On the y axis is represented the probability of being correctly classified as
PSC-IBD using the BA analytes. The green markers represent patients with PSC-IBD and the pink markers represent patients with IBD. The
circles represents patients that were correctly assigned to their disease group. The classification accuracy of the linear discriminant
analysis (LDA) was 73%, with a sensitivity and specificity of 86.7% and 60% respectively.
Table 2. Stool bile acids (BAs) in primary sclerosing cholangitis
associated with inflammatory bowel disease (PSC-IBD) and
inflammatory bowel disease (IBD) patients.
BAs PSC-IBD IBD p value
Primary BAs 9.5 (18) 4.2 (15.2) 0.29
Secondary BAs 89.4 (24.6) 91.2 (15.1) 0.57
CA 4.6 (6.45) 1.49 (4.77) 0.06
CDCA 4.73 (10.4) 2.72 (11.0) 1.0
DCA 52.5 (23.5) 43.6 (14.3) 0.55
LCA 34.1 (33.8) 46.2 (1.9) 0.14
UDCA 1.1 (1.9) 1.8 (3.9) 0.37
Tauro/glyco conjugates 0.47 (0.67) 0.34 (0.69) 0.98
Sulfated BAs 2.1 (3.1) 2.4 (16.3) 0.41
Conjugated BAs 4.5 (13.7) 2.7 (6.9) 0.23
CA: cholic acid; CDCA: chenodeoxycholic acid; DCA: deoxycholic acid; LCA:
litocholic acid; UDCA: ursodeoxycholic acid.
BAs are expressed as percentage median (interquartile range) of total BAs.
Distributions were compared with non-parametric tests (Mann–Whitney).
Due to a small amount of minor BA species in stool (muricholic acid,
hycholic acid, hyodeoxycholic acid, or ursodeoxhycolic acid) which are con-
sidered by some authors as ‘tertiary BAs’, the sum of primary and second-
ary BAs is not 100%.
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differential genera by PSC status, we found that all 16
OTUs of Blautia genus were reduced while four of five
OTUs of Ruminococcus genus and Ruminococcaceae
family were enriched in PSC samples.
Correlation between microbiota genera and
stool BAs
Correlations between microbiota genus and the stool
BA were calculated as described in our method section
to test the interactions between gut microbiota and
stool BA. Without stratifying by PSC status, we
found four genera, including Blautia and Veillonella
to be correlated to specific types of BAs. In PSC-IBD,
bacteria with significant correlations with BA metabol-
ites mostly belonged to the Firmicutes phylum, specif-
ically within the Clostridia and Bacilli classes. Different
correlations were observed in IBD (Supplementary
Material, Table 2). Compared with IBD, seven genera
appeared and two genera disappeared in PSC-IBD. The
total relative abundance of genera correlated to BA was
12% in PSC-IBD, compared with 0.4% in IBD. Two
Firmicutes, Lachnospira and Veillonella, which were
significantly reduced in PSC-IBD, showed strong cor-
relations with multiple BA, only in PSC-IBD.
Discussion
Herein, for the first time we have analyzed the stool BA
profiles and their correlation with the faecal microbiota
composition in patients with PSC-IBD as compared
with IBD alone. The serum BA pool was increased
and the stool BA pool was significantly reduced in
PSC-IBD as compared with IBD alone. No significant
differences in the individual stool BA components were
found, but their overall composition differed from IBD
(Figure 1). A significantly different microbiota compos-
ition based on the unweighted UniFrac distances was
found between IBD and PSC-IBD, indicating differ-
ences in taxon composition for rare taxa (Figure
2(a)). Specifically, PSC-IBD patients presented an
enrichment in bacteria belonging to the genera
Ruminococcus and Fusobacterium as compared with
IBD alone (Figure 2(c)). Finally, specific microbiota-
stool BA correlations were observed in PSC-IBD
(Supplementary Material, Table 2).
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Figure 2. Overall microbiota dissimilarities between samples grouped by primary sclerosing cholangitis (PSC) and inflammatory bowel
disease (IBD) status. (a) Dissimilarities were measured using UniFrac unweighted distances and visualized using a multidimensional plot
(MDS) plot. The smaller circle represents patients with IBD, while the larger circle the samples from PSC-IBD patients. (b) The boxplots
show the mean and variance of the richness of the microbial community between different disease status (Chao1 in the left and Shannon
index on the right); no significant differences are seen (p value: 0.36 and 0.23 respectively). (c) Top discriminative bacteria in primary
sclerosing cholangitis associated with inflammatory bowel disease (PSC-IBD) and IBD patients as determined by LEfSe analysis (linear
discriminant analysis (LDA)). On the right are represented the increased taxa in PSC-IBD, while on the left the decreased taxa in PSC-IBD,
as compared with IBD.
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In the past, some authors have hypothesized that the
increased risk of right-sided colorectal neoplasia in
PSC-IBD could be linked to an increase in secondary
BA, although this had never been demonstrated.2,7
Normally, most of the BAs secreted by the liver are
efficiently reabsorbed in the terminal ileum, through
the sodium-dependent BA transporter (ASBT), leaving
only approximately 5% of the total BAs to reach the
colonic lumen. In the right colon, primary BAs are
transformed in to secondary BAs mostly by bacterial
mediated deconjugation, oxidation/reduction, epimeri-
zation, and dehydroxylation.40 Therefore, faecal BA
are mainly deconjugated, secondary BAs. A small frac-
tion of secondary BA is passively absorbed through the
colonic mucosa, whilst the rest will be extruded with
faeces.41 During obstructive cholestasis, the expression
of the apical BA transporter, which permits intracellu-
lar absorption of BAs, is down-regulated, as a compen-
satory mechanism.42 This could hypothetically lead to a
relative increase in the proportion of BAs entering the
proximal colon in PSC-IBD patients, where they would
be converted from primary into secondary BAs.
Interestingly, secondary BAs have been shown to
have anti-inflammatory properties but at the same
have been shown to bear carcinogenic proper-
ties.19,32,43–45 Herein, we observed a significant reduction
in the total stool BAs in PSC-IBD as compared with
IBD, which was expected taking into consideration the
obstructive cholestatic nature of PSC. However, we did
not find an increase in the relative proportion of the
stool secondary BAs in PSC-IBD patients, as previously
hypothesized.7,12 No significant differences in individual
proportion of serum or stool BAs were found, which
could perhaps be due to the small sample size. The pro-
portion of DCA, a secondary BA was increased in PSC-
IBD, although this did not reach statistical significance.
Furthermore, the proportion of conjugate BAs was also
non-significantly increased in PSC-IBD as compared
with IBD, which could indirectly indicate a decrease in
the deconjugation activity of the microbiota. The
decrease in Bacteroides, Clostridium, Bifidobacterium,
and Lactobacillus genus, observed at the OTU level,
and known to be involved in BA deconjugation, could
hypothetically be involved in this finding.46 In this
cohort, patients with PSC-IBD demonstrated an enrich-
ment in bacteria from the Ruminococcus and
Fusobacterium taxa, and a decrease in bacteria from
the genus Dorea, Veillonella, Lachnospira, Blautia, and
Roseburia. At the OTU level most shifts were observed
within the Firmicutes (73%) and Bacteroidetes phylae
(17%). Some of our findings are in consonance with
recently published results on PSC microbiota also show-
ing an increase of Fusobacterium13 (a bacterial taxon
that has been linked with adenomas and colorectal
cancer) and in Ruminococcus in stool from patients
with PSC-IBD or a decrease in Roseburia genus.
However, others are not; Kummen et al. reported PSC
patients to have a significant increase in Veillonella genus
in comparison with healthy controls and patients with
IBD.14 In this cohort, Veillonella genus was positively
correlated with disease severity and was more abundant
in patients that had undergone OLT. Indeed, this genus
has been reported to be increased in fibrotic conditions
such as liver or lung fibrosis or cystic fibrosis.47–50 In
cirrhosis, Veillonella has also been associated with com-
plications such as hepatic encephalopathy.51 In another
large cohort of patients with PSC-IBD, Veillonella was
only significantly elevated in patients with PSC that pre-
sented concomitant liver cirrhosis.13 Of note, in our PSC
population, only two patients presented early liver cir-
rhosis, no patient presented severe PSC as measured by
the PSC Mayo score or had undergone liver transplant.
Also worthy of note is the well described disconnect
between mucosa and stool microbiota, as in a prior
work Blautia was increased in the mucosa from PSC-
IBD patients as compared with healthy controls.12
No study had yet looked at the correlations between
stool BA and the stool microbiota in PSC-IBD.However,
BA pool size and composition have been shown to be
important factors in regulating the gut microbiota.24,52,53
Herein, despite our relatively small sample size, and after
correcting for multiple comparisons, we were able to
observe unique correlations between stool microbiota
and stool BAs in PSC-IBD. Within IBD alone, this
broad BA-microbiota correlation disappeared. In par-
ticular, in PSC-IBD, the taxa that significantly correlated
to the stool BA corresponded to!12%of the totalmicro-
biota, while in IBD, this was less than 1%. Without any
functional data, we may only speculate that these results
suggest that under PSC conditions, the BA changes may
have dominant effects on defining the gut microbiota
shifts, potentially towards a more pro-carcinogenic pro-
file. Interestingly, bacteria from the genus of both
Fusobacterium and Ruminococcus, are known to be
involved in oxidation, epimerization and desulfation of
BAs.46
The major limitation of this study is our small
sample size, which prevented us from adjusting for
potential confounders in the microbiota and BA ana-
lysis. To overcome this, we tried to make our cohort as
uniform as possible. All patients had pancolitis, and no
patient had prior abdominal surgery or history of liver
transplantation; all patients had mild to moderate PSC,
as measured by the Mayo score, and dietary intake was
also similar within groups as assessed by the food fre-
quency questionnaire. Furthermore, all patients
stopped UDCA intake for two weeks and had no anti-
biotics or bowel preparation within at least three
months of sample collection, all external factors that
could potentially impact microbiota composition.
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While it may be argued that a two-week interval to stop
UDCA may not be enough to remove its effects, we did
not observe any differences in the faecal BA compos-
ition or in the microbiota composition between those
who were medicated with UDCA as compared with
those who were not, consistent with what has been pre-
viously reported.13
In summary, in this exploratory study, patients with
PSC-IBD had a distinct stool BA and stool microbiota
composition, as well as specific microbiota-stool BA
correlations when compared with IBD. Whether these
changes are associated with or may predispose to the
specific PSC-IBD phenotype including the increased
risk of colorectal neoplasia needs to be further clarified
and warrants further research.
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BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC,
termed PSC-IBD) are at increased risk for colorectal cancer, but their risk following a diagnosis
of low-grade dysplasia (LGD) is not well described. We aimed to determine the rate of advanced
colorectal neoplasia (aCRN), defined as high-grade dysplasia and/or colorectal cancer, following
a diagnosis of indefinite dysplasia or LGD in this population.
METHODS: We performed a retrospective, longitudinal study of 1911 patients with colonic IBD (293 with
PSC and 1618 without PSC) who underwent more than 2 surveillance colonoscopies from 2000
through 2015 in The Netherlands or the United States (9265 patient-years of follow-up eval-
uation). We collected data on clinical and demographic features of patients, as well as data from
each surveillance colonoscopy and histologic report. For each surveillance colonoscopy, the
severity of active inflammation was documented. The primary outcome was a diagnosis of aCRN
during follow-up evaluation. We also investigated factors associated with aCRN in patients with
or without a prior diagnosis of indefinite dysplasia or LGD.
RESULTS: Patients with PSC-IBD had a 2-fold higher risk of developing aCRN than patients with non-PSC
IBD. Mean inflammation scores did not differ significantly between patients with PSC-IBD
(0.55) vs patients with non-PSC IBD (0.56) (P [ .89), nor did proportions of patients with
LGD (21% of patients with PSC-IBD vs 18% of patients with non-PSC IBD) differ significantly
(P [ .37). However, the rate of aCRN following a diagnosis of LGD was significantly higher in
patients with PSC-IBD (8.4 per 100 patient-years) than patients with non-PSC IBD (3.0 per 100
patient-years; P [ .01). PSC (adjusted hazard ratio [aHR], 2.01; 95% CI, 1.09–3.71), increasing
age (aHR 1.03; 95% CI, 1.01–1.05), and active inflammation (aHR, 2.39; 95% CI, 1.63–3.49) were
independent risk factors for aCRN. Dysplasia was more often endoscopically invisible in pa-
tients with PSC-IBD than in patients with non-PSC IBD.
aAuthors share co-first authorship.
Abbreviations used in this paper: aCRN, advanced colorectal neoplasia;
aHR, adjusted hazard ratio; CRC, colorectal cancer; EHR, electronic
health record; HGD, high-grade dysplasia; IBD, inflammatory bowel dis-
ease; IBD-U, inflammatory bowel disease undifferentiated; IND, indefinite
dysplasia; LGD, low-grade dysplasia; PSC, primary sclerosing cholangitis;
UC, ulcerative colitis.
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CONCLUSIONS: In a longitudinal study of almost 2000 patients with colonic IBD, PSC remained a strong
independent risk factor for aCRN. Once LGD is detected, aCRN develops at a higher rate in
patients with PSC and is more often endoscopically invisible than in patients with only IBD. Our
findings support recommendations for careful annual colonoscopic surveillance for patients
with IBD and PSC, and consideration of colectomy once LGD is detected.
Keywords: Surveillance; Colon Cancer; Crohn’s Disease; Ulcerative Colitis; Primary Sclerosing Cholangitis.
Patients with inflammatory bowel disease (IBD)are at an increased risk of developing colorectal
cancer (CRC).1,2 The co-occurrence of primary scle-
rosing cholangitis (PSC),1,3 a chronic liver disease char-
acterized by progressive inflammation and fibrosis of
the bile ducts,4 increases this risk substantially.5
Although an estimated 70% of patients with PSC have
a concomitant diagnosis of IBD (termed PSC-IBD),6
only 3% to 5% of patients with IBD have concomitant
PSC, with the diagnosis more common in patients with
ulcerative colitis (UC).5,7 The PSC-IBD phenotype often
is characterized by extensive colitis with rectal-
sparing and backwash ileitis, albeit with a mild and
often asymptomatic clinical course.8–13 However,
despite their mild clinical colitis, patients with PSC-
IBD compared with patients with only IBD colitis have
a 3- to 5-fold higher risk of CRC, and the cancers occur
more often in the right colon.14,15 As such, current
guidelines recommend that patients with PSC-IBD be
enrolled in a CRC surveillance program with an annual
colonoscopy from the time of PSC diagnosis, regardless
of their duration of IBD. This is in contrast to patients
with IBD colitis and no PSC (non-PSC IBD), in which
CRC surveillance is recommended after 8 years of
colonic disease.5,16–18
The development of neoplasia in IBD colitis follows a
multistep sequence from chronic inflammation and no
dysplasia or indefinite dysplasia (IND) to low grade-
dysplasia (LGD) and high-grade dysplasia (HGD), before
final malignant transformation to adenocarcinoma. As
such, the presence and grade of dysplasia remain the
best current indicators of cancer risk in IBD. There is an
increasing tendency to keep patients with LGD on
intensive surveillance instead of recommending procto-
colectomy.19,20 However, very few studies have
described the risk of advanced colorectal neoplasia
(aCRN) in patients with PSC-IBD after a diagnosis of IND
and/or LGD.21,22 Furthermore, the studies that do report
on the risk of neoplasia in patients with PSC-IBD were
performed in an era in which imaging-enhanced endos-
copy and high-resolution endoscopy were not used
routinely.
The aims of the present study were to report on the
risk of aCRN in a well-characterized cohort of patients
with PSC-IBD enrolled in a surveillance program in the
modern endoscopic era, and to describe the rate of aCRN
after a diagnosis of IND and/or LGD in these patients
compared with patients with non-PSC IBD and long-
standing IBD colitis also undergoing surveillance.
Methods
Study Population and Case Identification
Patients with established IBD colitis undergoing
colonoscopic surveillance between 2000 and 2015 were
identified retrospectively from 2 databases: a Dutch
database inclusive of 2 secondary and 6 tertiary centers
and the Mount Sinai Hospital database in New York City
inclusive of 1 tertiary IBD referral center. Cases were
identified by query of the electronic health record (EHR)-
linked database using both International Classification of
Diseases, 9th and 10th revision codes, and free text
searches for cases of IBD and also free text searches
for PSC.
Patient Selection: Inclusion and
Exclusion Criteria
After initial identification through the EHR query,
individual charts were reviewed. For patients with PSC-
IBD, a clinical diagnosis of PSC had to be confirmed by
distinctive features on cholangiography or liver biopsy
(for patients with small-duct PSC). Additional inclusion
criteria were as follows: (1) diagnosis of IBD (UC, CD, IBD
undifferentiated [IBD-U]) with colonic involvement
confirmed endoscopically and histologically; (2)
confirmed colonic disease duration of at least 8 years for
patients with non-PSC IBD or any colonic disease dura-
tion for patients with PSC-IBD; (3) enrollment in a sur-
veillance program; and (4) at least left-sided colitis (UC
or IBD-U) or involvement of more than 30% of the
colonic surface (CD or IBD-U). Patients with a history of
colectomy before enrollment or a history of aCRN before
or at the index colonoscopy during the defined study
period were excluded. Surveillance procedures were
defined as colonoscopies in which either segmental
random biopsies or chromoendoscopy were used. Colo-
noscopies with other indications (eg, medically re-
fractory disease), were excluded. The index colonoscopy
was defined as the first surveillance colonoscopy per-
formed within the study period (2000–2015).
Data Collection
Database coding was identical for all study pop-
ulations. The date of study entry was set at the first
surveillance colonoscopy in the database. The time of
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onset of PSC or IBD was determined from EHR review.
The date of the last colonoscopy was set as the last day of
follow-up evaluation.
The following baseline demographic and clinical data
were abstracted: date of birth, sex, date of PSC diagnosis
(if applicable), date of IBD diagnosis, IBD type, maximum
disease extent, and date of prior diagnosis of IND and/or
LGD (if applicable). Maximum disease extent was defined
as the maximum documented extent of endoscopic disease
on any colonoscopy and was coded as follows: extensive/
pancolitis (>50%) or intermediate/left-sided (30%–50%).
Medication exposure (at least 1 prescription) was recorded
for mesalamine, thiopurines, and biologics.
Data from each surveillance colonoscopy were
recorded, including date of examination, quality of bowel
preparation (adequate or inadequate), most proximal
extent examined, use of chromoendoscopy, presence and
severity of endoscopic inflammation, presence of post-
inflammatory polyps (pseudopolyps), stricture(s), and
visible lesions. Endoscopically detected neoplastic
lesions were categorized based on morphology (polypoid/
nonpolypoid). Endoscopically invisible neoplasia was
defined as neoplasia detected in a random biopsy with no
corresponding morphologic lesion seen on endoscopy.
Right-sided lesions were defined as those proximal to the
splenic flexure. Because this was a retrospective study,
there was no a priori protocol in place to record endo-
scopic activity in a uniform way. Thus, for each surveil-
lance colonoscopy, the severity of active endoscopic
inflammation was scored on a 4-point scale for each
colonic segment visualized to allow for standardization: 0,
no inflammation/remission; 1, mild inflammation; 2,
moderate inflammation; or 3, severe inflammation. A
mean inflammatory severity score per patient and per
colonoscopy was calculated by dividing the sum of in-
flammatory severity scores by the total number of colonic
segments visualized per colonoscopy and then by the total
number of surveillance colonoscopies.
Histology
Dysplasia was recorded as IND, LGD, or HGD. All his-
tologic diagnoses were as reported in the original pa-
thology report; no specimens were re-reviewed or altered
for this study. Of note, it is routine clinical practice at each
participating institution that colorectal neoplasia is
reviewed at the time of diagnosis and agreed upon by at
least 2 pathologists.
Primary and Secondary Outcomes
The primary outcome was a diagnosis of aCRN,
defined as HGD or CRC, during follow-up evaluation.
Secondary outcomes were a diagnosis of IND and/or LGD
during follow-up evaluation and the development of
aCRN after a diagnosis of IND and/or LGD. Factors
associated with a diagnosis of aCRN in patients with
PSC-IBD or patients with non-PSC IBD with or without a
prior diagnosis of IND and/or LGD were explored.
Statistical Analysis
Basic descriptive statistics were generated for patients
meeting inclusion criteria. Chi-square and Fisher exact
tests were used to compare categoric variables and
dichotomous outcomes, whereas the Student t test and the
Mann–Whitney U test were used for analyzing continuous
data. Incidence rates were calculated as the number of
cases per 100 patient-years of follow-up evaluation. Uni-
variate and multivariate Cox-regression modeling was
used to identify factors associated with aCRN. The pro-
portional hazards assumption of time-static covariates
was assessed using log–log plots and Schoenfeld residuals.
Because inflammatory scores were not stable over time,
these were input as time-changing covariates into the
models. Mean inflammation scores were recalculated at
every time point for each patient to correct for the vari-
able number of colonoscopies. A P value of .10 or less was
used as the cut-off value for selecting variables for the
multivariate analysis. Kaplan–Meier survival curves were
generated to compare cumulative incidence rates. Follow-
up data were censored at the last point of colonoscopic
follow-up evaluation, aCRN diagnosis, or colectomy.
All data analyses were performed using SPSS version 22
(IBM Corp, Armonk, NY).
Study Oversight
The Institutional Review Board at each of the
included sites approved the creation and analysis of a
longitudinal retrospective cohort database of patients
with colonic IBD undergoing surveillance.
Results
Baseline Demographic and Clinical
Characteristics
Of 1911 patients with colonic IBD in the combined
database meeting inclusion criteria, 293 patients were
confirmed to have PSC-IBD; the remaining 1618 patients
with non-PSC IBD served as the comparison group
(Figure 1). The main demographic and clinical features of
the cohort are detailed in Table 1. Compared with the
non-PSC IBD group, patients with PSC-IBD were more
often male and younger at study entry, although the age
at IBD diagnosis was similar between groups (P ¼ .11).
As expected, UC was the predominant IBD type in the
PSC-IBD group. Patients with PSC-IBD were less
frequently exposed to IBD therapy compared with pa-
tients with non-PSC IBD. In 151 patients (51.5%), the
PSC diagnosis was established after the IBD diagnosis,
while in 36 patients (12.3%) PSC was established before
the IBD diagnosis. For the remainder, PSC and IBD were
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diagnosed within the same year or the sequence of
diagnoses was not recorded.
The mean follow-up period for the total cohort was
4.8 years (SD, !3.0 y), with a total of 9265 patient-years
of follow-up evaluation; there was no difference in
follow-up time between patients with PSC-IBD and pa-
tients with non-PSC IBD. The number of surveillance
colonoscopies performed within the study period was
higher in patients with PSC-IBD compared with patients
with non-PSC IBD (3.8 vs 3.3; P < .01).
Inflammatory Activity
The endoscopic severity of inflammation on surveil-
lance examinations was similar between patients with
PSC-IBD and patients with non-PSC IBD (Supplementary
Table 1). The proportion of procedures in which exten-
sive active disease was observed in patients with PSC-
IBD vs patients with non-PSC IBD patients was 27% vs
12% (P < .01), 23% vs 10% (P < .01), and 27% vs 10%
(P < .01) for the first, second, and third surveillance
colonoscopy, respectively. The proportion of patients in
endoscopic remission on each of their surveillance
colonoscopies during the entire study period was higher
in patients with non-PSC IBD compared with patients
with PSC-IBD (P ¼ .02).
Occurrence of Advanced Colorectal Neoplasia
and Associated Risk Factors
Among patients with PSC-IBD, aCRN was diagnosed in
17 patients (5.8%), with CRC in 7 (2.4%) and HGD in 10
patients (3.4%) (Table 2). The frequency of aCRN during
follow-up evaluation was significantly lower in patients
with non-PSC IBD (2.9%), with CRC and HGD diagnosed
in 1.4% and 1.5% patients, respectively (P ¼ .01). The
incidence rate of aCRN in patients with PSC-IBD
compared with patients with non-PSC IBD was signifi-
cantly higher (1.3 vs 0.6/100 patient-years; P < .01)
(Figure 2). Although aCRN was more often right-sided in
patients with PSC-IBD compared with patients with non-
PSC IBD, this was not statistically significant (53% vs
31%; P ¼ .12). Among 40 patients with PSC-IBD (14%)
in whom the diagnosis of PSC was newly established
within the study period, 3 cases of aCRN occurred, with a
mean duration of 4.0 years (!2.5 y) between the PSC
diagnosis and aCRN occurrence. The primary outcomes
stratified by study site are detailed in Supplementary
Table 2.
On multivariate Cox-regression analysis, PSC
(adjusted HR [aHR], 2.01; 95% CI, 1.09–3.71), increasing
age (aHR, 1.03; 95% CI, 1.01–1.05), and active inflam-
mation (aHR, 2.39; 95% CI, 1.63–3.49) remained inde-
pendent predictors of aCRN diagnosis during follow-up
evaluation (Table 3). Correcting for geography (United
States vs The Netherlands) did not affect these findings
(Supplementary Table 3).
Figure 1. Description of patient selection and main outcomes
in each database. NL, The Netherlands.







Male, % 205 (70.0%) 796 (49.2%) <.001
Age at study inclusion,
y, means (SD)
39 (14) 45 (13) <.001
IBD type <.001
Ulcerative colitis 203 (69.3%) 912 (56.4%)
Crohn’s colitis 76 (25.9%) 661 (40.9%)
Indeterminate colitis 14 (4.8%) 45 (2.8%)
Disease extent <.001
Not specified 34 (11.8%) 154 (9.6%)
Limited extent/proctitis 13 (4.5%) 49 (3.1%)
Intermediate/left-sided 41 (14.2%) 572 (35.8%)
Extensive/pancolitis 201 (69.6%) 823 (51.5%)
Age at IBD diagnosis,
y, mean (SD)
27 (13) 28 (12) .11
IBD duration, y, mean (SD) 12 (10) 17 (9) <.001
Age at PSC diagnosis,
y, mean (SD)
32 (14) - -
Medication use
Mesalamine 221 (75.4%) 1316 (81.3%) .02
Thiopurines 93 (31.7%) 825 (51.0%) <.001
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Risk of Advanced Colorectal Neoplasia After a
Diagnosis of Indeterminate Dysplasia and/or
Low-Grade Dysplasia
The number of patients in the total cohort with at
least 1 diagnosis of IND was 147 (7.7%). In 101 patients
(5.3%) no additional dysplasia was detected. Among
patients with a diagnosis of IND, the rate of developing
aCRN after detection of IND was higher in patients
with PSC-IBD compared with patients with non-PSC IBD
(P ¼ .02) (Supplementary Figure 1). However, when
patients with a synchronous or metachronous diagnosis
of LGD (n ¼ 46) were excluded from this analysis (ie, no
grade of dysplasia higher than IND), this difference was
no longer significant.
The occurrence of at least 1 LGD-containing lesion
during the study period was similar for both patients
with PSC-IBD and patients with non-PSC IBD (21% vs
18%; P ¼ .37). Despite a similar proportion of patients
with LGD, the rate of developing aCRN after detection of
LGD was almost 3-fold higher in patients with PSC-IBD
compared with patients with non-PSC IBD (8.4 vs 3.0/
100 patient-years; P ¼ .01) (Figure 3).
For the subgroup of patients with LGD, the number of
patients in whom endoscopically invisible LGD was
detected over the course of surveillance was higher in
patients with PSC-IBD (38% vs 22%; P ¼ .01). The
proportion of invisible LGD cases among the total num-
ber of LGD cases (per-colonoscopy analysis) also was
higher. In a subanalysis of The Netherlands population,
we corrected for the total number of random biopsy
specimens taken (107,745 biopsy specimens in total);
the number of random biopsy specimens needed to
detect invisible dysplasia was 826 in patients with PSC-
IBD compared with 1703 in patients with non-PSC IBD.
On univariate Cox regression analysis, only PSC and
multifocal dysplasia were associated with a higher risk of
aCRN diagnosis after LGD detection, whereas polypoid
morphology of the lesion (vs nonpolypoid or invisible)
was associated with a lower risk. On multivariate anal-
ysis, only polypoid morphology remained significant and
was associated with a reduced risk of aCRN (aHR, 0.31;
95% CI, 0.14–0.65) after LGD detection compared with
nonpolypoid or endoscopically invisible lesions
(Supplementary Table 4).
Discussion
In this large, multicenter, cross-national, longitudinal
cohort study of patients with confirmed IBD colitis un-
dergoing colonoscopic CRC surveillance, we report a
higher risk of aCRN in patients with concomitant PSC
compared with those without PSC, in the current era of
improved endoscopic technology and more effective
medical therapy for inflammation. Although these find-
ings corroborate previous studies, we further expand
knowledge in the field by reporting an even higher risk
of aCRN after detection of LGD (but not IND alone). That
LGD was endoscopically invisible more often in patients
with PSC-IBD compared with patients with non-PSC IBD
justifies the more intensive management considerations
for this population. Our findings suggest that although
continued meticulous CRC surveillance with annual co-
lonoscopy is indicated in the absence of dysplasia for
patients with PSC-IBD, the detection of LGD or higher-
grade pathology should lead to a careful weighting of
the pros and cons of more aggressive therapeutic man-
agement, including colectomy.
In our well-characterized surveillance cohort of pa-
tients with PSC-IBD undergoing surveillance, we found
Table 2. Description of the Outcomes During the Study Period
PSC-IBD (n ¼ 293) Non-PSC IBD (n ¼ 1618) P value
Advanced neoplasia (aCRN) 17 (5.8%) 47 (2.9%) .01
CRC 7 (2.4%) 22 (1.4%) .19
HGD 10 (3.4%) 25 (1.5%) .03
LGD, patients with "1 LGD lesion 60 (20.5%) 295 (18.2%) .37
IND, patients with IND as highest grade lesion 27 (9.2%) 74 (4.6%) .001
Time from IBD diagnosis to aCRN diagnosis, y, mean 19.4 24.3 .15
Time from database entry to aCRN diagnosis, y, mean 4.2 3.4 .31
Time from LGD to aCRN diagnosis, y, mean 0.7 1.7 .12
Figure 2. Kaplan–Meier time-to-event (aCRN) analysis, all
patients since study entry.
- 2018 Advanced Colorectal Neoplasia in PSC-IBD 5
that having PSC-IBD is associated with a 2-fold higher
risk of aCRN. This risk is slightly lower than prior studies
and a recent meta-analysis of 16 studies that reported a
3.4-fold higher odds for colorectal neoplasia in patients
with PSC-IBD.23 Importantly, the increased risk in our
study remained after correcting for active endoscopic
inflammation over time (which was used as a time-
changing covariate rather than a mean overall score).
Endoscopic activity assessed during subsequent colo-
noscopies was associated strongly with the risk of future
aCRN, congruent with studies in the population with
non-PSC IBD.24–26 Whether the outcomes of endoscopic
inflammation compared with histologic inflammation are
distinct remains a question for future investigation.
The increased risk of CRC in patients with PSC and
concomitant colonic IBD has firmly been established,
although the underlying mechanisms remain unclear.3,27–30
The nearly 3-fold higher rate of aCRN (HGD and/or CRC)
diagnosis after LGD detection, as well as the difference in
location, morphology, and endoscopic conspicuousness of
dysplasia in patients with PSC-IBD compared with patients
with non-PSC IBD, suggests nuances in the pathogenesis of
neoplasia between these groups. Several investigators have
proposed a role for altered colonic bile composition in
carcinogenesis. A right-sided predominance of neoplasia
reinforces this hypothesis, as well as several studies directly
measuring the bile acid composition in both animals and
human beings.29,31,32 There is also evidence supporting the
notion that patients with PSC have an altered colonic
microbiome irrespective of concurrent IBD or ursodeox-
ycholic acid treatment.33 Still, whether these bacterial al-
terations are a cause or a consequence of the disease
characteristics specific to PSC remains to be clarified. Pa-
tients with PSC also share a distinct genotype,34 which may
predispose them further to neoplastic progression. More
likely, the underlying etiologies are multifactorial with roles
for gene–environment interactions, the microbiome, and
epigenetic modifications. Further investigations will hope-
fully open new avenues for novel therapeutic discovery and
primary and secondary prevention.
All told, because the mechanisms underlying PSC as an
independent risk factor for CRC in the setting of IBD colitis
are unclear, the best strategy for CRC prevention in pa-
tients with PSC-IBD remains frequent, attentive surveil-
lance colonoscopy. An important observation from our
study that distinguishes patients with PSC-IBD from pa-
tients with non-PSC IBD, is that dysplasia was detected
more often in random biopsies. Although previous retro-
spective studies have shown a low overall yield for
dysplasia with random biopsies as opposed to only tar-
geted biopsies of visible lesions, there was higher yield for
dysplasia on random biopsy in patients with concurrent
PSC.35,36 Our data further add to this body of evidence,
and it therefore can be questioned whether the current
recommendation, based on the results of prospective
studies, to move away from random biopsies as part of
CRC surveillance should apply to patients with PSC-
IBD.37,38 During surveillance examinations, particular
attention should be paid to the proximal colon because
right-sided cancers seem to be more common in patients
Table 3. Univariate and Multivariate Cox-Regression Analysis for the Overall Risk of aCRN: All Patients
Variable
Univariate Multivariate
HR 95% CI P value aHR 95% CI P value
Age, y 1.02 1.01–1.04 .03 1.03 1.01–1.05 .007
Age at IBD diagnosis 1.00 0.98–1.02 .78
Sex, reference: male 1.83 1.08–3.08 .02 1.62 1.94–2.79 .08
PSC 2.13 1.22–3.70 .01 2.01 1.09–3.71 .03
Inflammation severity, mean (0–3)a 2.14 1.48–3.09 <.001 2.39 1.63–3.49 <.001
IBD type, reference: UC 0.99 0.60–1.61 .95
Maximum disease extent, reference: pancolitis 1.43 0.85–2.41 .18
Thiopurine exposure 0.84 0.51–1.40 .85
Biological exposure 0.72 0.36–1.46 .36
Mesalamine exposure 1.14 0.58–2.25 .70
Number of surveillance procedures 0.96 0.84–1.09 .53
aEntered as time-changing covariate; 0, no inflammation/remission; 1, mild; 2, moderate; 3, severe.
Figure 3. Kaplan–Meier time-to-event (aCRN) analysis,
patients with LGD only.
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with PSC-IBD compared with patients with non-PSC IBD
colitis.32 Although the proportion of right-sided aCRNwas
higher in the PSC-IBD subgroup, this difference was not
statistically significant in the present study and may be
owing to insufficient power; it also may reflect selection
bias because one of our inclusion criteria for the non-PSC
IBD subgroup was at least left-sided disease extent or
more than 30% involvement, and thus may not represent
the overall IBD population. Our study confirms that the
date of PSC diagnosis is particularly relevant when risk-
stratifying patients because it seems that the risk of
neoplastic progression is highest within the first few years
of the PSC diagnosis.39 Thus, although CRC surveillance is
recommended after a disease duration of 8 years in pa-
tients with colonic IBD and no PSC,40 CRC surveillance at
the time of diagnosis in the setting of PSC is recommended
and further corroborated by our findings.
Our study had several strengths. In addition to being a
large IBD surveillance cohort in themodern era, our cohort
is particularly robust because each patient was confirmed
to have colonic IBD and to be actively enrolled in a colo-
noscopic CRC surveillance program. Comprehensive data
on disease history and endoscopic findings during sur-
veillance allowed for more accurate neoplastic risk
assessment, particularly with respect to measurement of
inflammatory burden over time. Importantly, detailed in-
formation on inflammatory activity at each colonoscopy
was incorporated into the analysis for more accurate
assessment of aCRNdevelopment in patientswithPSC-IBD.
Our study also had some limitations, most notably the
retrospective design. Despite the large size of our PSC-
IBD cohort, additional subanalyses, such as stratifica-
tion according to IBD type or medication use, yielded
insufficient power to permit meaningful conclusions.
Although we combined surveillance cohorts from 2
different countries, we predefined the inclusion/exclu-
sion criteria, variables to be assessed, and definitions of
outcomes. Combining these 2 cohorts enhanced not only
our power to detect meaningful differences, but also the
generalizability of our findings given that our study
population included patients from affiliated community-
based sites as well as tertiary IBD referral centers. That
said, there may be unmeasured differences in care
pathways between The Netherlands and the United
States, leading to heterogeneity in our study results. It is
important to note, however, that after adjusting for study
site and clinical–demographic differences between The
Netherlands and US cohorts, our results remained sig-
nificant (Supplementary Table 3). The lack of standard-
ized guidelines for the use of chromoendoscopy for CRC
surveillance in patients with IBD colitis unfortunately
precluded a meaningful analysis of its impact on
dysplasia detection because 10% or fewer examinations
were performed with chromoendoscopy. Finally,
although no samples were re-reviewed by pathologists
for the purposes of this study, it is routine practice at all
institutions participating in this study that whenever
there is a diagnosis of CRN, that the specimen is
reviewed by 2 pathologists and consensus is reached
before final reporting.
In summary, using a large well-characterized cohort
of patients with confirmed colonic IBD undergoing sur-
veillance between 2000 and 2015, we substantiated
prior smaller reports of the increased risk of aCRN in
patients with concurrent PSC-IBD compared with pa-
tients with only IBD colitis undergoing surveillance.
Novel findings of our study include the significantly
higher rate of aCRN diagnosis after a diagnosis of LGD in
the setting of PSC complicating IBD. This finding together
with a higher risk of invisible dysplasia in patients with
PSC-IBD highlights the need for an ongoing strict CRC
surveillance program in these patients and a low
threshold to advise colectomy once LGD is detected in
this select population.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2018.01.023.
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Supplementary Figure 1. Kaplan–Meier time-to-event
(aCRN) analysis for patients with IND; time from first IND
within study interval to event (P ¼ .02, log-rank test). aCRN
was defined as CRC and/or HGD.
Supplementary Table 1. Inflammatory Parameters During Surveillance
PSC-IBD Non-PSC IBD P value
Severity of active inflammation, mean (0–3)a 0.55 0.56 .89
Extent of active inflammation, mean (0–3)a 1.36 1.17 .003
Activity ratio for all surveillance colonoscopies, active:inactive 45% 41% .19
No inflammation on all surveillance colonoscopies 76 (27.1%) 546 (34.1%) .02
Inflammation extent, first colonoscopy .001
No activity 127 (53.6%) 864 (57.9%)
Limited 7 (3.0%) 89 (6.0%)
Intermediate 38 (16.0%) 363 (24.3%)
Extensive/pancolitis 65 (27.4%) 176 (11.8%)
Inflammation extent, second colonoscopy <.001
No activity 125 (55.3%) 866 (61.2%)
Limited 9 (4.0%) 109 (7.7%)
Intermediate 40 (17.7%) 297 (21.0%)
Extensive/pancolitis 52 (23.0%) 141 (10.0%)
Inflammation extent, third colonoscopy <.001
No activity 102 (57.3%) 584 (63.6%)
Limited 6 (3.4%) 79 (8.6%)
Intermediate 22 (12.4%) 164 (17.9%)
Extensive/pancolitis 48 (27.0%) 92 (9.9%)
Endoscopic inflammation severity, first colonoscopy .20
No activity 160 (57.1%) 924 (57.8%)
Mild 100 (35.7%) 495 (30.9%)
Moderate 19 (6.8%) 131 (8.2%)
Severe 1 (0.4%) 50 (3.1%)
Endoscopic inflammation severity, second colonoscopy .77
No activity 125 (53.6%) 864 (59.3%)
Mild 89 (38.2%) 445 (30.5%)
Moderate 16 (6.9%) 101 (6.9%)
Severe 3 (1.3%) 48 (3.3%)
Endoscopic inflammation severity, third colonoscopy .17
No activity 102 (55.4%) 583 (61.6%)
Mild 63 (34.2%) 276 (29.2%)
Moderate 13 (7.1%) 64 (6.8%)
Severe 6 (3.3%) 23 (2.4%)
aCorrected for total number of surveillance colonoscopies per patient.
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Male 674 (53.1%) 327 (50.9%) .37
Age at study inclusion, means (SD) 45 (12) 41 (15) <.001
Age at IBD diagnosis, means (SD) 29 (12) 26 (14) <.001
PSC 171 (13.5%) 122 (19.0%) .002
Age at PSC diagnosis, means (SD) 33 (12) 32 (16) .37
IBD type <.001
Ulcerative colitis 800 (63.0%) 315 (49.1%)
Crohn’s colitis 434 (34.2%) 303 (47.2%)
Indeterminate colitis 35 (2.8%) 24 (3.7%)
Extensive disease/pancolitis 686 (54.1%) 338 (52.6%) .56
Medication use
Mesalamines 999 (78.7%) 543 (83.8%) .008
Thiopurines 556 (43.8%) 362 (56.4%) <.001
Biologicals 156 (12.3%) 284 (44.2%) <.001
Number of surveillance colonoscopies, means 3.4 3.3 .25
Interval between surveillance colonoscopies, y, means 1.6 1.2 <.001
Neoplasia outcomes
CRC 17 (1.3%) 12 (1.9%) .37
HGD 15 (1.2%) 20 (3.1%) .003
LGD 264 (20.8%) 88 (13.7%) <.001
Supplementary Table 3. Univariate and Multivariate Cox-Regression Analysis for the Overall Risk of aCRN (All Patients),
Corrected for Study Site
Variable
Univariate Multivariate
HR 95% CI P value aHR 95% CI P value
PSC 2.13 1.22–3.70 .008 1.85 1.00–3.43 .049
Inflammation severity (0–3)a 2.14 1.48–3.09 <.001 2.08 1.42–3.07 <.001
Sex (reference: male) 1.83 1.08–3.08 .02 1.68 0.97–2.89 .06
IBD type (reference: UC) 0.99 0.60–1.61 .95
Maximum disease extent (reference: pancolitis) 1.43 0.85–2.41 .18
Age at IBD diagnosis 1.00 0.98–1.02 .78
Age (years) 1.02 1.01–1.04 .03 1.03 1.01–1.05 .004
Thiopurine exposure 0.84 0.51–1.40 .85
Biological exposure 0.72 0.36–1.46 .36
5-aminosalicylate exposure 1.14 0.58–2.25 .70
Number of surveillance procedures 0.96 0.84–1.09 .53
Population (reference: US) 2.82 1.72–4.62 <.001 2.20 1.30–3.74 .003
NOTE. aCRN was defined as colorectal cancer and/or HGD.
aEntered as time-changing covariate; 0, no inflammation/remission; 1, mild; 2, moderate; 3, severe.
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Supplementary Table 4. Univariate and Multivariate Cox-Regression Analysis for the Risk of aCRN After Detection of LGD
Variable
Univariate Multivariate
HR 95% CI P value aHR 95% CI P value
PSC 2.52 1.19–5.31 .02 1.79 0.83–3.88 .14
Sex, reference: male 1.23 0.60–2.49 .57
Thiopurine exposure 1.20 0.60–2.40 .60
Biological exposure 0.74 0.23–2.44 .74
Mesalamine exposure 1.07 0.44–2.59 .88
Dysplasia characteristics
Distal location 1.69 0.77–4.32 .17
Multifocality 2.46 1.22–4.95 .01 1.90 0.93–3.87 .08
Polypoid morphology 0.27 0.13–0.57 .001 0.31 0.14–0.65 .002
Invisible dysplasia 1.64 0.76–3.53 .21
Nonpolypoid morphology 1.82 0.70–4.74 .22
NOTE. aCRN was defined as colorectal cancer and/or HGD.
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